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ABSTRACT 
   
Solid tumors advance from benign stage to a deadly metastatic state due to the 
complex interaction between cancer cells and tumor microenvironment (TME) including 
stromal cells and extracellular matrix (ECM). Multiple studies have demonstrated that 
ECM dysregulation is one of the critical hallmarks of cancer progression leading to 
formation of a desmoplastic microenvironment that participates in tumor progression. 
Cancer associated fibroblasts (CAFs) are the predominant stromal cell type that 
participates in desmoplasia by depositing matrix proteins and increasing ECM stiffness. 
Although the influence of matrix stiffness on enhanced tumorigenicity has been well 
studied, the biological understanding about the dynamic changes in ECM architecture and 
the role of cancer-stromal cell interaction on ECM remodeling is still limited.  
In this dissertation, the primary goal was to develop a comprehensive cellular and 
molecular level understanding of ECM remodeling due to the interaction of breast tumor 
cells and CAFs. To that end, a novel three-dimensional (3D) high-density tumor-stroma 
model was fabricated in which breast tumor cells (MDA-MB-231 and MCF7) were 
spatially organized surrounded by CAF-embedded collagen-I hydrogel (Aim 1). Further 
the platform was integrated with atomic force microscopy to assess the dynamic changes 
in ECM composition and stiffness during active tumor invasion. The results established 
an essential role of crosstalk between breast tumor cells and CAFs in ECM remodeling. 
The studies were further extended by dissecting the mode of interaction between tumor 
cells and CAFs followed by characterization of the role of various tumor secreted factors 
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on ECM remodeling (Aim 2). The results for the first time established a critical role of 
paracrine signaling between breast tumor cells and CAFs in modulating biophysical 
properties of ECM. More in-depth analysis highlighted the role of tumor secreted 
cytokines, specifically PDGF-AA/BB, on CAF-induced desmoplasia. In aim 3, the 
platform was further utilized to test the synergistic influence of anti-fibrotic drug 
(tranilast) in conjugation with chemotherapeutic drug (Doxorubicin) on desmoplasia and 
tumor progression in the presence of CAFs. Overall this dissertation provided an in-depth 
understanding on the impact of breast cancer-stromal cell interaction in modulating 
biophysical properties of the ECM and identified the crucial role of tumor secreted 
cytokines including PDGF-AA/BB on desmoplasia.  
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PREFACE                    
This dissertation includes original research articles that have been published in peer 
reviewed journals by the first author. Chapter 2 which have described the use of 3D 
microengineered model to study the impact of tumor stroma interactions on ECM fibrosis 
is currently a manuscript in preparation. Chapter 4 which studies the influence of 
desmoplasia and anti-fibrotic drug tranilast in improving the efficacy of 
chemotherapeutic drug doxorubicin is a published article in cellular and molecular 
bioengineering (Saini et al., 2018).  
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Chapter 1 
Introduction 
1.1 Breast Cancer 
According to recent statistics, breast cancer is the leading cause of death amongst women 
across the globe (Bray et al., 2018). It is estimated that in 2019 there will be 268,800 new 
cases of breast cancer and 41,760 number of deaths in United States alone (Howlader N, 
2019). Despite multiple advancements in breast cancer diagnosis, the underlying basis of 
successful treatment remains the early detection of this devastating disease. Recent 
surveys by American Cancer Society show that while the five-year survival rate for early 
stage disease is ~ 99%, the advanced stage of the disease suffer from a low survival rate 
of ~27% ((ACS), 2017). The disparity in effectiveness of treatment at different stage of 
the cancer can be directly related to metastatic spread of the tumor in the body. At earlier 
stages, the tumor cells are localized in the native tissue and hence, the treatment options 
including surgery and radiation therapy are successful in restraining the cancer (Board., 
2019).  However, at an advanced stage the malignant cells have broken the barrier of the 
local tissue and invaded the surrounding region and further metastasized to distant organs 
(Place, Jin Huh, & Polyak, 2011). At the invasive and metastatic phase of the disease, the 
commonly administered treatment regime is a combination of surgery that removes all 
detectable tumors along with adjuvant therapy that aims to minimize the risk of relapse of 
the disease due to the presence of undetectable tumors (Giordano, 2003). However, due 
to the presence of various micro metastases at this stage the disease can relapse leading to 
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reduced disease-free survival (Redig & McAllister, 2013a). Additionally, multiple 
malignant cells incur drug resistance and therefore do not respond to the therapies leading 
to reduced effectiveness of the treatment (Moulder, 2010). 
The lack of a successful treatment modality for invasive and metastatic stage of 
breast cancer is partly due to our incomplete understanding of the complex biology of 
disease progression (Nitish Peela et al., 2017). While the field of cancer biology initially 
focused on role of genetic mutations in tumor cells and their role in disease progression, a 
growing body of literature now demonstrate that the local tumor milieu named as “tumor 
microenvironment (TME)” plays a crucial role in tumorigenesis and metastasis. To that 
end, it is now become evident that more in-depth mechanistic studies are required to 
better understand the complex milieu of interaction between cancer cells and TME to 
understand their specific role in disease progression and design more effective targeted 
therapies. 
1.2 Tumor Microenvironment 
Breast cancer progression at various stages has been accepted to be caused by complex 
crosstalk between tumor and their stromal components in addition to the genetic 
alteration within the tumor cell (Bissell & Hines, 2011; Douglas Hanahan & Coussens, 
2012). Breast cancer cells are supported by a structural framework comprising of 
extracellular matrix (ECM) in addition to vasculature and different non-malignant cell 
types including fibroblasts, immune cells, adipocytes, bone-marrow mesenchymal 
stromal cells and pericytes (Bussard, Mutkus, Stumpf, Gomez-Manzano, & Marini, 
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2016). Multiple studies have shown that stromal cells present in the TME share 
phenotypic and genetic similarities to cells participating in wound healing and 
inflammation (Balkwill, Capasso, & Hagemann, 2012; Grivennikov, Greten, & Karin, 
2010). Similar to wound healing and associated inflammation, stromal cells can interact 
with native malignant cells by either cell-cell interaction or through secretion of growth 
factors, chemokines and cytokines (Balkwill et al., 2012; Grivennikov et al., 2010). In 
classical case of wound healing, tissue injury leads to activation of multiple processes 
(Stroncek JD, 2008); within few seconds of the injury fibrin clot is formed at the site of 
tissue injury to minimize the blood loss (Sundaram, Quah, & Sampath, 2018). Formation 
of fibrin attracts multiple immune cells including macrophages to clear out the dead cells 
and fight any infection at the site of injury. Additionally, fibroblasts cells migrate and 
proliferate at the site of injury and transform into myofibroblasts phenotype. These 
myofibroblasts initiate the deposition of collagen and various other matrix proteins to 
restore the scaffold of the area similar to native tissue before the injury (Sundaram et al., 
2018). Epithelial cells, keratinocytes also migrate to this area and perform proliferation to 
repopulate the area with composition similar to pre-injury state (Sundaram et al., 2018). 
Once the tissue site is healed, the stimulus for the cells to proliferate, migrate and 
remodel decreases thereby causing the transformed cells to undergo quiescence 
(Sundaram et al., 2018). As opposed to wound healing, cancerous tissue does not lose the 
stimulus and hence the state of hyperproliferation and migration continues. Due to 
continued release of growth factors/cytokines by cancer cells, stromal cells maintain their 
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activated phenotype and participate in tumor progression. Different cell types which 
undergo phenotypic changes to participate in tumor progression are discussed below. 
 
Figure 0-1: Schematic of Tumor Metastatic Cascade. 
 (A) Tumor growth and development results in ECM remodeling as well as 
differentiation of cancer stem cells and fibroblasts. (B) Subsequently, angiogenesis, 
cancer cell invasion, and intravasation occur. (C) Finally, surviving cancer cells 
and cancer stem cells circulate through the body, attach to blood vessels, and extravasate 
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to form secondary metastases. Adapted with permission from Biomaterials (Nitish Peela 
et al., 2017). For copyright please refer to Appendix D. 
Cancer Associated Fibroblasts (CAFs):  
Fibroblasts are the predominant stromal cell type found within the breast 
TME(Buchsbaum & Oh, 2016). In a normal healthy mammary tissue, fibroblasts assist in 
tissue homeostasis by participating in ECM production, basement membrane synthesis as 
well as in immune cell recruitment (Alkasalias, Moyano-Galceran, Arsenian-Henriksson, 
& Lehti, 2018). Additionally, normal fibroblasts (NFs) play an essential role in 
suppressing the growth of malignant cells by a process known as ‘neighbor suppression’ 
(Alkasalias et al., 2018; Klein, 2014). On the other hand, the transformation of NFs into 
activated CAFs like phenotype alters the tumor suppressing microenvironment to tumor 
promoting microenvironment and thereby participates in tumor growth, invasion and 
anti-cancer drug resistance as shown in Figure 1-1A (Kalluri & Zeisberg, 2006).  CAFs 
have been implicated in multiple clinical studies as a poor prognostic marker of breast 
cancer. Utilizing patient tissue samples, it has been shown that high proportions of α-
smooth muscle actin (α-SMA) positive CAFs correlates with tumor of high grade and 
reduced overall survival (Buchsbaum & Oh, 2016; SUROWIAK et al., 2007). CAFs can 
interact with tumor cells by cell-cell interaction (Camp et al., 2011) and paracrine 
signaling including soluble factor signaling (Shimoda, Mellody, & Orimo, 2010) and 
exosomes (X. Yang, Li, Zou, & Zhu, 2019). Utilizing this multilayered crosstalk with the 
tumor cells, CAFs play a crucial role in tumor initiation, tumor invasion, angiogenesis, 
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lymphangiogenesis, ECM remodeling, inflammation, metabolic reprogramming and anti-
cancer drug resistance (Luo, Tu, Liu, & Liu, 2015). For instance, Rozenchan et.al showed 
in their study that CAFs alter the gene expression profiles of normal mammary epithelial 
cells such as MCF10A and upregulate stress responsive and pro-survival genes 
(Rozenchan et al., 2009). On the other hand, studies led by Soon et.al. showed that CAFs 
can enhance the expression of mesenchymal related markers such as vimentin in 
MCF10A thereby providing evidence of epithelial to mesenchymal transition (EMT) 
leading to tumorigenesis and tumor progression (Soon et al., 2013). In another study by 
Weigel et.al., CAFs were shown to express insulin like growth factor (IGF)- binding 
proteins which inhibit the process of anoikis in MCF10A cells further strengthening the 
role of CAFs in tipping the regulatory mechanisms towards cell survival as opposed to 
cell death (Weigel et al., 2014). Multiple chemokines such as stromal derived factor 
(SDF1-α), hepatocyte growth factors (HGF), transforming growth factor (TGFβ1) 
vascular endothelial growth factor (VEGF) and CCl2 (Tsuyada et al., 2012) are secreted 
by CAFs that can participate in various stages of tumor progression  (Chen et al., 2012; 
Costanza, Umelo, Bellier, Castronovo, & Turtoi, 2017; De Francesco et al., 2013; Fiori et 
al., 2019; Huang, Li, Zhang, & Nan, 2010; Kojima et al., 2010; Orimo et al., 2005; Tyan 
et al., 2011). Similar to their normal and wound healing counterparts, CAFs play a key 
role in ECM remodeling by secreting a variety of matrix components including matrix 
metalloproteinases (MMPs), collagen, fibronectin, hyaluronic acid, lysyl oxidase, etc. 
(Santi, Kugeratski, & Zanivan, 2018). They also assist in collagen fiber realignment 
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thereby providing tracks for cancer cells to invade and migrate with minimal resistance in 
TME (Erdogan et al., 2017). In an interesting study by Labernadie et.al. and Miyazaki 
et.al., it was demonstrated that CAFs can promote collective migration of cancer cells by 
upregulating tight junctions such as N-cadherin at CAFs membrane and E-cadherin at 
cancer cell surface in squamous cell and pancreatic cancer. While these are interesting set 
of results that further shed light on physical interaction of CAFs with tumor cells, more 
investigation is needed to understand the mechanisms which promote such heterotrophic 
cell junction formation between these two cell types (Labernadie et al., 2017; Miyazaki et 
al., 2019). Responding to ECM structural realignment, CAFs can also generate high 
mechanical force which recently has been attributed as a positive feedback for prolonged 
ECM secretion as well as vasculogenesis (Lu, Weaver, & Werb, 2012; Sewell-Loftin et 
al., 2017). CAFs also assist tumor cells in immune cell activation and recruitment to the 
TME. Cohen et.al. demonstrated that fibroblasts activated by breast tumor cells express 
high level of chitinase 3-like 1 (Chi3L1) which further promote tumor cell migration in 
wound closure assays and upregulates the expression of proinflammatory and invasive 
factors including MMP9, CXCL1, CXCL2, IL-6 and CCL2. Knockdown of Chi3L1 in 
CAFs decreased macrophage infiltration in xenograft tumors and reduced their 
transformation to tumor promoting M2 like phenotype which is known to be tumor 
promoting in nature (Cohen et al., 2017). In another study by Yavuz et.al., macrophage 
recruitment and activation was studied in response to conditioned media collected from 
CAFs, NFs and cancer cells (Gok Yavuz et al., 2019). It was observed that in contrast to 
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NFs conditioned media, CAFs conditioned media was able to promote migration of 
monocytes and activate them to tumor promoting M2 phenotype confirmed by 
upregulated expression of CD163 and CD 206 which are predominately M2 markers 
(Gok Yavuz et al., 2019). Furthermore, the authors showed that CAFs educated 
macrophages also reduced proliferation of CD4+ T cells thereby providing a 
immunosuppressive environment to tumor cells (Gok Yavuz et al., 2019). Overall, CAFs 
are an important stromal component which modulates cancer cell and other stromal cell 
behavior at various stages of cancer metastasis and therefore is an important regulator of 
tumor progression. 
Endothelial Cells:  
Endothelial cells are the cell type which form the inner lining of the blood vessels 
that participate in transport of nutrients, gas exchange and waste in and out of the tissue 
while maintaining the direction of blood flow (Dudley, 2012). Tumor like normal tissues 
need a constant supply of nutrients to maintain themselves and perform their metabolic 
functions (Nishida, Yano, Nishida, Kamura, & Kojiro, 2006). When tumors grow beyond 
1-2 mm3, the neoplastic cells cannot maintain their metabolic needs and hence initiate a 
cascade of events which leads to an angiogenic switch and formation of new blood 
vessels from existing vessels, a process commonly known as angiogenesis (Nishida et al., 
2006; Nitish Peela et al., 2017). In a physiological state, angiogenesis involves a cascade 
of events where a gradient of angiogenic factors cause local degradation of the basement 
membrane (Douglas Hanahan & Folkman, 1996). Next, endothelial cells change their 
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shape and undergo hyperproliferation and invasion into the surrounding area which is 
primarily dictated by angiogenic factors (Douglas Hanahan & Folkman, 1996). 
Endothelial cells then reverse themselves into their original phenotype and form 
intercellular tight junctions leading to formation of new lumen that can allow passage of 
blood flow and maintain the direction of the flow (Douglas Hanahan & Folkman, 1996). 
New blood vessels are usually accompanied by a layer of pericytes and basement 
membrane that provides stability to the neo-vessels (Dvorak, 2015; Nitish Peela et al., 
2017). Multiple studies have noted stark differences in the process of normal and tumor 
angiogenesis (Nishida et al., 2006). For instance, TME provides an imbalance of pro-and 
anti-angiogenic factors (Nishida et al., 2006). Specifically, it is noted that the TME has an 
abundance of pro-angiogenic factors including VEGF, bFGF, angiogenein, angiostatin, 
TGF-β, TNF-α, MMP9, HGF and PDGF and lower expression of anti-angiogenic factors 
including tissue inhibitors of matrix metalloproteinases (TIMP), thrombospondin and 
interferon etc. (Nishida et al., 2006).  Using animal models and 3D models, it has been 
shown that the new vessels formed in TME are immature, thin and leaky in nature (S. 
Nagaraju, D. Truong, G. Mouneimne, & M. Nikkhah, 2018; Nitish Peela et al., 2017). 
Tumor blood vessels are generally surrounded by a reduced number of pericytes and lack 
a basement membrane (Dvorak, 2015; Nitish Peela et al., 2017). Additionally, the tumor 
endothelial cells have reduced expression of intercellular junctions that can lead to large 
transcellular holes. Together all these changes in tumor vasculature cause the new blood 
vessels to leak the plasma proteins into the TME which act as a good resource of 
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sequestered growth factors that leads to enhanced tumor cell migration, intravasation and 
macrophage recruitment to tumor sites as shown in Figure 1-1B (Nitish Peela et al., 
2017). 
Overexpression of multiple growth factors by cancer and other stromal cells play 
a crucial role in tumor angiogenesis. VEGF has been implicated to play a crucial role in 
tumor angiogenesis which is known to be secreted by tumor cells and CAFs (Watnick, 
2012). Presence of hypoxic microenvironment due to hyperproliferation of tumor cells 
further enhance the expression of pro-angiogenic factors due to the activation of hypoxia 
inducible factor (HIF) based pathways in tumor cells (Muz, de la Puente, Azab, & Azab, 
2015).  Other stromal cell types including tumor associated macrophages (M2) are also 
known to aid in angiogenesis by assisting in immune suppression, upregulation of 
endothelial proliferation and secretion of multiple pro-angiogenic factors including 
CCL2, FGF-2, Insulin like growth factor 1 (IGF1), placental growth factor (PGF) etc 
(Corliss, Azimi, Munson, Peirce, & Murfee, 2016).    
Immune Cells: 
TME is comprised of various types of immune cells including macrophages, T-
cells, NK cells and myeloid derived suppressor cells. During normal tissue homeostasis, 
most of the immune cells inhibit the growth of malignant cells, however, when the tumor 
progresses to an invasive and metastatic stage, immune cells alter their phenotype to 
create an immunosuppressive microenvironment. Various immune cells that participate in 
tumor progression are detailed below. 
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Macrophages are generally the resident of various organs of the body such that 
immune response can be elicited against any foreign body present in the organ (Williams, 
Yeh, & Soloff, 2016). These are specifically known as tissue resident macrophages which 
maintain themselves in the organ by using proliferative signaling induced by chemokine 
Colony stimulating factor (CSF1) (Williams et al., 2016).  In TME macrophages account 
for a large proportion of immune cells due to the presence of various malignant tumor 
cells (Williams et al., 2016). At initial stages of cancer, macrophages have tumoricidal 
role such that it promotes anti-tumor immunity (Noy & Pollard, 2014). However, at later 
stages these cells adapt to a milieu of signals in TME and change its phenotype similar to 
that of trophic macrophages thereby participating in tissue repair, cancer cell survival, 
migration, intravasation and metastasis as shown in figure 1-1B (Noy & Pollard, 2014). 
Macrophages can usually achieve two different polarization state, M1 and M2, which are 
distinguished based on their ability to express two opposing functions (Hao et al., 2012). 
M1 phenotype of macrophages have tumoricidal and pro inflammatory abilities and 
release cytokines which will recruit more monocytes from circulating stream and will 
present antigens to adaptive immune cells such as T-cells (Hao et al., 2012). On the other 
hand, M2 phenotype of macrophages are specialized to suppress inflammation and 
thereby secrete anti-inflammatory cytokines and assist in cancer cell survival, tissue 
remodeling and angiogenesis (Hao et al., 2012). M1 type of macrophages are also known 
to be classically activated whereas M2 phenotype of macrophages are said to be 
alternatively activated (Sica, Schioppa, Mantovani, & Allavena, 2006; Williams et al., 
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2016). M1 type of macrophages are regulated in the presence of proinflammatory stimuli 
such as Interferon (IFN- γ), Tumor Necrosis Factor (TNF-α), Granulocyte macrophage 
colony stimulating factor (GM-CSF) and release tumoricidal cytokines such as 
superoxide anions, nitrogen free radicals, immunogenic cytokines IL-1,2,6 and 12 (Sica 
et al., 2006). On the other hand, M2 state of macrophages is activated when there are 
anti-inflammatory cytokines such as IL-4, 13,10 and Transforming growth factor (TGF-
β) and release polyamines, chemokine ligand (CCL) 17,18,22 and various other factors 
that make the environment immunosuppressive (Sica et al., 2006). 
While M1 and M2 macrophages present opposing functions within TME, their 
activation state depends heavily on tumor progression stage. It has been observed that at 
initial stages of cancer, tissue resident macrophages or those recruited from the blood 
flow are usually of M1 phenotype and thus inhibit the activity of the tumor cells (Noy & 
Pollard, 2014). However, as the tumor cells undergo proliferation and progresses to 
advanced stages, tumor associated macrophages switch to M2 phenotype under hypoxic 
environment and various other signals derived from tumor and stromal cells (Noy & 
Pollard, 2014). At these advanced stages of cancer, macrophages participate in cell 
migration, angiogenesis and metastasis due to crosstalk between tumor and stromal cells 
(Bussard et al., 2016; Noy & Pollard, 2014; Williams et al., 2016). In particular, tumor 
associated macrophages are involved across all the steps of cancer metastasis including 
cell migration towards blood vessels, angiogenesis, intravasation as well as extravasation 
(Hao et al., 2012). Tumor associated microphages secrete chemokines such as epidermal 
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growth factor (EGF) which interacts with its receptor EGFR on cancer cells and allow the 
cells to move in chemotactic fashion towards the blood vessel that have macrophages in 
their proximity (Hao et al., 2012). The cancer cells in turn release colony stimulating 
factor (CSF1) which promotes the proliferation of macrophages and allow for their 
recruitment within the TME from circulating stream (Hao et al., 2012; Williams et al., 
2016). In addition to release of EGF, tumor associated macrophages also release various 
MMPs including MMP2 and MMP9 which promote cancer metastasis by degrading 
ECM and promoting cancer cell migration (Hao et al., 2012). Tumor associated 
macrophages also secrete various proangiogenic factors such as VEGF, PDGF, bFGF etc 
which promote angiogenesis (Hao et al., 2012). Further, in hypoxic environment under 
the effect of HIF-1α, expression of these factors in further enhanced (Hao et al., 2012).  
Other type of immune cells which are found in the TME include regulatory T-
cells, cytotoxic T-cells, myeloid derived suppressor cells and NK cells (Chew, Toh, & 
Abastado, 2012). From previous research it has been established that while NK cells and 
cytotoxic T-cells promote anti-tumor immunity, regulatory T cells and myeloid derived 
suppressor cells are pro-tumor in nature (Segovia-Mendoza & Morales-Montor, 2019). 
During early stages of cancer, dendritic cells and antigen presenting cells presents 
neoantigens to CD8+ T cells and hence maintain tumor suppressive microenvironment 
(Mittal, Gubin, Schreiber, & Smyth, 2014). However, at an equilibrium phase the anti-
tumor and pro-tumor signals are balanced out which cause the tumor to stay in dormant 
stage (Dunn, Old, & Schreiber, 2004). Prolonged periods of equilibrium phase put a 
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selective pressure on tumor cells thereby causing selection of mutant aggressive cells 
which may mutate surface antigens to avoid immunosurveillance and move to an escape 
phase of immunoediting (Chew et al., 2012; Segovia-Mendoza & Morales-Montor, 
2019). In this phase the regulatory T cells and myeloid derived suppressor cells gets 
recruited into the tissue leading to creation of an immunosuppressive microenvironment 
(Chew et al., 2012; Segovia-Mendoza & Morales-Montor, 2019). At this stage a more 
detailed investigation is required to better understand the role of multiple type of immune 
cells in tumor progression and development of effective immunotherapies (Segovia-
Mendoza & Morales-Montor, 2019).  
Besides above-mentioned stromal cell types, TME is also made up of adipocytes 
and mesenchymal stem cells whose role in tumor progression has recently been 
elucidated by different studies (Carter & Church, 2012; Choi, Cha, & Koo, 2018; 
Farahmand, Esmaeili, Eini, & Majidzadeh-A, 2018; Lee & Hong, 2017; Maffey et al., 
2017; Nickel et al., 2018; Patel et al., 2010; Y. Y. Wang et al., 2017). For instance, 
Nickel. et.al. demonstrated in their study that coculture of varied breast tumor cells with 
adipocytes induce differential gene expression dependent on the tumor subtype. To 
visualize the effect of 3T3-L1 adipocytes on breast tumor cells genetic phenotype; the 
tumor cells and adipocytes were cultured on a transwell system such that two cell types 
don’t intermix but interact through soluble factor signaling (Nickel et al., 2018). Using 
microarray system, it was identified that adipocytes upregulated estrogen (Er+) regulated 
genes in ER+ MCF7 and T47D cells whereas enhanced expression of inflammatory genes 
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in triple negative MDA-MB-231cells. Pathway analysis further demonstrated that 
adipocytes conditioned soluble factors inflammatory pathway such as NF-ĸB signaling 
(Nickel et al., 2018). Additionally, coculture of 3T3-L1 adipocytes with MDA-MB-231 
cells enhanced their invasive abilities thereby suggesting a crucial role of these cells in 
tumor progression (Nickel et al., 2018).  In an interesting study by Patel et.al. authors 
demonstrated a crucial role of mesenchymal stem cells (MSCs) in immunosuppressing 
the TME by inhibiting the proliferation and cytotoxic effects of peripheral blood 
mononuclear cell (PBMC) (Patel et al., 2010). Using 2D platforms authors observed that 
when breast cancer cells such as MCF7, T47D and MDA-MB-231 cells are co-cultured 
with MSCs the proliferation and migration rate of CD4+ cells was significantly reduced 
(Patel et al., 2010). Additionally, MSC’s shielded the tumor cells from cytotoxic effects 
of natural killer (NK) and cytotoxic T lymphocytes (CTLs). Using ELISA and 
knockdown studies authors showed that MSCs derived TGF-β play a crucial role in 
inhibiting the cytotoxic effects of PBMCs as well as in Treg expansion(Patel et al., 2010). 
In addition to various cellular components, TME also comprises of non-cellular 
scaffold in which different cell types are embedded. Such as complex network of fibrils, 
extracellular proteins and glycoproteins in known as ECM which has been discussed in 
detail in the following section. 
Extracellular Matrix:  
The extracellular matrix (ECM) in the stroma is primarily made up of fibrillar and non-
fibrillar collagens in addition to various proteoglycans and glycoproteins (Lu et al., 
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2012). Besides providing structural support to the tissue, it also presents various 
biophysical and biochemical cues to the cancer cells thereby assisting in disease 
progression through different signaling pathways (Xiong & Xu, 2016). Due to the 
presence of fibrillar collagen and various other proteins, tumor ECM provides unique 
physical properties in terms of its rigidity, pore size and fiber orientation in addition to 
providing anchorage sites (Samani, Zubovits, & Plewes, 2007). For instance, tumor cells 
in the presence of a rigid matrix demonstrate upregulated integrin signaling which 
participates in epithelial to mesenchymal transition of the cells (Kalluri & Weinberg, 
2009). Additionally, if fiber thickness within the ECM is high with anisotropic fiber 
orientation then it can act as a migration barrier for the motility of the cancer cells (Lu et 
al., 2012). Tumor ECM also comprises of various growth factors immobilized on its 
surface which provides chemotactic gradients to the cancer cells allowing their 
directional movement (Lu et al., 2012). Due to the action of various proteases secreted 
into ECM many immobilized biomolecules also activated and initiate signal transduction 
such as those involved in FGF, WNT, etc. (Lu et al., 2012). Pickup et.al. demonstrated 
the tumor ECM plays significant role across various hallmarks of the cancer including 
proliferative signaling, angiogenesis, avoiding immune destruction, tumor promoting 
inflammation (Pickup, Mouw, & Weaver, 2014).  
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Figure 0-2: Change in ECM Composition due to Cancer Initiation and Metastasis. 
Adapted with full permission from Advanced Drug Delivery Reviews (Insua-Rodríguez 
& Oskarsson, 2016). For copyright please refer to Appendix D. 
Normal mammary ECM can be broadly classified into two components namely 
basement membrane and interstitial matrix as shown in figure 1-2 (Mueller & Fusenig, 
2004).  Basement membrane is a specialized ECM which separates the epithelial and 
myoepithelial cell layer from the stromal cells as shown in figure 1-2 (Mueller & 
Fusenig, 2004). It participates in maintaining the polarity of the tissue and exhibit tumor 
suppressive properties (Oskarsson, 2013). On the other hand, interstitial matrix provides 
the connective framework to the tissue along with other cell types to maintain the tissue 
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homeostasis (Mueller & Fusenig, 2004). While basement membrane is made up of 
collagen type IV, laminin and entactins, interstitial matrix is primarily made up of 
fibrillar collagen including collagen type I, III, V, VI, VII, XII, fibronectin, hyaluronan 
and other various other glycoproteins and proteoglycans (Mueller & Fusenig, 2004). It 
has been observed that as cancer progresses through different stages, tumor ECM also 
undergoes remodeling similar to wound healing (Lu et al., 2012; Mueller & Fusenig, 
2004). For instance, as carcinomas progresses to a pre-malignant phenotype, interstitial 
matrix show activation of fibroblasts with increased number of macrophages, higher 
deposition of collagen and enhanced angiogenesis while the basement membrane remains 
intact (Kalluri & Zeisberg, 2006; Mueller & Fusenig, 2004). On the other hand, when 
carcinomas become invasive in nature, the basement membrane is degraded and cancer 
cells come in contact with stromal components which include high amounts of collagen 
type 1, proteases, macrophages and myofibroblast with leaky blood vessels (Kalluri & 
Zeisberg, 2006; Mueller & Fusenig, 2004). To that end, tumor ECM or matrix is 
significantly different in its composition from physiological matrix. In general, tumor 
related matrix is comprised of different type of collagens including type I, III, V 
(Oskarsson, 2013).  Furthermore, it contains large amounts of elastin, vitronectin, 
fibronectin, hyaluronon and laminin (Xiong & Xu, 2016). Additionally, tumor matrix is 
known to contain high amounts tenascin-c which otherwise is absent from normal healthy 
matrix (Xiong & Xu, 2016). Tumor matrix also contains large of amount of osteopontin 
and periostin (POSTN) that participates in cancer cell metastasis (Oskarsson, 2013; 
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Xiong & Xu, 2016). In addition to increase in protein content, many biophysical 
properties of the cancer matrix also modify. This includes, high stiffness of the tumor 
associated ECM due to overproduction of collagen modification enzymes including 
prolyl-4-hydroxylase (P4H), lysyl hydroxylase (PLOD) and lysyl oxidase (LOX) 
subsequently leading to enhanced collagen fiber crosslinking (Oskarsson, 2013; Xiong & 
Xu, 2016). The collagen fibers also become more aligned in tumor matrix such that they 
can assist in cancer cell migration by providing paths of least resistance (Kalluri & 
Zeisberg, 2006). Different type of proteases including matrix metalloproteinases 
(MMPs), urokinase plasmogen activator (UPA) and serine proteases are upregulated in 
tumor ECM such that various pathways can be activated such as FGF, PDGF, 
angiogenesis (Oskarsson, 2013) . 
1.3  Role of various cell types in engineering stromal matrix: 
 Multiple studies have demonstrated that the tumor ECM components are secreted by 
both stromal cells as well as by cancer cells (Xiong & Xu, 2016). Major contributors of 
the tumor ECM synthesis include CAFs due to their abundant population amongst 
stromal cells (Cirri & Chiarugi, 2011; Kalluri & Zeisberg, 2006). CAFs are known to 
secrete collagen fibrils including collagen type I, III, V that accounts for the most 
abundant protein of the matrix (Cirri & Chiarugi, 2011; Kalluri & Zeisberg, 2006). 
Besides deposition of collagen, it also deposits large amount of fibronectin and 
hyaluronan such that tumor growth, and migration can be enhanced as well other stromal 
cell like macrophages can be recruited (Kalluri & Zeisberg, 2006). Additionally, ECM 
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remodeling enzymes such as MMPs including MMP 1 and 3 as well as UPA are secreted 
(Cirri & Chiarugi, 2011; Kalluri & Zeisberg, 2006). Other factors released by CAFs 
include tenascin-c which is generally absent in adult tissue but is overly expressed in 
cancerous matrix (Cirri & Chiarugi, 2011; Kalluri & Zeisberg, 2006; Xiong & Xu, 2016). 
In order to influence the stiffness of the matrix, collagen modification enzymes such as 
LOX are also secreted by CAFs at all stages of cancer (Cirri & Chiarugi, 2011; Kalluri & 
Zeisberg, 2006). Various cytokines such as insulin growth factor as well as hepatocyte 
growth factor that participate in tumor migration and invasion are also secreted by CAFs 
(Cirri & Chiarugi, 2011; Kalluri & Zeisberg, 2006). 
Besides CAFs, other stromal cells including tumor associated macrophages, 
adipocytes and bone marrow derived mesenchymal cells also participate in tumor ECM 
deposition (Bussard et al., 2016; Williams et al., 2016). This type of macrophages 
secretes various types of MMPs including MMP 9/13 such that elastin can be generated 
which can in turn be useful to recruit monocytes (Bussard et al., 2016; Williams et al., 
2016). It also secretes fibronectin which can be useful for establishing cancer cell 
adhesiveness and migration (Bussard et al., 2016; Williams et al., 2016). Other molecules 
secreted by macrophages include UPA, cathepsins and serine proteases (Bussard et al., 
2016; Williams et al., 2016). Bone marrow derived mesenchymal cells are also known to 
secrete MMP 2/9 (Kessenbrock, Plaks, & Werb, 2010). Since these cells can differentiate 
to CAFs they can be responsible for remodeling of ECM similar to CAFs thereby 
conferring chemoresistance. Adipocytes also release MMP13 while endothelial cells 
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mainly secrete components of basement membrane (Kessenbrock et al., 2010; Lu et al., 
2012). In addition to stromal cells, recent studies have demonstrated that cancer cell 
themselves also participate into deposition of TME matrix (Xiong & Xu, 2016). For 
instance, it has been observed that cancer cells deposit various matrix proteins including 
laminin, hyaluronan and tenascin-c and thrombospondin 1 (Xiong & Xu, 2016). While 
hyaluronan deposited by cancer cell promotes cell proliferation, migration, invasion, 
multidrug resistance and angiogenesis, tenascin-c promotes lung metastases (Xiong & 
Xu, 2016). Thrombospondin 1 released by cancer cells are known for their anti-
angiogenic effect inhibiting the blood vessel penetration into the tumor (Xiong & Xu, 
2016). Additionally, collagen modification enzymes such as PLD and LOX are also 
expressed by cancer cells under hypoxic conditions using HIF-1 pathway (Xiong & Xu, 
2016). Cancer cells also participate in preparing metastatic niche such as that in lung 
metastases by deposition various components of matrix such as tenascin c-. It has been 
observed that cancer cell deposited tenascin-c initiates the process of cancer cell 
metastases which then signals more production of tenascin c by stromal cells (Xiong & 
Xu, 2016). Thus, both cancer and stromal cells play a significant role in tumor matrix 
deposition. In this regard, we can conclude that the mixture of cancer cells with stromal 
cells including fibroblasts, macrophages, bone marrow derived mesenchymal stem cells 
and adipocytes will deposit interstitial matrix of the natural cancer matrix. Additionally, 
stromal cells such as fibroblasts, macrophages mixed with endothelial cells secrete the 
basement membrane that surrounds the blood vessels. Similarly, epithelial cells mixed 
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with stromal cells including fibroblasts, macrophages, bone marrow derived 
mesenchymal cells will produce the basement membrane separating the epithelium from 
the stroma in normal tissue.  
1.4 Engineered Models to study Tumor ECM Remodeling 
Patient Biopsy based studies:  
Human breast tumor biopsies also known as ‘research biopsies’ are useful 
platforms to visualize changes in the TME including presence of different stromal cell 
types, expression of various proteins and change in ECM structure (Olson, Lin, Krop, & 
Winer, 2011). A systematic and scientific approach of performing various assays on fresh 
tissue assist in determining the biophysical and biochemical changes within the TME 
(Olson et al., 2011). Multiple studies have taken advantage of these tissue-based assays to 
study the changes in ECM architecture during tumor progression (Acerbi et al., 2015; 
Conklin et al., 2011; Olson et al., 2011; Plodinec et al., 2012; Samani et al., 2007). For 
instance, Acerbi et.al. obtained fresh tissue from patients and stage matched across 
various tumor subtypes to visualize the changes in ECM architecture and biomechanical 
properties (Acerbi et al., 2015). Specifically, authors demonstrated that when tumor 
progresses from normal healthy tissue to invasive ductal carcinoma (IDC) collagen 
density increases accompanied by enhanced organization of the collagen fibers into a 
linearized orientation as shown in figure1-3A(Acerbi et al., 2015). It was also noted that 
the regions of high orientation in the stroma of invasive carcinoma had 4-fold higher 
stiffness than the stroma of normal healthy tissue (Acerbi et al., 2015). The change is 
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ECM architecture led to an upregulated integrin-based mechanosignaling which 
increased the phosphorylation of focal adhesion kinase and myosin light chain that are 
known to impact multiple downstream pathways including cell proliferation, invasion 
and EMT (Figure 1-3A) (Acerbi et al., 2015). Interestingly collagen fiber alignment was 
proposed as a prognostic signature in human breast carcinoma by keely group who 
established multiple tumor associated collagen signatures known as TACS based on 
collagen fiber orientation at multiple stages of breast cancer (Conklin et al., 2011).  By 
utilizing second harmonic generation Keely’s group at University of Wisconsin-Madison 
studied 169 breast carcinomas and established that at invasive stages of breast cancer, 
collagen fibers orient and align themselves perpendicular to the tumor boundary, a 
signature known as TACS-3 (Conklin et al., 2011). Further statistical analysis of their 
data established that TACS-3 can act as a prognostic signature independent of tumor 
subtype and is poorly corelated to disease free survival. TACS-3 was also demonstrated 
to be correlated to syndecan-1 receptors for collagen binding such that regions with high 
TACS-3 score had high expression of syndecan-1 receptors (Conklin et al., 2011). Some 
other groups such as schoenenberger utilized other sophisticated techniques such 
indentation type atomic force microscopy (AFM) to acquire stiffness maps of fresh breast 
tumor biopsies at various stages of the disease (Plodinec et al., 2012). The authors 
demonstrated that malignant breast tissue have a characteristic bimodal stiffness 
distribution as compared to healthy tissue which has a unimodal stiffness map (Figure 1-
3B). Such heterogeneous distribution of stiffness in malignant tissue was correlated back 
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to the tissue architecture such that the softer tumor cells were observed to invade into the 
stiffer peripheral stromal region (Plodinec et al., 2012).  
 
While the patient biopsy-based models provide us with clinically relevant 
information and establish prognostic markers, there are multiple challenges associated 
with these platforms. Most of the studies require a large sample size to visualize ECM 
changes due to the patient heterogeneity. Additionally, samples should be acquired from 
patients at different stages which are segregated based on tumor grade, size and subtype 
to establish the correlation between prognostic marker and tumor associated features 
including receptor status, tumor stage and molecular subtypes. Acquiring and analyzing a 
large sample size can be therefore be time consuming and laborious. Additionally, most 
of these studies are end point assays that are useful to perform correlation studies 
between multiple factors but can’t be utilized to establish cause and effect relationship 
between specific biological cue and cancer cell behavior.  
In vivo models:  
Animal models are usually considered the gold standard in biomedical research. 
Due to anatomical and physiological similarities of animals with humans, these models 
are considered ideal for testing drugs, testing efficacy of various regenerative therapies 
and studying progression of multiple diseases (Barré-Sinoussi & Montagutelli, 2015). 
These models also provide a 3D microenvironment with presence of various other cell 
types, vasculature and lymphatic system making them ideal to carry long term study of 
diseases such as cancer progression (Barré-Sinoussi & Montagutelli, 2015). In 
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comparison to patient tissue biopsy models, which is an end point analysis animal models 
allow design of experiments with appropriate controls that can allow us to visualize the 
physiological changes in presence and absence of the variable in question. In vivo models 
further allow us to study the progression of the disease and identify unknown factors 
participating in disease progression by carrying multiple downstream studies such as 
RNA-sequencing and proteomics.   
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Figure 0-3: Previous Research Models to Study ECM Dysregulation in Breast 
Cancer. 
 (A) Representative birefringence maps (Q-POL) and immunofluorescent images 
demonstrating enhanced stromal density, matrix stiffness and fiber organization leading 
to upregulated mechanosignaling during tumor progression. Adapted with permission 
from Integrative Biology (Acerbi et al., 2015) (B) Representative histograms of stiffness 
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distribution showing characteristic bimodal distribution of elastic modulus for stiff 
invasive carcinoma as compared to unimodal distribution in normal healthy tissue. 
Adapted with permission from nature nanotechnology (Plodinec et al., 2012). (C) 
Immunofluorescent imaging showing high contractile ability (pMLC) of basal cells (K8+) 
in the absence of DDR1. Adapted with permission from genes development (K. Takai et 
al., 2018) (D) Representative immunofluorescent images depicting high collagen 
accumulation and activation of SMAD signaling pathway in tumors transplanted with 
CAFs. Adapted with permission from Oncotarget (Ken Takai, Le, Weaver, & Werb, 
2016). (E) Representative second harmonic generation images overlaid with fluorescent 
images of tumor cells showing perpendicular orientation of collagen fibers to the cell 
membrane when incubated on high density collagen in presence of prolactin. Adapted 
with permission from journal of biological chemistry (Barcus, Keely, Eliceiri, & Schuler, 
2013). (F) Representative immunofluorescent images for MCF10A cells demonstrating 
loss of acinar structure on stiff matrices as compared to soft matrices with minimal 
change in fibronectin expression. Adapted with permission from nature material 
(Chaudhuri et al., 2014). For copyright please refer to Appendix D. 
Various research groups have utilized animal models to visualize desmoplasia in 
solid tumors such as breast cancer. One of the earliest successful xenograft models for 
breast cancer desmoplasia was established by Shao et.al. in 2000 (Shao, Nguyen, & 
Barsky, 2000).  Authors utilized multiple ER+ (W9, W7, neo MCF7) and Er- cell lines 
(MDA-MB-231, MDA-MB-468) and successfully created a desmoplastic xenograft 
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model with W9 cell line in the absence of estrogen (Shao et al., 2000). It was observed 
that the stroma for these desmoplastic tumors comprised of 30% stromal cells with 
abundance of collagen (Shao et al., 2000). Additionally, upon transfection of W9 cells 
with PDGF-A dominant negative mutant, the desmoplastic response was minimized 
suggesting that tumor cell secreted PDGF can act as an initiator of stromal desmoplasia 
(Shao et al., 2000). It is crucial to note here that loss of PDGF in W9 cell line did not 
affect the secretion of other cytokines including TGF-β, IGF or reduced the 
tumorigenicity of the cell line (Shao et al., 2000). This further underlines the influence of 
tumor cell secreted PDGF in stromal desmoplastic response. In a recent study by Valerie 
Weaver and Zena Werb group, authors utilized a xenograft mouse model to understand 
the role of discoidin domain receptor 1 (DDR1) as either pro- or anti-cancer and its 
possible role in fibrosis (K. Takai et al., 2018). DDR1 is a well-known collagen receptor 
whose role in cancer is controversial. Multiple studies have demonstrated that DDR1 at 
early stages of mammary ductal growth participates in epithelial cell proliferation, 
differentiation and migration, however, loss of DDR1 at late stages is related to increased 
expression of collagen in the stroma and therefore participating in mammary carcinoma 
fibrosis leading to cancer metastasis. By crossing a DDR1 knockout mice with MMTV-
PyMT mouse, authors observed that loss of DDR1 leads to higher expression of basal 
markers (vimentin and keratin 14) as compared to luminal markers (E-cadherin, Keratin 
8) within tumor region suggesting that the tumor formed by loss of DDR1 is basal in 
nature (K. Takai et al., 2018). Additionally, the tumors formed due to the loss of DDR1 
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were necrotic leading to an upregulation of hypoxia inducible factor (H1F-α). Results 
from immunofluorescence for pMLC staining and AFM further revealed high expression 
of contractile and stiffer tumor as compared to DDR1+/+ tumors (Figure 1-3C) (K. Takai 
et al., 2018). Enhanced stiffness lead to an upregulated contractility and integrin based 
signaling which is shown to participate in tumor proliferation, migration and metastasis 
to distant organs (K. Takai et al., 2018). Another interesting study by Cox et.al. 
demonstrated the role of LOX in breast tumor fibrosis and creating a tumor permissive 
microenvironment that can support metastatic colonization and survival at distant organs 
including lung and liver. In this study, authors first created successful hepatic and lung 
fibrotic in vivo models by using bleomycin (lung fibrosis) and dimethylnitrosamine (liver 
fibrosis) (Cox et al., 2013). In both fibrosis models, significant upregulation of α-SMA, 
collagen, fibronectin and LOX was observed. When the fibrotic models were treated with 
anti-LOX antibody, the fibrosis were reduced although levels of α-SMA remained the 
same (Cox et al., 2013). Next, mammary fat pads were injected with 4T1 mammary 
carcinomas and primary tumor growth within breast tissue remained unchanged in 
presence or absence of fibrotic environment within lungs or liver (Cox et al., 2013). 
However, after 3 weeks an enhanced metastasis of tumor cells was visualized in fibrotic 
organs suggesting that the fibrotic niche support metastatic colonization and survival of 
tumor cells (Cox et al., 2013). The metastatic load was minimized when the fibrotic 
organs were treated with anti-LOX antibody. Similar observations about metastatic 
colonization of 4T1 cells were made when they were injected through rat tail thus 
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augmenting the significance of fibrotic environment for tumor cell persistence and 
survival (Cox et al., 2013). While most of the studies focused on role of cytokines and 
matrix components in inducting ECM desmoplasia, limited studies have been done to 
study the role of stromal cell types on inducing an ECM desmoplastic reaction within 
breast tumor. In a study performed by Takai et.al. 4T1 tumors were implanted in a 
BALB/c mice and with and without CAFs (Ken Takai et al., 2016). It was observed that 
presence of CAFs enhanced tumor growth and increased lung metastases number. 
Additionally, presence of CAFs led to an enhanced expression of matrix proteins 
including such as collagen and an upregulated TGF-β signaling as shown in figure 1-3D 
(Ken Takai et al., 2016). The anti-fibrotic model thus created was then utilized by the 
authors to test the effect of anti-fibrotic drug pirfenidone (Approved for Idiopathic 
pulmonary fibrosis) on the efficacy of chemotherapeutic drug doxorubicin. Their results 
demonstrated that addition of pirfenidone significantly reduced the tumor growth in 
comparison to empty vehicle as well as doxorubicin. Additionally, lung metastases 
number and growth was minimized suggesting a crucial role of CAF induced 
desmoplasia in breast cancer progression and anti-cancer drug resistance (Ken Takai et 
al., 2016). 
  While the animal models provide an advantage over the biopsy-based models to 
visualize disease progression in a 3D microenvironment, these models are complex in 
nature and present with multiple confounding factors such as different cell types, 
unknown cytokines (Nitish Peela et al., 2017). Additionally, it is very difficult to perform 
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mechanistic studies within animal models due to physiological variability between 
animals and humans. This necessitates to develop 3D microengineered in vitro tumor 
models that can assist in performing a well-controlled study with appropriate controls and 
accurate cancer pathophysiology as well as perform real time analysis of various metrics 
during the course of culture (Nitish Peela et al., 2017). 
In vitro models: 
 Most in vitro models have primarily focused on studying the role of ECM in 
various steps of breast cancer metastatic cascade. Researchers utilize various biomaterials 
whose stiffness can be modulated to demonstrate an upregulated proliferation and 
invasion abilities of tumor cells due to the difference in biomechanical properties of the 
matrix (Barcus et al., 2013; Cavo et al., 2016; Chaudhuri et al., 2014). For instance, 
Chaudhuri et.al. utilized a hydrogel composed of interpenetrating network formed by 
alginate and reconstituted basement membrane (Chaudhuri et al., 2014). The authors 
demonstrated that when normal mammary epithelial cells such as MCF10A are 
encapsulated on alginate-rBM based hydrogels, increase in matrix stiffness leads to a 
malignant transformation of the cells leading to loss of acinar structure as shown in figure 
1-3F (Chaudhuri et al., 2014). Similar transformation of cells into a malignant phenotype 
was observed when the change in stiffness due to alginate concentration is accompanied 
by change in rBM concentration. These results are in contrast when the MCF10A cells 
are encapsulated within pure rBM hydrogels and high stiffness in these gels maintain the 
acinar phenotypes suggesting a crucial role of ECM stiffness and matrix composition on 
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tumor cell initiation and growth (Chaudhuri et al., 2014). Another study by Barcus et.al. 
utilized collagen matrices and observed that stiff collagen matrices switches the signaling 
of prolactin from physiological to pro-tumorigenic (Barcus et al., 2013). Specifically, 
authors utilized T47D cells and cultured them in low density and high-density gels and 
incubated them with prolactin. Their initial results demonstrated that when T47D cells 
are cultured on stiffer collagen matrix, a significant 2 fold reduction of STAT5 signaling 
and enhanced activation of ERK1/2 pathway was observed upon incubation with 
prolactin (Barcus et al., 2013). Additionally, on low density collagen prolactin leads to 
formation well differentiated clusters of T47D cells whereas on a stiff hydrogel prolactin 
disrupts the cluster formation. The change in cellular phenotype on stiff hydrogels in 
response to prolactin was accompanied by increase in MMP expression, tumor 
invasiveness and upregulated alignment of collagen fibers (Figure 1-3E) (Barcus et al., 
2013).  
 While the aforementioned studies demonstrated the significant role of biophysical 
properties of the ECM in aiding tumor progression, notably, not many in vitro models 
focused on studying ECM remodeling during active invasion of tumor cells. Recently, 
few labs invested themselves in developing 3D in vitro models that can be utilized to 
perform in situ measurement of ECM rheology in pancreatic tumor stroma cultures. For 
instance, Jones et.al. encapsulated pancreatic tumor cells PANC-1 and pancreatic 
fibroblast cell line such as MRC-5 within a neutralized collagen hydrogel with 
fluorescent probes (Jones, Hanna, Cramer, & Celli, 2017). Using video microcopy and 
33 
 
particle tracking analysis the mean square distance of the probes was assessed. 
Interestingly the authors observed high mean square distance of probes when PANC-1 
cells were cultured alone in collagen I hydrogel as compared to their coculture with 
fibroblasts and in ECM free hydrogels (Jones et al., 2017). They also used GSER 
technique to use frequency dependent rheological measurements of collagen hydrogel 
and demonstrated high storage modulus of coculture group over monoculture of PANC-1 
cell suggesting ECM remodeling due to tumor-stroma interactions (Jones et al., 2017). 
While the model is one of the first few platforms to study the effect of tumor stroma 
interaction on ECM remodeling, there are many limitations to the study. The model can 
be fabricated in a 96 well plate and hence is high throughput in nature, however, the 
model doesn’t have a physiologically relevant tumor stroma organization which has been 
shown to be important to model various steps of metastatic cascade (S. Nagaraju et al., 
2018; Truong et al., 2016). Additionally, similar to previous studies the model did not 
study the biomechanical properties of ECM during active tumor invasion. Overall, there 
is still a critical gap in engineering in vitro models that can be utilized to not only study 
the effect of ECM on tumor progression but can also be used to perform in situ 
mechanical measurements of the matrix during dynamic cultures. While most of the 
models and previous studies have shed some light on role of factors such as LOX and 
TGF-β in CAF induced desmoplasia, there is still a critical knowledge gap on 
mechanistic studies about role of tumor stroma interactions on fibrosis. 
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1.5 Thesis Overview 
While the previous models were paramount in establishing the crucial role of ECM 
dysregulation in cancer progression, we still do not understand the molecular mechanism 
of matrix remodeling due to tumor-stroma interactions. Additionally, most of the 
previous studies focused on end point measurement of matrix properties rather than 
studying the temporal changes thereby providing minimum information about alterations 
in ECM architecture during active tumor invasion.  In this regard, it is imperative to 
establish an in vitro desmoplastic model in which multiple factors including different cell 
types and various growth factors can be studied with appropriate controls to dissect their 
individual role in stromal fibrosis. Additionally, integration of the platform with 
nanoindentation techniques including AFM and confocal microscopy will assist in 
assessing various biochemical and biophysical changes across the culture period thus 
enabling a comprehensive study of cancer induced desmoplasia. Building such an in-
depth analysis about regulation of tumor ECM remodeling will be significant to not only 
advance cancer biology but also design better targeted therapies to improve the efficacy 
of multiple anti-cancer drugs.  
  In my doctoral studies, we have developed a 3D high-density breast tumor-stroma 
model which can be utilized to study the cellular and molecular crosstalk of tumor and 
stromal cells. Additionally, due to open top nature of the platform, we were able to study 
the change in biomechanical alterations of stromal ECM during active tumor progresses. 
The overall goal of the study is to visualize ECM remodeling by assessing changes in 
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collagen fiber deposition and matrix stiffness due to the complex crosstalk between tumor 
cells and stromal cells (i.e. CAFs) which can then assist in tumor progression including 
invasion and proliferation. As a proof of concept, this platform was utilized for breast 
cancer studies, while the capabilities of the platform enable it to be utilized for various 
other form of cancer including pancreatic cancer. 
Specific Aim 1: Development of 3D tumor model to characterize matrix stiffness in 
presence of tumor (MDA-MB-231/MCF7) and single class of stromal cells (CAFs) : In 
this aim for the first time we developed a 3D high density tumor-stroma platform that can 
be integrated with AFM to characterize biophysical properties of the matrix during active 
invasion of tumor cells in the presence of CAFs. Additionally, to understand the impact 
of crosstalk between tumor cells of varied tumorigenicity and CAFs on matrix stiffness, 
we performed extensive studies on biomechanical properties of matrix for both highly 
invasive MDA-MB-231 cells as well as MCF7 cells.  
Specific Aim 2: In depth characterization of the crosstalk between tumor cells and 
CAFs influencing matrix stiffness While the previous literature has shown that tumor 
cells depict increased tumorigenicity on enhanced matrix stiffness, not much is known 
about the necessary signaling molecules between tumor and stromal cells. With this in 
mind, we extended our studies by studying the mode of interaction between tumor and 
stromal cells followed by identification of tumor secreted factors that participate in CAF 
based desmoplasia. To identify various secretomes influencing stromal fibrosis we 
utilized two approaches including ELISA and label free proteomics.  
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Specific Aim 3: Study the influence of commercially available anti-fibrotic drug 
(Tranilast) on alleviating desmoplasia to improving efficacy of anti-cancer 
therapeutics: In this aim we studied the influence of commercially available anti-fibrotic 
drug (Tranilast) on alleviating desmoplasia to improving efficacy of anti-cancer 
therapeutics. As stiffness has been identified by various previous studies as an important 
regulator of tumor progression leading to limited chemotherapeutics efficacy, we utilized 
a commercially available anti-fibrotic drug to reduce the stiffness of the matrix as well as 
study its synergistic influence on chemotherapeutic drug (doxorubicin) in the presence of 
single class of stromal cells (CAFs). 
While specific aim 1 and specific aim 2 are detailed in chapter 2, specific aim 3 is 
described in chapter 4. Chapter 3 provides a detailed write up about the adopted methods 
and results of label free proteomics which were utilized to identify various known and 
unknown tumor secreted factors as outlined in specific aim 2.   
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The Crucial Role of Breast Tumor Stromal Interaction in ECM Remodeling and 
Tumorigenicity within a Microengineered 3D Platform 
2.1 Introduction 
Metastatic breast cancer is known as one of the leading killers amongst women across 
United States with estimated 14% of deaths in 2017 (Siegel, Miller, & Jemal, 2017). It is 
now established that besides tumor cells, the surrounding mammary tissue 
microenvironment also plays a significant role in cancer progression from early benign 
stage to invasive and metastatic phases (Redig & McAllister, 2013b). The tumor stroma 
is predominantly composed of cancer associated fibroblasts (CAFs) besides other cell 
types (Balkwill et al., 2012; Kalluri & Zeisberg, 2006). Many studies have demonstrated 
that CAFs play multifaceted role in tumor progression as they influence various 
hallmarks of cancer (Kalluri, 2016). For instance, CAFs play a crucial role in epithelial to 
mesenchymal transition (EMT) of neoplastic cells enabling cell motility and invasion 
through the stroma (Yu et al., 2014). CAFs also assist in matrix remodeling by secreting 
proteins such as collagen I as well as proteases including matrix metalloproteinases 
(MMPs) (Cirri & Chiarugi, 2011). Due to overexpression of collagen and crosslinking 
enzymes such as lysyl oxidase (LOX), CAFs modulate the stromal stiffness leading to a 
significant alteration of the biophysical characteristics (Chen et al., 2012; Cirri & 
Chiarugi, 2011; Schedin & Keely, 2011; Yu et al., 2014).  
In the past, various in vivo models have been utilized to develop an in depth 
understanding on the influence of CAFs on breast tumor growth and metastasis (Cohen et 
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al., 2017; Orimo et al., 2005; Ken Takai et al., 2016). These studies have been paramount 
in identifying molecular mechanisms through which CAFs exhibit pro-tumorigenic 
activity however, there are many limitations associated with these models (Nitish Peela et 
al., 2017). For instance, it is not trivial to assess the dynamic changes in biophysical 
properties of the matrix including matrix deposition, degradation as well change in 
stiffness. While some previous in vivo models have been able to assess the stiffness of the 
cancerous tissues by utilizing biopsies and indentation techniques such as AFM  (Acerbi 
et al., 2015; Plodinec et al., 2012), a mechanistic study on the influence of stromal and 
tumor cells on change in matrix stiffness cannot be achieved due to lack of control 
condition and presence of confounding factors such as other cell types (Asghar et al., 
2015; M. E. Katt, A. L. Placone, A. D. Wong, Z. S. Xu, & P. C. Searson, 2016; Nitish 
Peela et al., 2017; Shen et al., 2014).  Further, such models cannot isolate the stiffness of 
matrix or tumor cells from that of the bulk tissues, thereby limiting their use for such an 
in-depth analysis (M. E. Katt et al., 2016). In this regard, various 3D tumor models have 
been engineered to study the influence of matrix stiffness on cancer cell migration, 
growth rate and drug resistance (Kraning-Rush, Carey, Lampi, & Reinhart-King, 2013; 
Peela et al., 2016; Nitish Peela et al., 2017; Sung et al., 2013; Truong et al., 2016). These 
studies modulate the stiffness of the matrix in various ways including increase in matrix 
density (Zaman et al., 2006), utilization of synthetic(Ehrbar et al., 2011) and use of 
composite hydrogel (Chaudhuri et al., 2014) as well as by crosslinking with enzymes 
such as glutaraldehyde (Lang et al., 2015). While these approaches have been successful 
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to study the influence of matrix stiffness on cancer cell migration, they do not incorporate 
essential stromal cells such as CAFs to study extracellular matrix (ECM) remodeling 
caused by dynamic interaction between tumor and stromal cells. While these models have 
successfully assessed the mode of interaction such as cell-cell interaction and paracrine 
signaling for tumor progression; similar set of assessments for ECM remodeling are still 
largely missing.  
In this regard, we fabricated a microengineered high-density 3D tumor entity 
incorporated with breast cancer cells, with surrounding stroma made up of collagen I 
embedded with CAFs. Most importantly, our model enables us to mechanistically assess 
the biomechanical changes within the matrix using AFM and confocal reflection imaging.  
Further, we utilized RT-qPCR and ELISA to assess the change in expression of profibrotic 
genes and cytokines.  We also characterized cancer cell invasion and migration using live 
cell imaging to correlate CAF based desmoplasia with tumor growth and progression. Our 
findings notably suggested that the crosstalk between tumor and stromal cell is necessary 
to cause significant changes in stiffness of the ECM while monoculture of either cell type 
can’t modulate the biophysical properties of the matrix. Using RT-qPCR we observed high 
expression of matrix genes when tumor cells and CAFs are co-cultured as compared to 
monoculture of tumor cells. Our conditioned media (CM) results demonstrated crucial role 
of paracrine signaling between cancer cells and CAFs such that tumor cells secreted 
cytokines activate fibrotic pathways within fibroblasts. Our ELISA results suggested 
crucial role of tumor secreted PDGF cytokines including PDGF- AA and BB in inducing 
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fibrotic pathways within CAFs. By specifically blocking PDGFR based signaling using 
various concentrations of CP673451 drug, we further demonstrated the crucial role of 
PDGF pathway in CAF based desmoplasia. We also observed that CAFs increased the 
tumorigenicity of breast tumor cells by influencing multiple hallmarks of cancer including 
proliferation and invasion. 
2.2  Materials and Methods 
Materials: PDMS (Sylgard 184 Silicon Elastomer Kit, Dow Corning) was used to 
fabricate PDMS holders and stamps (Figure 2-1A). PDMS holders were surface treated 
using 2-aminopropyl-triethoxy-silane (APTES) and glutaraldehyde. Confocal dishes on 
the other hand were surface treated using Poly-D-Lysine (PDL). For surface treatment of 
PDMS stamps, Pluronic-F 127 was utilized. 
Cells: MDA-MB-231 cells expressing red fluorescence was obtained from Dr. Ros’s lab 
at Arizona State University. MCF7 cells expressing red fluorescence was a generous gift 
from Dr. Mouneimne lab at University of Arizona. Breast cancer associated fibroblasts 
(CAFs) used in this study were bought from ATCC. All the cells were maintained in 
DMEM 1X media supplemented with 10% FBS, 1% PenStrep and 1% L-Glutamine. The 
cells were grown in T-75 flasks within an incubator maintained at 37°c and 5% Co2.  
Antibodies: In order to characterize the cells for various markers, anti-pan-cytokeratin 
(1:100), vimentin (1:100) and anti-α-smooth muscle actin (α-SMA, 1:100) antibodies 
were utilized. Further to perform cell proliferation assay Click-iT EdU Alexa Fluor 488 
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Imaging Kit (Thermo Fisher) was used. To visualize cytoskeleton of cells, Alexa Fluor 
488 phalloidin was used at 1:40 dilution.  
Surface treatment: The PDMS holders and stamps used to micropattern the platform was 
designed using AutoCAD. The dimensions of the holders were 8 by 8 mm such that they 
can fit within a well of 24 well plate. The PDMS stamps on the hand had 300 µm posts of 
75 µm diameter with 250 µm center to center distance. Each stamp had an array of 15 by 
15 posts in order to fabricate high density tumor microarray. PDMS holders and stamps 
were casted off the silicon wafer using soft lithography techniques as explained 
previously (Truong et al., 2016). For surface treatment of PDMS holders, they were 
cleaned using scotch tape and further treated with air-based plasma for the duration of 4 
minutes 30 seconds. The treated holders were immediately immersed into freshly 
prepared 2% APTES solution in 95% ethanol and incubated at 60 °c for 60 minutes. 
Next, the APTES solution was aspirated and the holders were immersed in 100% ethanol 
and ultrasonicated for 20 minutes at high frequency using water based ultrasonication. 
The ethanol solution was replaced with fresh 100% ethanol and washed 5 times 
consecutively with 10 minutes interval on a plate shaker to remove residual APTES. The 
treated holders were then incubated at 80° c for one hour. Next, the holders were 
incubated in 2% glutaraldehyde solution in DI water for one hour. To remove excess 
glutaraldehyde the treated holders were washed with DI water 5 times for 5-minute 
interval followed by overnight incubation at 80 °c. The confocal dishes were treated by 
PDL at concentration of 0.5 mg/ml for 1 hour followed by 2% glutaraldehyde treatment. 
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The dishes were then incubated at 80° c oven overnight. To make PDMS stamps protein 
resistant, they were immersed in 1% Pluronic F-127 solution in DI water overnight in 4° 
c. 
Fabrication of 3D tumor model. Our micropatterned 3D tumor model was fabricated as 
explained previously by nelson et.al. with brief changes. Collagen 1 was used at the 
concentration of 4 mg/ml. For coculture condition, CAFs were mixed with collagen I at 
the cell density of 2 x 106 cells/ml. PDMS stamps were then removed from Pluronic 
solution and washed three times with DI water. The collagen solution prepared was then 
added to each stamp immediately and further inverted on top of the PDMS holders. The 
whole assembly was then kept for polymerization for 30 minutes at 37 °c. After 
polymerization of the gel, the stamps were lifted off gently and the microwells were 
seeded with cancer cells at a density of 7 x106 cells/ml for 2-3 minutes. The cells from 
unpatterned surface were removed by washing with media as explained in previous 
protocols (Nelson, Inman, & Bissell, 2008). The prepared samples were kept inside the 
incubator for 15 minutes to allow attachment of cells to collagen wells. After 15 minutes, 
the samples were immersed within 500 µl of media in each well of 24 well plate.  
Breast Cancer Invasion assay: In order to quantify the breast cancer invasion, samples 
from all groups were imaged using Zeiss Inverted microscopy and Apotome 2.0 on day 0, 
2 and 4. Using phase contrast and fluorescent imaging, images were acquired of 2 x 2 tile 
at 2 random locations of the sample. Next, we isolated the co-ordinates of the tumor cells 
within each image using ImageJ and with custom-written MATLAB code performed 
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delaunay triangulation modelling. The area of each triangle within each delaunay plot as 
well as standard deviation was calculated using MATLAB. Further, we calculated 
average area of all triangles and quantified area disorder for each delaunay plot using 
following equation 
 𝐴𝑟𝑒𝑎 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟 = 1 − (1 + (
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑟𝑒𝑎
))^ − 1    
Migration Index was calculated using area disorder by using following formula 
𝑀𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝐼𝑛𝑑𝑒𝑥 =
(𝐴𝑟𝑒𝑎 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟 𝑜𝑛 𝐷𝑎𝑦 1 − 𝐴𝑟𝑒𝑎 𝐷𝑖𝑠𝑜𝑟𝑑𝑒𝑟 𝑜𝑛 𝐷𝑎𝑦 3)
𝐴𝑟𝑒𝑎 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟 𝑜𝑛 𝐷𝑎𝑦 1
 
MCF7 cluster area was quantified using Image J analyze particles plugin. The average 
cluster area for day 2 and 4 for all the samples in each condition were normalized with 
respect to day 0. 
Cell proliferation assay: The cell proliferation was quantified by using Click iT-Edu 
Imaging Kit. The assay was performed as per manufacturer’s instruction. In order to 
quantify the cancer cell proliferation, the DsRed positive cell with EdU positive nuclei 
was counted in Image J using cell counter plugin. The CAF proliferation was quantified 
by counting the cells which were not DsRed Positive but had an EdU positive nuclei. To 
calculate percentage of proliferative cells, the EdU positive cancer cells or CAF cells was 
divided by total number of cancer cells or CAF cells respectively.  
AFM 
Asylum Research MFP-3D-BIO AFM was used to conduct the force-indentation 
measurements. Team NanoTec LRCH-750 AFM probes with sphere-cone geometry were 
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used. The spring constants (nominal k~0.2 N.m-1) were determined using thermal energy 
dissipation method (Butt & Jaschke, 1995; Hutter & Bechhoefer, 1993). Samples were 
measured and imaged at 37 C in 1X Hank’s Balanced Salt Solution (HBSS) containing 
calcium and magnesium. The samples were also buffered with 25 mM HEPES to 
maintain their pH during the measurements. Quasi-static measurements with cantilever 
approach and retraction speed 2 µm.s-1 were conduct to collect elastic modulus data. In 
90µm×90µm area in the middle of four micro-wells a grid of 4×4 indentations was 
acquired by applying trigger force of 40-75 nN which resulted in 10-17µm of indentation. 
The choice of trigger force was made to obtain desired indentation intervals. The first 10 
µm of the force-indentation curves were fitted to a non-adhesive quasi-static contact 
model for a canonical indenter with a spherical tip that features continuous curvature at 
the transition point (Staunton, Doss, Lindsay, & Ros, 2016). 
 
 
 
 
 
 
 
𝑏 = 𝑅 cos 𝜃                                                                              (1) 
45 
 
𝛿(𝑎 ≤ 𝑏) =
1
2
𝑎ln (
𝑅 + 𝑎
𝑅 − 𝑎
)                                                                  (2) 
𝐹(𝑎 ≤ 𝑏) =  
𝐸
(1 − 𝜈2)
[
1
2
(𝑎2 + 𝑅2)ln (
𝑅 + 𝑎
𝑅 − 𝑎
) − 𝑎𝑅]                                       (3) 
𝛿(𝑎 > 𝑏) = 𝑎ln (
𝑅 + 𝑎
√𝑅2 − 𝑏2 + √𝑎2 − 𝑏2
) + 𝑎 cos−1 (
𝑏
𝑎
) cot 𝜃                              (4) 
𝐹(𝑎 > 𝑏)
=
𝐸
(1 − 𝜈2)
[𝑎2 cot 𝜃 cos−1 (
𝑏
𝑎
)
+ 𝑏 cot 𝜃√𝑎2 − 𝑏2 − 𝑎𝑅 + √(𝑅2 − 𝑏2)(𝑎2 − 𝑏2) +   𝑎2 ln (
𝑅 + 𝑎
√𝑅2 − 𝑏2 + √𝑎2 − 𝑏2
)
−
𝑅2
2
ln (
𝑎2𝑅2 − (𝑏2 − √(𝑅2 − 𝑏2)(𝑎2 − 𝑏2))
2
𝑏2(𝑅 + 𝑎)2
)]                                          (5) 
Dynamic measurements, with the same probe approach and retraction speed, were 
conducted to collect viscoelastic data. In the same 90µm×90µm area of each quasi-static 
measurement a grid of 2×2 indentations was acquired by applying trigger force of 3-7 nN 
which resulted in 1.5-6µm of quasi-static indentation. At the quasi-static indentations 
depth (δ0) oscillatory part of indentation (δ(ω)), with amplitude of 50 nm, at different 
angular frequency (ω) was applied by oscillating the z-piezo and measuring the 
oscillatory force respond of the sample. Later, amplitudes of force and indentation 
oscillation along with the phase lag between force-time and indentation-time curves were 
analyzed by the dynamic contact model derived from [Eq. 5] to calculate the viscoelastic 
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properties of sample (i.e. complex modulus). The dynamic experiment is carried out at 
frequencies (1, 3.16, 10, 21.54, 31.62, 46.42, 100 Hz). 
𝐺𝑆𝑝ℎ𝑒𝑟𝑒𝑐𝑜𝑛𝑒
∗ (𝜔) = 𝐺′(𝜔) + 𝑖𝐺"(𝜔) =
1 − 𝑣
4𝑎0,𝑆𝑝ℎ𝑒𝑟𝑒𝑐𝑜𝑛𝑒
(
𝐹(𝜔)
𝛿(𝜔)
− 𝑖𝑏ℎ=0𝜔) 
Where quasi-static contact radius 𝑎0,𝑆𝑝ℎ𝑒𝑟𝑒𝑐𝑜𝑛𝑒 is the solution of equation 6. 
                                          𝛿0 = 𝑎0ln (
𝑅+𝑎0
√𝑅2−𝑏2+√𝑎02−𝑏2
) +
𝑎0 cos
−1 (
𝑏
𝑎0
) cot 𝜃                                   (6) 
The viscoelastic features of collagen matrix can be explained by soft glassy model 
(Gevorkian, Allahverdyan, Gevorgyan, & Hu, 2011). Frequency sweep of the complex 
modulus (𝐺∗(𝜔)) was fitted to soft glassy model (Rother, Nöding, Mey, & Janshoff, 
2014; Sollich, 1998). 
Confocal reflectance microscopy 
Picoquant Microtime 200 confocal laser scanning microscope was used to obtain 
reflectance microscopy images. Each reflectance scan was 80µm×80µm, 512×512 pixels 
(156nm/Pixel) and tool approximately 2.5 minutes. A 60×, 1.1 NA, 1.5 mm W.D. water 
immerse objective was used (Olumpus LUMFL60X). Continuous blue diode laser (ex: 
470 nm) was used to illuminate the sample and the reflected light was collected and went 
through a 30 nm pinhole, and was detected by a single-photon counting modulus 
(Picoquant PDM series). Intensity micrograph of the scans are constructed in the 
operating software (Picoquant SymphoTime). 
47 
 
Live Cell Tracking: To quantify cancer cell migration parameters, we performed 12 hours 
live cell tracking at the time period of 72 hours of the culture. The movie was acquired 
using Zeiss inverted microscope along with Apotome 2.0. The microscope stage was 
surrounded by an in-house built incubator integrated with heater and Co2 supply to 
maintain optimum culture conditions. The z-stack images were acquired every 45 
minutes using 10x objective across a depth of 50-60 µm. The images were analyzed using 
cell tracking script within MATLAB (Cell Tracker, Budapest, Hungry). Each cell was 
manually tracked frame by frame to record the cell coordinates. Using the software, cell 
velocity and persistence was calculated for each cell across all the samples. We analyzed 
15 cells per movie with duplicate replicates. Each experiment was repeated three times 
such that 90 cells were tracked for each condition. The cell tracks were obtained using 
ibidi Chemotaxis and Migration Tool with an ImageJ plugin. 
Conditioned media Experiments: To perform conditioned media experiments, MDA-MB-
231 and MCF7 cells were cultured within our model in both monoculture and coculture 
condition for 4 days and media was collected on day 2 and day 4. The conditioned media 
was them centrifuged at 4000 RPM for 10 minutes at 4°c to remove any cell debris and 
further stored in -80 °c. To study the interactions between tumor and stromal cells, CAFs 
were cultured in monoculture condition within our 3D model for 4 days. Right after 
initial AFM measurement of the CAF only samples on day 0, day 2 conditioned media 
were added. The measurements were repeated on day 2 for the same samples followed by 
incubation in day 4 conditioned media and final measurement on day 4. 
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Western Blot: Western blot was performed according to a protocol provided by Bio-rad. 
Briefly, cells were lysed with a solution containing protease inhibitors. These samples 
were denatured in loading buffer. Proteins were separated with Gel Electrophoresis using 
a 10% polyacrylamide gel. The proteins were transferred to a PVDF membrane using 
Bio-rad Trans Blot Turbo blotting system. Membranes were blocked in 5% BSA and 
stained using mouse primary antibody and 800 nm tagged goat-anti-mouse secondary 
antibodies. These membranes were imaged using the licor Odyssey imager. For all our 
blots, vinculin was used as our loading control. 
RT-qPCR: Cells were isolated from our 3D tissue by incubating the samples in 2mg/ml 
collagenase I dissolved in 1X PBS for 30 minutes inside the incubator. The samples were 
then mechanically digested by pipetting. The collagenase I solution was then collected 
and centrifuged to form a cell pellet. The cells were then mixed with 300 µl RNA lysis 
buffer from Zymos to lyse the cell and collect total RNA. The RNA was purified using 
Zymos micro RNA prep Kit. To digest genomic DNA, isolated RNA was subjected to 
DNAse I treatment. The quality of RNA was confirmed by using NanoDrop and reading 
A260/A280 and A260/A230 values. Using 1 ug as starting RNA template, cDNA was 
prepared by using Quantabio cDNA supermix. The qRT-PCR was performed by using 
Luminaris Color HiGreen qPCR Master Mix (Thermo Scientific) with appropriate 
controls as per manufacturer’s Instructions. The qPCR plates were ran in triplicates using 
qTower  2.0 (Analytik Jena US). The primer sequences for various genes have been 
detailed in the table below. 
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ColI αI Forward Primer  CCTGGATGCCATCAAAGTCT 
ColI αI Reverse Primer CGCCATACTCGAACTGGAAT 
ColIII αI Forward Primer TAGGTCCATCTGGTCCTGCT 
ColIII αI Forward Primer CGAAGCCTCTGTGTCCTTTC 
FN Forward Primer GATGCTCCCACTAACCTCCA 
FN Reverse Primer CGGTCAGTCGGTATCCTGTT 
LOX Forward Primer TGCCAGTGGATTGATATTACAGATGT 
LOX Reverse Primer AGCGAATGTCACAGCGTA CAA 
TGF-β1 Forward Primer CAGAGGAGAGTGGCTGAAGG 
TGF-β1 Reverse Primer CCAGGACTCAATCCCTGTGT 
GAPDH Forward Primer TGCACCACCAACTGCTTAGC 
GAPDH Reverse Primer GGCATGGACTGTGGTCATGAG 
 
Quantification of cytokines within our 3D tumor model: The relative expression of 
cytokines was measured in our 3D samples by utilizing a custom made Quantibody array 
from Raybiotech. The custom-built array was built to study the expression levels of IL-4, 
IL-13, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and TGF-β within our samples. 
FBS containing CM was collected on day 4 from our samples and centrifuged at 4000 
rpm for 10 minutes at 4 °c. The supernatant was collected and stored at -80 °c until 
further use. Due to the presence of serum in our CM, the media was diluted 5-fold using 
sample diluent. A media blank was also added to our samples to normalize the 
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concentration of various cytokine within our samples. The assay was performed as per 
the manufacturer’s instruction and then shipped to Raybiotech for extracting the 
fluorescent values.  
Statistical Analysis: All the experiments were repeated three times with triplicates 
samples per condition. The invasion and elastic modulus data were analyzed using two-
way ANOVA with Sidak’s multiple comparison test. The standards for our cytokine 
expression data was plotted by using Sigmoidal 4PL curve in Prism and unknown 
concentration of our samples was interpolated from these curves. The relative expression 
was compared across samples by using one-way ANOVA followed by Dunnet multiple 
comparison test. All other data was analyzed using paired t-test. p value less than 0.05 
was considered significant for all the results. The statistical analyses and data 
representation were performed using GraphPad Prism v 7.0. All the data was presented as 
mean ± standard deviation. 
2.3 Results 
Fabrication of high-density 3D breast tumor array:  
In order to spatially organize cancer cells surrounded by stroma in our 3D tumor model 
we utilized micropatterning technique to engineer the platform. Specifically, the model 
was fabricated by using PDMS stamps and micromolding techniques to construct a high-
density array of microwells within collagen I hydrogel similar to the previous reports 
(Figure 2-1A) (Nelson et al., 2008). The stromal region of the model comprised of CAFs 
embedded in collagen I matrix while the tumor region was engineered by seeding breast 
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cancer cells (MDA-MB-231, MCF7) within microwells (Figure 2-1A). The model was 
further integrated with AFM to assess the biophysical properties of the stroma such as 
matrix stiffness as shown in Figure 2-1B. As a control, the tumor cells were also cultured 
in monoculture condition surrounded by collagen I in the stroma. Figure 2-1 C 
demonstrates successful fabrication of monoculture and coculture group where cancer 
cells are spatially organized in microwells (DsRed) surrounded by collagen I in absence 
or presence of CAFs. 
 
Figure 2-1: Microengineering of 3D In Vitro Tumor-Stroma Model. 
(A) Schematic of microfabrication of 3D tumor model. (B) Schematic of AFM. (C) 
Representative images showing microfabricated 3D high density tumor model across 
monoculture and coculture group.  
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Prior to proceeding to further biological experiments, we characterized breast cancer 
cells and CAFs for expression of proteins including α-smooth muscle actin (α-SMA), 
vimentin and pan-cytokeratin using immunofluorescence and western blot techniques. 
While CAFs expressed α-SMA, MDA-MB-231 and MCF7 cells did not show positive for 
the protein (Supplementary Figure 1, APPENDIX A). On the other hand, vimentin a 
mesenchymal marker, was expressed by MDA and CAFs while pan-cytokeratin was 
expressed by MDA-MB-231 and MCF7 cells (Supplementary Figure 1, APPENDIX A). 
These data indicated that the fibroblasts used for the experiments were activated while 
MDA-MB-231 and MCF7 breast tumor cells depicted varied genomic make up and 
phenotype.  
Breast cancer invasion assay 
To visualize the effect of CAFs on breast tumor cells invasion, we performed an initial 
assessment using phase contrast and fluorescent imaging across culture period of 4 days. 
Our results demonstrated single cell invasion of MDA-MB-231 cells into the stroma 
across all experimental conditions (Figure 2-2A). While in monoculture condition, these 
highly invasive cancer cells aggregated near the microwells, they demonstrated cellular 
scattering within stroma when cultured with CAFs (DsRed, Figure 2-2A). To quantify the 
phenomenon of cell scattering, we further utilized mathematical and computation 
geometry model known as delaunay triangulation. As shown in delaunay plots in Figure 
2-2B, MDA-MB-231 cells were initially located within microwells in both monoculture 
and coculture conditions on day 0. However, by day 4 of the culture period, tumor cells 
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scattered within the stroma, away from the microwells in coculture condition (Figure 2-
2B). In contrast, amongst monoculture group, these cells maintained their positions and 
aggregated near the microwells through the duration of culture period of 4 days (Figure 
2-2B).  To quantify cell dispersion across monoculture and coculture group, a custom 
metric migration index was calculated (see Materials and Methods) using triangulation 
graphs. As shown in Figure 2-2D the migration index of MDA-MB-231 cells upon 
coculture with CAFs was significantly higher than monoculture group on day 2 and day 4  
Such an analysis thus confirmed scattering of MDA-MB-231 cells in co-presence of 
CAFs thereby depicting enhanced invasion abilities of tumor cells in coculture condition. 
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Figure 2-2: Invasion Assay. 
 (A) Representative phase contrast and fluorescent images across monoculture and 
coculture group of MDA-MB-231 cells over culture period of 4 days. (B) Representative 
color coded delaunay triangulation graphs across experimental groups demonstrating 
cellular scattering. (C) Representative phase contrast and fluorescent images across 
monoculture and coculture group of MCF7 cells. (D) Migration Index of MDA-MB-231 
cells in monoculture and coculture conditions. (E) Quantified cluster area of tumor cells 
across experimental groups for day 2 and day 4 normalized to day 0. (F) Quantification of 
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percentage of EdU+ cancer cells between monoculture and coculture groups for MDA-
MB-231 and MCF7 cells. (G) Quantification of percentage of EdU+ CAF cells between 
monoculture and coculture groups. All scale bar represents 100 µm. * represents p value < 
0.05.  
In contrast to MDA-MB-231 cells, less invasive MCF7 cells depicted colony 
forming tendencies within the 3D tumor model, consistent to the previous reports (Kenny 
et al., 2007) (Figure 2-2C, Supplementary Figure 2B, APPENDIX A). During the culture 
period of 4 days, MCF7 cells clustered and filled up the microwells initially seeded into 
across all experimental groups (Figure 2-2C). While in monoculture condition, these less 
invasive cells invaded in the form of single cells, they formed clusters within coculture 
group in the stroma (Figure 2-2C, Supplementary Figure 2B, APPENDIX A). 
Quantification of normalized cluster area for day 2 and day 4 suggested that the 
clustering abilities of MCF7 cells enhanced in the presence of CAFs (Figure 2-2E).  3D 
z-stack actin images, shown in supplementary Figure 2 (APPENDIX A), further 
demonstrated that while MDA-MB-231 cells invaded across different planes, MCF7 cells 
invaded as single layer on top of the gels across all the conditions. Such a difference in 
invasion abilities between two tumor cells can be attributed to their genomic make up 
which was maintained when cocultured with CAFs (Kenny et al., 2007). Overall our 
results show that while MDA-MB-231 cells enhanced their invasion abilities, MCF7 cells 
depicted a higher tendency towards cluster formation in the presence of CAFs.  
 Tumor and stromal proliferation  
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It is widely known that tumor cells depict the phenomenon of invasion-proliferation 
dichotomy such that highly migratory cells lose their proliferative phenotype during 
invasion (Fedotov & Iomin, 2007; Hatzikirou, Basanta, Simon, Schaller, & Deutsch, 
2012; Hecht et al., 2015). In this context, EdU assay was performed to isolate the 
influence of CAFs on cancer cell migration from proliferation to visualize the dividing 
tumor cells through fluorescent imaging. As shown in Supplementary Figure 3 
(APPENDIX A), dividing cancer cells were marked for newly synthesized DNA (co-
expressing DsRed and GFP) and demonstrated proliferation across all experimental 
groups. Quantification for EdU positive cancer cell (DsRed) suggested an enhanced 
proliferative behavior of MCF7 cells upon coculture with CAFs as compared to their 
monoculture group (Figure 2-2F). On the other hand, MDA-MB-231 cells did not 
demonstrate any significant change in their proliferation rate when cultured with CAFs 
(Figure 2-2F). Such a stark difference in proliferative behavior of different breast tumor 
cell lines combined with invasion results suggest that while CAFs enhanced MDA-MB-
231 cells invasion, it primarily influenced the proliferation of MCF7 cells. 
In addition to tumor cell proliferation, we also investigated CAFs proliferation 
across different coculture groups within our 3D tumor model. CAFs (non DsRed cells) 
depicted proliferation across all the experimental groups as shown in Supplementary 
Figure 4 (APPENDIX A). An enhanced proliferation of CAFs was observed in presence 
of both MDA-MB-231 and MCF7 cells (Figure 2-2G, Supplementary Figure 4, 
APPENDIX A). These results are in agreement to previous clinical studies where the 
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cancerous tissue is observed to have high number of α-SMA expressing CAFs as 
compared to the healthy tissue (Nakagawa et al., 2016). Thus, overall these results 
suggest that the crosstalk between tumor and stromal cells can profoundly influence 
proliferative behavior of each other. 
 Real time single cell tracking of tumor cells 
While our invasion and proliferation assays provided comprehensive analysis of the 
influence of CAFs on tumor cells, in-depth mechanistic analysis including mode of 
migration, cell speed and persistence was performed through real time tracking of cancer 
cells across various experimental conditions (Figure 2-3). As shown in supplementary 
movie 1 and 2 (APPENDIX A), MDA-MB-231 cells migrated as single cells across 
monoculture and coculture conditions. The representative cell tracks further demonstrated 
enhanced dissemination of tumor cells in the presence of CAFs as compared to 
monoculture condition (Figure 2-3A). Using live cell tracking script, we quantified 
average cell speed and persistence and observed no significant difference for the bulk 
population of tumor cells between the experimental groups (Figure 2-3C, G). In contrast, 
when we analyzed the frequencies of various cell speeds in monoculture and coculture 
condition, higher percentage of MDA-MB-231 cells were observed to migrate at faster 
speeds (≥0.2 µm/min) in the presence of CAFs (Figure 2-3B) suggesting increased 
heterogeneity between tumor cells. Thus, after thresholding average cell speed at 0.2 
µm/min from the histogram in Figure 2-3B, enhanced number of cells were observed to 
migrate at faster speeds (≥ 0.2 µm/min) in coculture condition as compared to 
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monoculture group (Figure 2-3D). Similar analysis of distribution of cell persistence 
between two groups was made and increased number of MDA-MB-231 cells exhibited 
high persistence (≥ 0.3) in coculture condition (Figure 2-3H). While the percentage of 
cells at high persistence were more in coculture group, this outcome was not statistically 
significant (p = 0.0532) (Figure 2-3H). Thus, our results demonstrated that when MDA-
MB-231 cells are cocultured with CAFs, heterogeneity within tumor population increases 
with a greater number of cells acquiring enhanced migratory characteristics.  
 
Figure 2-3: Real Time Cell Migration Assay. 
(A) Representative cell tracks across monoculture and coculture group for MDA-MB-231 
and MCF7 cells respectively. (B) Histogram of cell speed and persistence for MDA-MB-
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231 and MCF7 cells within each group. (C) Average speed of MDA-MB-231 cells across 
all culture conditions. (D) Quantification of percentage of MDA-MB-231cells with 
average speed greater than or equal to 0.2 µm/min across all groups. (E) Average speed of 
MCF7 single cells across all culture conditions. (F) Quantification of cell speed for MCF7 
cells above 0.2 µm/min across all groups. (G) Average persistence of MDA-MB-231 cells. 
(H)  Quantification of percentage of cells with average persistence greater than 0.3 µm/min 
across all groups. (I) Average persistence of MCF7 cells. (J) Quantification of percentage 
of MCF7 cells with average persistence greater than 0.3 µm/min across all groups. * 
represents p value < 0.05. 
Similar real-time analysis was also performed for MCF7 cells as shown in Figure 
2-3 and supplementary movie 3, 4 (APPENDIX A). Interestingly we observed that while 
MDA-MB-231 cells migrated as single cells, MCF7 cells on the other hand demonstrated 
a high clumping and proliferative activity during migration across all experimental 
groups. While MCF7 clusters were also observed to migrate within the matrix, it was 
difficult to quantify them due to continuous change in cluster size either due to division 
or clumping of more cells. Thus, we limited our analysis to single cells that neither 
proliferated nor clumped during 12-hour long migration (see Methods). Representative 
cell tracks for each condition suggest no noteworthy change in tumor cell dissemination 
are shown in Figure 2-3A. Further analysis demonstrated no significant differences in cell 
speed and persistence between monoculture and coculture group (Figure 2-3E, I). In 
contrast to MDA-MB-231 cells, histogram of cell speed distribution also exhibited no 
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significant differences between monoculture and coculture group in terms of cell speed 
(Figure 2-3B). However, our analysis showed a slight decrease in number of cells at high 
persistence in coculture group as compared to monoculture condition (Figure 2-3J, p 
value=0.042). Thus, overall our findings indicate that while CAFs influenced the 
migration of MDA-MB-231 cells by enhancing the heterogeneity of tumor cell speed and 
persistence, migratory characteristics of less invasive MCF7 cells were mostly unaffected 
in the presence of CAFs as compared to monoculture condition. 
ECM remodeling characterization 
A major step forward in our 3D tumor model lies within its ability to assess biophysical 
properties of the ECM including collagen I deposition and matrix stiffness due to 
stromal-tumor cross talk. To visualize biomechanical changes, specifically collagen 
matrix deposition and stiffness within our platform, we utilized AFM along with 3D 
imaging based on confocal reflectance microscopy. As shown in Figure 2-4A and B, 
collagen I density did not change significantly throughout the culture period of 4 days in 
monoculture group for both tumor cell lines. However, upon coculture with CAFs, 
collagen I expression gradually increased on day 2 and day 4 of the culture (Figure 2-4A, 
B). Such an increase in collagen deposition further influenced stiffness of the matrix, 
which was quantified by measurement of the elastic modulus of the matrix using AFM. 
As shown in Figure 2-4C, there was no significant difference in the stiffness of the matrix 
in monoculture and coculture condition at day 0. However, at day 4, coculture condition 
exhibited significantly marked difference in the matrix stiffness as indicated by higher 
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elastic modulus as compared to monoculture group (Figure 2-4C). Similar trend was also 
observed for MCF7 group where coculture condition had significantly enhanced elastic 
modulus at day 4 (Figure 2-4C).  Furthermore, when we grouped the measurements for 
each experimental condition and compared across various days of the culture period, we 
observed that neither the monoculture of tumor cells (MDAMB-231, MCF7) nor CAFs 
induced any change in the matrix stiffness (Figure 2-4C). Interestingly, only during the 
coculture of cancer and stromal cells, significant increase in elastic modulus was 
observed (Figure 2-4C). Our results also show that while change in elastic modulus of 
ECM in coculture condition of MDA group was progressive across culture period, it was 
delayed for MCF7 cells till day 4 (Figure 2-4C). Thus, overall our results demonstrate 
that a significant crosstalk is necessary between tumor and stromal cells to alter the 
stiffness of the tumor matrix. 
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Figure 2-4: ECM Stiffness Assay. 
(A), (B) Representative confocal images showing collagen deposition across various group 
of MDA-MB-231 and MCF7 cells over culture period of 4 days. (C) Elastic modulus of 
ECM across different culture conditions across 4 days demonstrating significant crosstalk 
between tumor and stromal cells. All scale bar represents 10 µm. (D),(E) Quantification of 
RNA expression for various matrix related genes across monoculture and coculture 
conditions of MDA-MB-231 and MCF7 cells. * represents p value < 0.05. 
To further our understanding on various biophysical changes caused by tumor-
stromal crosstalk we also analyzed different parameters of dynamic modulus including 
storage (G’) and loss modulus (G’’) as well as loss tangent (loss modulus/storage 
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modulus) to comprehend the viscoelastic properties of the matrix (Supplementary Figure 
5, APPENDIX A). Our results demonstrated a significant increase of storage modulus 
(G’) when MDA-MB-231 cells were cocultured with CAFs as compared to monoculture 
group on day 4 (Supplementary Figure 5A, APPENDIX A). On the other hand, the 
change in loss modulus (G’’) was not similar across monoculture and coculture condition 
(Supplementary Figure 5A, APPENDIX A). Similar change in dynamic modulus 
properties were also observed for MCF7 group where change in G’ was more in coculture 
group as compared to G’’ (Supplementary Figure 5C, APPENDIX A). This trend can 
also be inferred from loss tangent graphs where the absolute values were always less than 
1 (Supplementary Figure 5B, D, APPENDIX A). Thus, our results demonstrate that while 
a significant change was observed in viscoelastic properties of stroma matrix, elastic 
properties of collagen enhanced more in presence of CAFs as compared to viscosity of 
the matrix. 
Gene Expression Profile influencing ECM Remodeling 
To further probe ECM remodeling within our coculture samples, we performed a 
quantitative analysis on ECM deposition by performing qRT-PCR on matrix related 
genes including alpha I type I collagen (ColIα1), alpha I type III collagen (ColIIIα1), 
fibronectin (FN), Lysyl oxidase (LOX) and transforming growth factor beta (TGF-β) 
across different experimental groups (Figure 2-4D, E). Similar to confocal imaging, our 
gene expression results demonstrated higher expression of matrix proteins including Col 
IαI, Col IIIαI and FN amongst coculture groups as compared to monoculture of either 
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tumor cell line (Figure 2-4D, E). While coculture of highly metastatic MDA-MB-231 
cells with CAFs did not show upregulation of cross-linking enzyme LOX and 
multifunctional cytokine TGF-β, coculture of less invasive MCF7 cells with CAFs 
demonstrated an increased expression of these fibrosis related genes thereby suggesting a 
differential influence of CAFs on tumor cells of varied tumorigenicity (Figure 2-4D, E).  
Assessment of tumor-CAF cross talk for ECM remodeling 
 
Figure 2-5: Conditioned Media Assay. 
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 (A), (B) Representative confocal images showing deposition of collagen fibers when 
CAFs are incubated with CM obtained from various monoculture and coculture groups. 
(C) Elastic modulus of ECM for CAF only group upon incubation with CM from 
monoculture and coculture group of MDA-MB-231 cells. (D) Elastic modulus of CAF only 
group when incubated with CM from various groups of MCF7 cells. All scale bars 
represent 20 µm. * represents p value < 0.05. 
Since our elastic modulus results demonstrate the necessity for crosstalk between 
tumor cells and CAFs for ECM remodeling, we next evaluated the mode of interaction 
between these two cell types. Specifically, we studied that whether soluble factor 
signaling between tumor cells and CAFs can significantly increase the matrix stiffness 
over the culture period. To perform these studies, we collected conditioned media (CM) 
from different experimental groups of MDA-MB-231 and MCF7 cells and subsequently 
added them on monoculture of CAFs followed by assessment of elastic modulus of the 
matrix. As shown in Figure 2-5A, C, collagen fiber density and matrix stiffness of CAFs 
only group was significantly enhanced when CM from monoculture of MDA-MB-231 
cells was added to the samples on day 2 and 4 of the culture. Surprisingly, no significant 
change in matrix stiffness was observed when CM from coculture group of MDA-MB-
231 cells was added on CAF only group across entire culture period (Figure 2-5A, C). 
Similar trend was also observed across MCF7 experimental conditions, where CM of 
monoculture of MCF7 cells enhanced the elastic modulus of the matrix while the 
coculture CM had no significant impact (Figure 2-5B, D). Thus, overall, we can say that 
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tumor cells crosstalk with CAFs in a unidirectional fashion such that tumor cells secrete 
biochemical cues that are sensed by CAFs to initiate ECM remodeling. 
Assessment of Soluble Factor mediated CAF proliferation and Genetic Changes 
 
Figure 2-6: CAF Proliferation Assay. 
(A) Representative immunofluorescent images showing proliferation of CAFs upon 
incubation with CM from various groups using Edu assay. (B) Quantification of 
proliferative CAFs in various CM groups. (C), (D) Quantification of matrix related gene 
expression in CAF only group upon incubation with various CM. 
After establishing a significant role of soluble factor signaling in modulation of 
matrix biophysical properties by CAFs, we next wanted to evaluate changes in CAFs 
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phenotype and genotype under various CM experimental groups. In this regard, we first 
analyzed CAF proliferation upon incubation with CM obtained from different 
experimental groups of MDA-MB-231 and MCF7 cells. As shown in figure 2-6A, CAFs 
demonstrated proliferation under all the conditions. However, no significant difference 
was observed in proliferative behavior of CAFs when they were incubated with CM 
obtained either from monoculture or coculture group of MDA-MB-231 cells (Figure 2-
6B). On the other hand, MCF7 monoculture CM enhanced CAF proliferation rate as 
compared to the MCF7 coculture CM although the difference was not statistically 
significant (p=0.08, Figure 2-6B). These results are in line with our elastic modulus 
results where a significant increase in matrix stiffness was evident in MCF7 monoculture 
CM as compared to MCF7 coculture CM. Thus, overall these results suggest a 
differential influence of biochemical cues released by various tumor cells on biological 
traits of CAFs including proliferation. 
 Similar reassessment was also performed for expression of matrix genes in CAFs 
incubated with CM obtained from various experimental groups. Our results demonstrated 
that CAFs did not exhibit significant change in expression of any of the matrix genes 
across monoculture and coculture CM for both tumor cells (Figure 2-6C, D). These 
results thereby suggest that soluble factor signaling did not induce any genetic changes 
within CAFs. Therefore, in summary our results suggest that soluble factors from MDA-
MB-231 cells do not induce any change in genetic and biological traits of CAFs while 
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soluble factors released from MCF7 induced an upregulation of CAFs proliferation while 
maintaining their gene expression profiles.  
 Molecular Profiling of Tumor Cell Secreted Factors and Activation of Specific 
Receptors in CAFs 
 
Figure 2-7:Quantification of Pro-Fibrotic Factors in Tumor Conditioned Media. 
 (A) Quantification of IL-13, PDGF-AA, PDGF-BB, PDGF-AB in CM obtained from 
various groups. (B) Representative Immunofluorescent Images showing enhanced 
activation of PDGFR α/β in CAFs upon incubation with CM obtained from monoculture 
and coculture group of MDA-MB-231 and MCF7 cells. All scale bar represents 20 µM. * 
denotes p<0.05.  
Based on our CM results, it is clear that tumor cell secreted factors play a crucial role in 
upregulating the stiffness of the matrix by CAFs. To better understand this molecular 
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mode of interaction and the composition of tumor cell CM, we next performed ELISA to 
observe the presence of various known cytokines that participate in fibrosis. Specifically, 
we studied the expression of Interleukin 4 (IL-4), Interleukin 13 (IL-13), platelet derived 
growth factor AA (PDGF-AA), platelet derived growth factor AB (PDGF-AB), platelet 
derived growth factor BB (PDGF-BB), platelet derived growth factor CC (PDGF-CC) 
and transforming growth factor β (TGF-β). Based on our matrix stiffness results observed 
in our CM experiments, we hypothesized that the concentration of fibrotic factors would 
be significantly higher within our tumor (MDA-MB-231, MCF7) monoculture CM as 
compared to their respective coculture CM. Additionally, we also studied the expression 
of these cytokines by CAF monoculture CM to provide a broad understanding on 
expression of these factors by both tumor and stromal cells. Our results showed 
undetectable levels of IL-4 and PDGF-CC across all the experimental conditions. We 
speculate that these cytokines were not detected due to the low concentration of the 
analytes across all the samples. Further analysis showed expression of multiple cytokines 
including IL-13, PDGF-AA, PDGF-BB in all our samples (Figure 2-7A). We also 
observed detectable levels of PDGF-AB in various conditions, although it was found to 
be undetectable for CAF-CM (Figure 2-7A). Interestingly, we observed a significantly 
higher expression of PDGF-AA and PDGF-BB in MCF7 monoculture CM as compared 
to MCF7 coculture CM and CAF CM (Figure 2-7A). PDGF-AA was also observed to be 
highly expressed in MDA-MB-231 monoculture CM as compared to respective coculture 
CM and CAF CM however p value was greater than traditional value of 0.05 (p=0.10, 
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p=0.12, Figure 2-7A). Such high expression of PDGF-AA and PDGF-BB across tumor 
cell CM as compared to CAF-CM suggest that these ligands are primarily expressed by 
tumor cells. Additionally, these results are in accordance to our hypothesis where tumor 
monoculture CM had high expression of the fibrotic factors as compared to coculture CM 
thereby corroborating our elastic modulus results for all our conditioned media samples. 
To validate our ELISA results we next performed IF staining for phosphorylated PDGFR 
α/β (Figure 2-7B). Our results demonstarted that the activation of alpha and beta 
receptors were more prominent in CAFs incubated with MDA-MB-231/MCF7 
monoculture CM as compared to their respective coculture CM (Figure 2-7B).  
 
Figure 2-8: Effect of PDGFR Inhibitor on CAF Based Desmoplasia. 
(A) Representative immunofluoroscent images showing reduced activation of PDGFR 
α/β receptor after addition of drugs at different concentration in MDA-MB-231 
monoculture CM. (B), (C) Elastic modulus assessment of the matrix in CAF only group 
upon incubation with MDA-MB-231 and MCF7 CM supplemented with different 
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concentration of CP673451 respectively. All scale bar represents 20 µm. * denotes p 
value <0.05. 
Inhibition of PDGFR pathway in CAFs to study its role in fibrosis 
To investigate the role of tumor secreted PDGF AA/BB on CAF induced fibrosis, we 
next performed functional assessment by incubating tumor monoculture CM with 
concentration sweep of specific inhibitor of PDGFR (CP673451). We reassed activation 
of receptors and elastic modulus of the matrix in CAF only samples across the culture 
period. Our results demonstarted enhanced significant reduction in activation of the 
receptor at 50nM and 1uM concentration of the drug in MDA-MB-231 monoculture CM 
as shown in figure 2-8 A. Our quantitivate analysis demonstrated that the elastic modulus 
of the matrix significantly increased when CAFs were incubated with tumor monoculture 
CM (Figure 2-8B,C). At low concentration of the drug (~50 nM), similar increase in 
elastic modulus of the matrix was observed. However, when the concentration of the drug 
was increased to 1 µM no significant change in ECM stiffness was observed at day 2 and 
day 4 of the culture as compared to day 0 (Figure 2-8 B). Similar observation was also 
made when CAF only group was incubated with MCF7 monoculture CM substituted with 
1 µM concentration of the drug (Figure 2-8C). Overall, these AFM results in the presnce 
of PDGFR inhibitor validate our ELISA findings and confirm that tumor cells secreted 
PDGF-AA/BB ligands are profibrotic in nature which activate desmoplastic recation 
within CAFs.  
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2.4 Discussion 
CAFs are known to participate in tumor progression by depositing various proteins, 
degradation of the matrix as well as by increasing the stiffness of the ECM (Kalluri & 
Zeisberg, 2006). While the role of matrix stiffness in tumorigenicity has been studied by 
various in vivo and in vitro models, not much is known about the role of tumor and 
stromal cell crosstalk on modulation of biophysical properties of the matrix (Chaudhuri et 
al., 2014; Ehrbar et al., 2011; Lang et al., 2015; Peela et al., 2016).  In this study we 
developed a novel high-density 3D breast tumor model that can be utilized to 
mechanistically study the influence of tumor and stromal cells such as CAFs on alteration 
of biophysical properties of the matrix including collagen I deposition as well as stiffness. 
Due to the open top nature of the platform, we could integrate the platform with AFM to 
indent the matrix at nano scale to assess dynamic alteration of elastic modulus during live 
migration of cancer cell. Our study primarily focused on performing various functional 
and molecular assessments that helped in dissecting the key molecular regulators of the 
tumor stroma crosstalk that play a crucial role in ECM remodeling. 
Our results demonstrated that when both the tumor cells MDA-MB-231, MCF7 cells 
and cultured alone, no significant change is observed in matrix stiffness and collagen I 
deposition over the entire culture period. However, when the tumor cells are cocultured 
with CAFs there is significant and gradual increase of the matrix stiffness for 4 days. 
These findings are in line with previous in vivo studies which have shown that 
transplantation of tumor cells with CAFs in mouse models lead to an enhanced fibrotic 
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and stiff tissue as compared to the injection of tumor cells alone (Ken Takai et al., 2016). 
Unlike previous in vivo and in vitro studies, we also assessed the elastic modulus when 
CAFs were cultured alone and observed no change in matrix stiffness across the entire 
culture period. We also observed that CAFs demonstrated a high proliferative index when 
cultured with tumor cell as compared to the monoculture condition. Similar increase in 
CAF population within the cancerous tissue have been observed by many previous in 
vivo and clinical studies (Acerbi et al., 2015; Ken Takai et al., 2016). Many studies have 
correlated high proliferation of CAFs to a more dense and fibrotic cancerous tissue (Santi 
et al., 2018; Ken Takai et al., 2016). Similar phenomenon was also observed within our 
samples where high proliferation of CAFs within coculture samples was primarily 
associated with enhanced elastic modulus of the matrix.  Interestingly our qPCR results 
demonstrate that unlike tumor cells, CAFs have high expression of all matrix related 
genes, however still no change in matrix stiffness was observed when cultured alone. 
This clearly suggest that a crosstalk between tumor cells and CAFs is crucial such that 
tumor cells signal to CAFs to initiate and activate matrix deposition and increase in 
stiffness of the ECM.  
While most of the previous studies primarily focused on the role of CAFs on 
biophysical alteration of the matrix, our study took a step forward by analyzing the mode 
of mechanism by which tumor cells and CAFs interact with each other to participate in 
ECM remodeling.  Our CM results suggest that tumor cells and CAFs can interact with 
each other through paracrine signaling. We observe that tumor cell secreted factors are 
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essential to induce CAF based desmoplasia. Similar observation was made by Erik Sahai 
group who demonstrated that tumor secreted soluble factors participate in nuclear 
localization of transcription factor, Yes associated protein (YAP), to play role in normal 
fibroblast transformation, collagen deposition and proliferation (Calvo et al., 2013; 
Lampi & Reinhart-King, 2018). In this study when NF’s were cultured with 4T1 cell CM, 
the normal fibroblast cells demonstrated significant increase in gel contraction as 
compared to their culture in DMEM based media (Calvo et al., 2013). Additionally, CM 
induced NF cells significantly supported cancer cell invasion as compared to control NF 
cells suggesting crucial role of tumor secreted factors in inducing CAF like phenotype 
(Calvo et al., 2013). In line of these observation, our results further demonstrated an 
interesting trend where CM obtained from tumor monoculture group significantly 
induced the CAF based fibrosis whereas coculture CM failed to induce any significant 
change in the matrix stiffness. These findings thereby suggest that tumor cells secreted 
pro-fibrotic cytokines can be sensed by CAFs due to the presence of their respective 
receptors on their membrane. We further speculate that while these pro-fibrotic factors 
are available within the CM obtained from tumor monoculture, they are exhausted within 
the coculture CM thereby causing a differential effect on CAF based tumor fibrosis. We 
confirmed our hypothesis of differential expression of pro-fibrotic factors using ELISA 
where higher expression of platelet derived growth factor (PDGF)-AA and BB was 
observed in both MDA-MB-231 and MCF7 monoculture CM as compared to their 
respective coculture CM and CAF CM. Multiple in vivo studies in the past have shown 
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that PDGF can play an essential role in fibrosis in various diseases including pulmonary 
fibrosis, hepatic fibrosis, lung cancer and breast cancer (Antoniades et al., 1990; Shao et 
al., 2000; Ying et al., 2017). While most of the cancer fibrotic models have primarily 
studied the effect of more studied TGF-β and CTGF based signaling, very few studies 
have focused on the effect of PDGF in cancer desmoplasia (Kozono et al., 2013; 
Papageorgis et al., 2017; Ken Takai et al., 2016). For instance, in year 2000, shao et. al. 
created a desmoplastic xenograft model by utilizing Er+ breast tumor W9 cells which in 
the absence of estrogen led to enhanced accumulation of collagen and stromal cells 
within the tumor microenvironment (Shao et al., 2000). Authors demonstrated that if W9 
cells were transfected with a PDGF-A mutant domain the stromal fibrosis is significantly 
attenuated thereby demonstrating crucial role of  PDGF signaling in breast carcinoma 
desmoplasia (Shao et al., 2000). While previous PDGF focused studies have utilized 
xenograft models to study its influence in fibrosis; we had limited understanding about 
the interplay of the cytokine due to interaction between two cell types (i.e. tumor cells 
and CAFs) due to the presence of various confounding factors such as other cell types. To 
the best of our knowledge, this is the first study in which PDGF signaling has been 
identified to play an essential role in desmoplasia due to the interaction between breast 
tumor cells and CAFs. Additionally, due to the convenience of 3D model, we were able 
to confirm that tumor secreted PDGF ligands interacted with their specific receptors on 
CAFs to induce stromal desmoplasia. Using specific inhibitor against PDGFR 
(CP673451), we observed a minimal increase in matrix stiffness when the tumor cell CM 
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was substituted with 1µM concentration of the drug. These functional assessment results 
in addition to ELISA observation thereby suggest a crucial unidirectional crosstalk 
between two cell types where PDGF ligands are mainly secreted by tumor cells that bind 
to PDGFRs on CAFs and participate in desmoplasia. 
Another major finding from our study was how breast tumor cells of varied genomic 
make-up enhance their tumorigenicity across various hallmarks of cancer in the presence 
of CAFs within our model. Our findings clearly suggested that while MDA-MB-231 cells 
invaded more into the stroma in coculture condition as compared to monoculture group, 
MCF7 cells depicted higher clustering tendency. Further, our proliferation assays 
demonstrated that MCF7 cells had higher proliferative rate in the presence of CAFs while 
MDA cells proliferation rate diminished marginally. These results are in tune with the 
notion when cells become more invasive, they lose their proliferative tendency (Fedotov 
& Iomin, 2007; Hatzikirou et al., 2012). Similar conclusion can also be drawn from our 
live cell tracking results where CAFs influenced MDA-MB-231 cell speed and increased 
the heterogeneity of the tumor cell population, no discernible difference was observed for 
MCF -7 group in terms of cell speed. Thus, using an in vitro 3D tumor model, we were 
able to tease apart the necessary interaction between tumor and stromal cells and have 
successfully shown their significance in matrix remodeling as well as tumor progression.  
2.5 Conclusion 
In conclusion, we fabricated a 3D high density tumor stroma model to study the role 
of breast tumor cells and CAFs on ECM remodeling. By integrating our platform with 
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AFM, we clearly observed that the crosstalk between tumor cells and CAFs is necessary 
to induce desmoplasia. Additionally, for the first time, we provided evidence that tumor 
cells and CAFs interact with each other through soluble factor signaling. We also 
observed that tumor cells are the primary source of pro-fibrotic cytokines such that the 
elastic modulus of CAF embedded matrix was significantly enhanced when incubated 
with tumor monoculture CM as compared to coculture CM. Using ELISA, we observed 
that monoculture CM from MDA-MB-231 and MCF7 cells had higher expression of 
PDGF-AA and BB ligands as compared to their respective coculture CM. Lastly, we 
confirmed the role of PDGF signaling in CAF based desmoplasia by inhibiting the 
PDGFR activation using specific inhibitor.   
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 Chapter 3  
Identification of Tumor Secreted Factors Participating in Desmoplasia using Liquid 
Chromatography Mass Spectrometry 
3.1 Introduction:  
Intercellular signaling between various cell types is crucial in all aspects of 
developmental biology including tissue formation, tissue homeostasis and various 
pathophysiological conditions including cancer (GM., 2000b). Two cell types can 
communicate with each other either through physical cell-cell interaction or through 
secretion of cytokines including growth factors, hormones and chemokines that can act in 
paracrine/autocrine manner (GM., 2000b). While cell-cell interaction is shown to play a 
crucial role in regulating tissue architecture including apical-basal polarity of epithelial 
cells and modulating them in response to changes in TME, soluble factor signaling can 
regulate various other processes including cell proliferation, migration, differentiation, 
apoptosis etc (GM., 2000a, 2000b). In cancer, soluble factor signaling has been 
demonstrated to play a crucial role at all steps of metastatic cascade (Sever & Brugge, 
2015). Most of these soluble factors including TGF-β, PDGF, FGF, IGF, EGF, HGF, pro- 
and anti-inflammatory signals are released by one cell type and are sensed by either same 
cell or other cell type due to the activation of receptors that can regulate various 
downstream pathways (GM., 2000b; Sever & Brugge, 2015; Witsch, Sela, & Yarden, 
2010). For instance, it is well known that in cancer TGF-β is released by both cancer cells 
and stromal cells which upon activation can bind to multiple receptor types and 
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participate in either tumor suppression or tumor promotion in a context dependence 
manner (Massagué).  
 Multiple techniques are available which can be advantageous to study the 
expression of soluble factor signaling in different sample types including 2D cell culture, 
3D tissue sample, serum and plasma. These techniques mainly include ELISA, western 
blot and Luminex that can be used to study the expression of soluble factors with high 
sensitivity and specificity (Emilia Manole, 2018; Leng et al., 2008). However, all these 
assays are biased in nature and can only be used to quantify the expression of limited 
number of pre-determined factors across different sample types. On the other hand, 
implementing proteomics using liquid chromatography-mass spectrometry (LC-MS) 
provides an advantage to visualize and quantify the expression of both known and 
unknown factors within a sample type (Harlan & Zhang, 2014). Multiple studies have 
utilized the technique of proteomics to identify crucial soluble factors whose regulation 
can be changed in a pathological state as compared to normal tissue (Lawrence et al., 
2015; Srinivas, Verma, Zhao, & Srivastava, 2002; Yanovich et al., 2018). In this chapter 
we have utilized LC-MS as a technique to identify the secretome of tumor cells and 
CAFs in their monoculture and coculture condition within our 3D microengineered tumor 
stroma model. Our results suggest expression of various soluble factors that are 
associated with disease progression and participate in making the microenvironment 
tumor permissive in nature. We also discuss some of the possible factors that needs to be 
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optimized to fully utilize the advantage of LC-MS while working with 3D microscopic 
samples. 
3.2 Materials and Methods: 
Preparation and Collection of CM for LC-MS: 
We first fabricated our 3D tumor stroma model as explained previously in chapter 2. The 
model was cultured for 48 hours in regular media comprising of DMEM 1X substituted 
with 10% FBS, 1% PenStrep and 1% L-Glutamine. After 48 hours, the samples were 
washed with 1X PBS 3 times followed by incubation in serum free media. At day 4, the 
media was collected and centrifuged at 4000 rpm at 4°c for 10 minutes before storing at -
80°c until further use. 
Isolation of Proteins from Conditioned Media: 
The proteins in conditioned media were concentrated by utilizing methanol chloroform 
protein precipitation protocol followed by multiple ultracentrifugation steps ran for 
differential times. Briefly, add 1 volume of methanol to the protein sample and vortex 
followed by addition of ¼ volume of chloroform to the protein sample and mixing well 
by rigorous vortex. Next, ¾ volume of DI water is added so that the sample looks cloudy. 
The prepared solution is then centrifuged at 14000 g for 2 minutes and the supernatant is 
discarded carefully to avoid disruption of protein precipitate in between layers. The 
remaining pellet is again mixed with 1 volume of methanol and centrifuged at 14000 g 
for 3 minutes followed by careful removal of supernatant. The remaining solution is then 
air dried under vacuum and then resuspended in SDS buffer for In-gel digestion.   
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Removal of Serum Proteins from Conditioned Media and preparation of LC-MS samples: 
The proteins were separated by running on SDS Gel Page. Using a molecular weight 
ladder and Coomassie blue staining, the albumin band was detected at 68 KDa. The 
identified band was cut, and the rest of the gel was then subjected to in-gel digestion. 
Briefly the gel pieces were cut and washed with 10 volumes of Millipore water. The 
Coomassie blue staining was removed from gel pieces using100 mM (NH4 )HCO3 / 50% 
Methanol. The gel was then dehydrated using 200μl of 25 mM (NH4 )HCO3 /50% 
Acetonitrile followed by another incubation in 100% Acetonitrile for 30 seconds. 
To prepare samples for trypsin digestion, the gel pieces were rehydrated for 5 minutes at 
room temperature in 20μl [10ng/μl] Trypsin (Promega Sequence Grade Modified) in 
25mM (NH4 )HCO3 / 3% Acetonitrile [ pH =~8.5]. The rehydrated gel was then 
incubated with a minimum amount of 25mM (NH4 )HCO3 overnight at 37°c. Peptide 
were recovered 50μl Millipore water / 1% FA by vortexing 10 minutes at room 
temperature (max speed). An additional extraction was performed using 80μl of 70% 
ACN / 25% H2O / 5% FA. The sample was dried in vacuum for 1-2 hours and later 
reconstituted in 20μl of Millipore water / 0.1% FA by incubating for 5 minutes at room 
temperature with intermittent vortexing to use for LC-MS. 
Acquiring LC-MS data: 
The samples were run at the mass spectrometry core facility of Arizona State University 
at AB SCIEX 4800 MALDI TOF/TOF/ MS mass spectrometer. The results obtained 
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from mass spectrometry data was analyzed for peptide information and protein groups 
using MASCOT search engine. The results with FDR<0.05 were considered significant. 
Gene ontology, Protein-Protein Interaction studies and KEGG pathway analysis on LC-
MS Data: 
The statistical test including one tail t-test was ran on acquired LC-MS data using 
Perseus. The data with FDR<0.05 was considered statistically significant. Next, gne 
ontology was performed on differentially expressed proteins using DAVID and Pather 
Online tools. The Protein-Protein Interaction Maps as well as KEGG Pathway analysis 
were created using STRING database. 
3.3 Results: 
Identification of secreted factors in CM obtained from various culture groups. 
 
Figure 3-1: Quantification of Proteins Across Various Culture Groups. 
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(A), (B) Venn diagram representing number of unique and common proteins detected 
across various culture groups.  
In order to observe the difference in expression of various soluble factors between 
monoculture and coculture groups of MCF7 cells, we first prepared a Venn diagram to 
visualize the number of proteins secreted either uniquely or commonly by each cell type 
including monoculture of MCF7, monoculture of CAFs and coculture of MCF7 cells with 
CAFs. As shown in figure 3-1A, we identified 81 proteins across monoculture and 
coculture groups of MCF7 cells and CAFs. Amongst these 81 identified proteins, 19 
proteins were secreted by monoculture of MCF7 cells and 41 proteins were expressed by 
monoculture of CAFs, whereas 75 proteins were observed in MCF7+CAF coculture 
group. Our analysis demonstrated that 35 out of 75 proteins were expressed uniquely due 
to the coculture of MCF7 cells with CAFs suggesting a crucial crosstalk between two cell 
types modulating the biochemical milieu of the TME (Supplementary figure 1, 
APPENDIX B). We also observed that 5 proteins were uniquely expressed by 
monoculture of CAFs whereas only 1 protein was uniquely expressed by monoculture of 
MCF7 cells. 
 Similar analysis was repeated for monoculture and coculture groups of MDA-
MB-231 cells with CAFs. As shown in figure 3-1B, 35 different proteins were identified 
for various groups of MDA-MB-231 cells and CAFs. Similar to MCF7 cells we created a 
venn diagram and observed that 7 out of 35 proteins were found in CM obtained from 
monoculture of MDA-MB-231 cells whereas 31 proteins were secreted by CAFs. 
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Further, 27 out of 35 proteins were found in CM obtained from coculture of MDA-MB-
231 cells with CAFs.  As opposed to secretome of coculture of MCF7 cells with CAFs, 
we observed a very low number of proteins (~2 proteins including ECM protein 1 and 
heat shock cognate 71 KDA protein) being uniquely expressed by coculture of MDA-
MB-231 cells with CAFs. Additionally, only 1 protein (plasminogen) was uniquely 
expressed by monoculture of MDA-MB-231 cells whereas 7 proteins were uniquely 
expressed by monoculture of CAFs.  
Gene ontology analysis and Protein-Protein Interaction Studies  
 Since we observed an enhanced ECM stiffness and collagen density within our 
coculture groups (MDA-MB-231+CAF and MCF7+CAF), we first evaluated the 
biological role of proteins which were uniquely expressed due to the coculture of tumor 
cells with CAFs. As noted before, coculture group of MCF7 cells with CAFs had high 
number of secreted proteins (35) as compared to coculture group of MDA-MB-231 cells 
with CAFs (2). Thus, we performed our next analysis including gene ontology and 
protein-protein interaction studies on list of identified factors which were uniquely 
expressed in secretome obtained from MCF7+CAF group.    
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Figure 3-2: Gene Ontology Results. 
Pie Chart representing Gene Ontology results for biological process, molecular function 
and cellular component for unique proteins detected in MCF7+CAF group. 
Our analysis demonstrated that the factors secreted uniquely due to the coculture 
of MCF7 cells and CAFs participated in various biological functions including response 
to stimulus, cellular component organization, vesicle mediated transport, receptor 
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mediated endocytosis, ECM organization and supramolecular fiber organization (Figure 
3-2). Interestingly, about 15% of the proteins were observed to play a crucial role in cell-
cell adhesion whereas 12% of the proteins were found to participate in ECM organization 
(Supplementary table 1, APPENDIX B). We also observed that about 9% of the secreted 
factors are secreted in response to hypoxia and further participate in regulation of 
apoptotic process thereby suggesting the role of secreted factor in tumor homeostasis 
(Supplementary table 1, APPENDIX B). In terms of molecular function, 77% of the 
secreted factors were observed to be responsible for protein binding and about 21% of 
proteins participated in cell-cell adhesion (Supplementary table 2, APPENDIX B). When 
the cellular location for each of the secreted factors was studied, we visualized that about 
88% of proteins are usually found in extracellular exosome and about 65% and 62% are 
found in cytoplasm and cytosol respectively (Supplementary table 3, APPENDIX B). An 
average of 30% identified proteins were found in extracellular space suggesting that the 
secreted factors observed into the conditioned media came from different cellular 
locations (Supplementary table 3, APPENDIX B).   
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Figure 3-3: Protein-Protein Interaction Maps for Unique Proteins Detected in 
MCF7+CAF Group. 
We next proceeded to study the molecular and physical interaction of different 
proteins that were identified within the secretome of coculture group of MCF7 cells with 
CAFs. Using STRING database for all the identified proteins we observed that the 
secreted factors interacted with each other with low enrichment p value (5.55 e-16) 
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suggesting a significant biological interaction between them as compared to a random set 
of proteins obtained from genome (Figure 3-3). The STRING database suggested that 34 
proteins interacted with each other with an average node degree of 3.35. Interaction 
between 28 out of 35 proteins were identified as known interactions which have either 
been obtained from curated databases or experimentally determined (Figure 3-3). Some 
of the interactions between proteins were also predicted based on gene neighborhood, 
gene fusion and gene co-occurrence while others are expected due to protein co-
expression and homology (Figure 3-3).  
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Figure 3-4:Protein-Protein Interaction Map Highlighting the Interaction Amongst 
Proteins Which are Known to Participate in ECM Organization. 
We also visualized the protein-protein interaction between the genes that 
specifically participated in ECM organization and observed genes related to SPARC, 
laminin subunit beta 1, integrin beta 1 and Peroxidasin homolog as prominent players 
(Figure 3-4).  We next studied the KEGG pathway analysis for the identified proteins and 
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observed high number of proteins participating in biosynthesis of amino acids, carbon 
metabolism, Tight junction, Glycolysis, PI3K-AkT signaling pathways, focal adhesion 
amongst others (Supplementary table 4, APPENDIX B).  
Identification of tumor secreted factors participating in CAF induced desmoplasia. 
Since our elastic modulus results obtained from CM experiments demonstrated that 
secretome obtained from monoculture of tumor cells was able to induce desmoplasia as 
compared to coculture group CM, we hypothesized enhanced expression of fibrotic 
factors within tumor monoculture CM as compared to coculture CM. Keeping this in 
mind, we first analyzed the differential expression of factors which are secreted in both 
monoculture of tumor cells and coculture of tumor cells and CAFs.  
 
Figure 3-5: Statistical Analysis on Differential Proteins Across Monoculture and 
Coculture Group of MCF7 Cells and CAFs. 
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 (A) Venn diagram showing number of common proteins within monoculture and 
coculture group of MCF7 cells. (B) Bar graph showing expression of differently 
expressed proteins across different culture groups of MCF7. 
As shown in figure, 3-5A we found 19 common proteins between the secretome 
of monoculture of MCF7 cells and coculture of MCF7 cells with CAFs. Upon statistical 
analysis we observed differential expression of 5 proteins including Actin cytoplasmic 1, 
Antithrombin III, Collagen alpha 1 (VI) chain, gelsolin and lumican (Figure 3-5B). 
Expect for antithrombin III, all other proteins had higher expression in coculture group 
CM as compared to monoculture group CM (Figure 3-5B). 
 
Figure 3-6: Statistical Analysis on Differential Proteins in Monoculture And 
Coculture of CAFs With MCF7/MDA-MB-231 Cells. 
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 (A), (C) Table showing expression of unique protein which was detected only in 
monoculture of MCF7 and MDA-MB-231 cells. (B), (D) Differential expression of 
Protein disulfide isomerase A3 in coculture group as compared to CAF monoculture. 
Additionally, we observed high expression of fibulin-1 within the secretome of 
MCF7 monoculture while it was completely absent from secretome of coculture of MCF7 
cells with CAFs (Figure 3-6A). We also studied the differential expression of secretome 
obtained from CAF monoculture to the secretome of MCF7+CAF group and found 36 
proteins in common. Our analysis demonstrated upregulation of only one protein known 
as protein disulphide isomerase A3 (Figure 3-6B). We repeated our analysis for 
monoculture and coculture group of MDA-MB-231 cells and CAFs. We observed 6 
proteins which were expressed in secretome of both monoculture of MDA-MB-231 cells 
and coculture of MDA-MB-231 cells with CAFs. However, upon statistical analysis we 
did not find any secreted factor to be differentially expressed. We next studied the 
presence of unique proteins and observed expression of plasminogen in CM obtained 
from monoculture of MDA-MB-231 cells as compared to CM obtained from 
monoculture of CAFs and their coculture with MDA-MB-231 cells (Figure 3-6C). We 
also repeated our analysis for differential expression of proteins expressed in secretome 
of CAF monoculture and coculture of MDA-MB-231 cells with CAFs and observed high 
expression of protein disulphide isomerase A3 consistent with the results obtained from 
secretome of coculture group of MCF7+CAF (Figure 3-6D). 
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3.4 Discussion: 
Multiple studies have demonstrated that ECM dysregulation is a critical hallmark 
of breast cancer progression. Similar to wound healing, fibroblasts cells are the major 
regulator of ECM remodeling and thus participates in ECM breakdown, deposition of 
newly synthesized and aligned fibers and increased matrix stiffness. Various studies have 
demonstrated that NF transform themselves into a myofibroblast like CAF phenotype and 
enhance their ECM secretion due to the effect of multiple tumor secreted cytokines 
including TGF-β. While these studies have been paramount in studying the role of known 
pro-fibrotic factors in transforming NF into CAF like phenotype at earlier stages of the 
disease, the molecular mechanism of ECM deposition by CAFs in presence of tumor cells 
in still not well understood. Since the stroma at invasive and metastatic state of the 
disease is primarily comprised of CAFs as opposed to NF’s, a molecular mechanistic 
study is important to understand the mechanism of ECM remodeling by CAFs in the 
presence of tumor cells. 
Many previous studies attempting to understand the molecular mechanism of ECM 
remodeling have been performed using patient tissue biopsies or using in vivo models. 
While these models enabled us to visualize and measure biophysical properties of ECM 
at different stages of the disease, these models are only end point analysis in which the 
cause and effect relationship of various factors can’t be determined due to presence of 
confounding factors and lack of control groups. In vitro models on the other hand have 
primarily only focused on enhanced tumorigenicity of breast cancer cells by increasing 
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invasion and proliferation on stiff matrices as compared to the compliant surfaces. 
Additionally, most of the previous in vitro models lacked a stromal component and 
thereby remained inconclusive on the crosstalk between tumor and stromal cells (i.e. 
CAFs) influencing matrix stiffness. Therefore, in our study we utilized a 3D high density 
tumor stroma model to characterize the signaling factors that participate in ECM 
remodeling due to the crosstalk between tumor cells and CAFs. As noted in chapter 2, we 
observed a crucial role of paracrine signaling between two cell types on CAF induced 
desmoplasia. Further we observed that secretome obtained from tumor cell CM exhibited 
higher CAF based desmoplastic reaction as compared to the secretome obtained from 
coculture of tumor cells and CAFs. In chapter 2 we primarily focused on studying the 
differential expression of known profibrotic factors including IL-13, IL-6, PDGF-AA, 
BB, AB, CC and TGF-β in CM obtained from various culture groups by using ELISA. 
While this approach enabled us to better understand the role of tumor secreted PDGF, we 
also performed an unbiased analysis of tumor secreted factors by performing LC-MS on 
secretomes obtained from various culture groups.  
 Utilizing our 3D tumor stroma model, we assessed the expression of various 
soluble factors in monoculture and coculture groups of tumor cells and CAFs. Our initial 
results showed us high number of secreted factors (~35 proteins) being uniquely 
expressed due to the coculture of MCF7 cells with CAFs. While these proteins have been 
identified by gene ontology results to participate in multiple biological process, we 
observed expression of various proteins that participate in ECM organization. For 
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instance, we noticed high abundance of SPARC, which is also known as osteonectin 
usually found in bone extracts and is known to play a crucial role in proliferation, 
invasion and breast cancer bone metastasis. We also observed high expression of laminin 
beta 1 which has been clinically observed to be highly expressed in vascular membranes 
found in invasive and metastatic carcinomas. Prolyl -3- hydroxylase and Procollagen -
lysine, 2-oxoglutarate 5-dioxygenase 1 which are known to participate in collagen fiber 
crosslinking were also found in detectable levels in CM obtained form coculture of tumor 
cells and CAFs. Thus, overall the secretome that we obtained from coculture of MCF7 
cells with CAFs had secretion of multiple ECM components that can participate in ECM 
remodeling and creating a tumor permissive niche.  
 Although we were able to isolate and characterize proteins found in secretome of 
various culture groups, it should be noted that the number of proteins that we were able to 
detect in CM obtained from MCF7+CAF were low in number. In case of CM obtained 
from coculture of MDA-MB-231 cells and CAFs we could only detect 2 proteins. We 
encountered similar problem when analyzed the differential expression of pro-fibrotic 
factors within tumor cells and CAF monoculture CM and their coculture CM. We 
envision that the detection of low number of proteins within the CM from various groups 
can be due to various reason which are discussed here. Firstly, our CM was collected 
from a 3D microengineered platform which are smaller in scale as compared to the 
traditional approaches of 2D cell culture and in vivo models. While the microscopic scale 
can help us successfully study various phenomena including ECM remodeling and tumor 
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progression, the number of cells and proteins are less in number as compared to the those 
obtained from macroscopic 2D cultures. Secondly, our sample type was CM obtained 
from culture of cells as opposed to traditional cell lysates which are known to be 
abundant in protein concentration. Since we wanted to visualize tumor and stroma 
secreted factors, we had to switch to serum free media to minimize contamination from 
large and abundant serum associated proteins.  However, despite switching to serum free 
media after 48 hours culture with regular media, our CM had a large contamination of 
albumin even after multiple washes with 1X PBS. Hence, we had to utilize serum 
removal techniques to minimize the masking of low abundant proteins from serum 
related high abundant proteins. We utilized traditional technique of gel electrophoresis on 
to detect and remove the albumin band (68KDa Molecular weight). Upon detection we 
cut the albumin rich band from the gel and performed in gel digestion on the remaining 
gel. Although this method minimized the number of serum related factor in our mass 
spectrometry results, it is possible that multiple proteins of interest of variable size were 
lost due to low peptide yield associated with in gel digestion. Additionally, highly 
abundant proteins are commonly known to form complexes with low abundance protein 
and therefore depletion of them can possibly leads to a significant loss of cytokines of 
interest. Another factor that we envision that can possibly play a role in low number of 
tumor secreted cytokine is change in cellular phenotype and genotype in serum free 
media as opposed to regular media. Various studies have shown that removal of serum 
can lead to induction of stress in the cells that can alter their genotypic and phenotypic 
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behavior towards cell survival. We envision that switching media conditions can change 
cellular secretome that can possibly lead to reduced secretion of fibrotic factors. Since all 
our previous elastic modulus measurements were done in serum containing media, 
repeating the assay with serum free media can build an understanding on the role of 
serum in CAF based desmoplasia. Thus, overall, we can say that while use of label free 
proteomics is a useful technique to do an unbiased analysis of tumor cell secretome there 
are various optimizations that needs to be performed. The scale down of culture, role of 
serum and use of conditioned media are some of the important factors that we envision 
play a crucial role in successful LC-MS analysis. 
3.5 Conclusion: 
In summary we observed a significant number of proteins being secreted due to the 
coculture of MCF7 cells with CAFs and observed abundant expression of various ECM 
related proteins. We observed that most of the ECM related factors secreted in coculture 
CM has been previously related to enhanced tumorigenicity and hence can be crucial to 
create a tumor permissive niche. Due to low number of proteins being detected our LC-
MS analysis was not conclusive and require various optimizations. Amongst various 
factors, including sample preparation, role of serum, and scale of culture can be some 
crucial factors which needs to be optimized to integrate label free proteomics with our 3D 
tumor stroma model. 
  
98 
 
 Chapter 4  
The Role of Desmoplasia and Stromal Fibroblasts on Anti-Cancer Drug Resistance 
in a Microengineered Tumor Model 
4.1 Introduction: 
Breast cancer is known as the second most leading cause of death amongst women across 
the globe (Siegel et al., 2017). While the early stage of the disease can be treated with 
high success rates, the invasive and metastatic phase of the disease still suffer from poor 
therapeutic outcomes (Siegel et al., 2017). It is now widely accepted that the TME plays a 
crucial role in the disease progression as well as in inherent resistance to anti-cancer 
therapeutics during the metastatic cascade (Place et al., 2011; Tredan, Galmarini, Patel, & 
Tannock, 2007). Due to the complexity of the TME, chemotherapeutic drugs do not 
primarily perfuse through the parenchyma of the tissue in lethal amounts, primarily 
because of the high interstitial fluid stress, gradients of growth factors and hypoxia (Netti, 
Berk, Swartz, Grodzinsky, & Jain, 2000; Tredan et al., 2007). Additionally, the signaling 
crosstalk between the stromal and cancer cells induce resistance by upregulating pro-
survival mechanisms such as reduced cell death, enhanced proliferation and invasion etc 
(Farmer et al., 2009; D. Hanahan & Weinberg, 2011; Senthebane et al., 2017). In this 
regard, specific therapeutics are being developed to target the interactions between tumor 
and the surrounding stroma (Tredan et al., 2007). The stromal targeting drugs along with 
classical chemotherapeutics are now being considered as enhanced combinatorial 
treatment strategies compared to monotherapy regimes (Tredan et al., 2007).  
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Amongst various stromal cells found within breast TME, cancer associated 
fibroblasts (CAFs) are dominant in number (Kalluri, 2016). Previous studies have 
demonstrated that CAFs play a significant role in inducing the microenvironment 
conducive for the progression of the disease (Dumont et al., 2013; Kalluri, 2016; Tredan 
et al., 2007; Tripathi, Billet, & Bhowmick, 2012). For instance, CAFs deposit abundant 
and aligned ECM proteins such as collagen, fibronectin, lysyl oxidase within local TME 
as compared to their normal counterparts (i.e. mammary fibroblasts) (Dumont et al., 
2013; Tripathi et al., 2012). High expression of ECM proteins leads to the formation of a 
desmoplastic stroma with elevated biophysical properties (i.e. stiffness), which 
subsequently promote tumor cell invasion, proliferation, and also reduces the functional 
efficacy of drugs due to the upregulation of integrin and focal adhesion kinase (FAK) 
(Gjorevski, Piotrowski, Varner, & Nelson, 2015; Han et al., 2016; Hirata et al., 2015; 
Jeong, Lee, Shin, Chung, & Kuh, 2016; Netti et al., 2000; Stanisavljevic et al., 2015).  
Due to the significant role of ECM proteins and matrix properties (i.e. stiffness), 
in inherent drug resistance, many studies in the past have utilized anti-fibrotic drugs that 
directly target the desmoplastic stroma (Darakhshan & Ghanbari, 2013; Papageorgis et 
al., 2017; Seniutkin et al., 2018; Suklabaidya et al., 2016; Ken Takai et al., 2016; Zhang 
et al., 2016). Most of the previous in vitro studies in this regard have utilized two-
dimensional (2D) monolayer of cancer cells, either alone or in coculture with stromal 
cells, to study the influence of these drugs on tumor growth and invasion (Chuang & 
Khorram, 2017; Darakhshan & Ghanbari, 2013; Izumi et al., 2009; Mediavilla-Varela, 
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Boateng, Noyes, & Antonia, 2016; Okazaki et al., 2014; Saito et al., 2018; Sato et al., 
2010; Subramaniam, Ace, Prud'homme, & Jothy, 2011). These studies have provided 
valuable insight on cytotoxicity level of drugs and the biochemical pathways being 
influenced during the therapy (Chuang & Khorram, 2017; Darakhshan & Ghanbari, 2013; 
Nikkhah et al., 2011; Strobl, Nikkhah, & Agah, 2010). However, due to 2D nature of 
these platforms, the dynamic alterations in the biophysical properties of the matrix (i.e. 
stiffness) in the presence of anti-fibrotic drugs cannot be retrieved (Nitish Peela et al., 
2017). Additionally, the lack of a third dimension in 2D models does not enable 
recapitulation of the native characteristics of the TME, ultimately leading to notable 
differences in pharmacodynamic outcomes (Peela, Barrientos, Truong, Mouneimne, & 
Nikkhah, 2017). In vivo animal models, on the other hand, provide crucial insights on the 
role of the drugs in alleviation of stress, interstitial fluid pressure as well as deposition of 
stromal matrix proteins (Papageorgis et al., 2017; Sakai et al., 2016; Ken Takai et al., 
2016; Zhang et al., 2016). However, due to the physiological differences between animal 
models and humans, clinical translation of the drug target has been limited (Mak, 
Evaniew, & Ghert, 2014; Nitish Peela et al., 2017). Additionally, the inherent 
complexities of in vivo models, does not enable quantitative assessment of the alterations 
of ECM matrix during tumor progression in presence of a single class of stromal cells 
(i.e. CAFs) (Moriah E. Katt, Amanda L. Placone, Andrew D. Wong, Zinnia S. Xu, & 
Peter C. Searson, 2016; Peela et al., 2016; Plodinec et al., 2012). In this regard, 
microengineered 3D tumor models, integrated with novel biomaterials, provide enormous 
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potential to mimic the complexities of TME with precise control on various factors 
including the spatial organization of cancer and stromal cells, matrix composition and so 
forth (Supriya. Nagaraju, Danh. Truong, Ghassan. Mouneimne, & Mehdi. Nikkhah, 2018; 
Nitish Peela et al., 2017; Truong et al., 2016). Microengineered tumor models also enable 
better visualization of the dynamic changes within cell cytoskeleton and stromal matrix 
for enabling specific mechanistic studies (Nikkhah, Strobl, & Agah, 2008; Nitish Peela et 
al., 2017). 
In this study we developed a 3D microengineered platform incorporating high 
density of tumor cell-embedded microwells, surrounded by stromal cells such as CAFs. 
Due to the open top nature of the platform, we probed the matrix with AFM  to assess the 
alterations of the ECM stiffness over the experimental period. Further, we studied the 
impact of combinatorial action of anti-fibrotic drug tranilast and doxorubicin on ECM 
remodeling, tumor growth and cancer cell invasion in the sole presence of CAFs. We 
focused our study on breast cancer in this work, however, due to highly versatile nature 
of the proposed platform, the model can be adapted to various other types of 
desmoplastic cancer. 
4.2 Materials and methods 
Materials 
Poly dimethyl siloxane (PDMS Sylgard 184 Silicon Elastomer Kit, Dow Corning) was 
utilized to fabricate PDMS holders and stamps to engineer our 3D micropatterned breast 
tumor model. 2-aminopropyl-triethoxy-silane (APTES), Poly-D-Lysine (PDL) and 
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glutaraldehyde was utilized to surface treat our substrates (PDMS holders, glass bottom 
confocal dishes). PDMS stamps were treated with Pluronic F-127 to render them protein 
resistant. Tranilast was bought from TCI America and stock was prepared at the 
concentration of 100 mM in DMSO. Doxorubicin (alfa aesar) was diluted in DI water 
with stock solution of 1 mM 
Cell Culture 
In our study we utilized 3 different breast tumor cell lines namely MDA-MB-231, MCF7 
and MCF10A. MDA-MB-231 and MCF10A cells were transduced to express tdTomato   
fluorescence and was provided by McCarty lab (Oregon Health & Science University). 
MCF7 cells on the other hand were obtained from Mouneimne lab at University of 
Arizona Cancer Center and expressed mCherry fluorescence. CAFs, which were isolated 
from human mammary gland tissue peripheral to invasive ductal carcinoma, were 
purchased as an immortalized cell line from ATCC (HTB-125). MDA-MB-231, MCF7 
and CAFs were cultured in DMEM 1X media supplemented with 10% FBS, 1% PenStrep 
and 1% L-glutamine. MCF10A cells were maintained in a DMEM: F12 supplemented 
with 1% Lglutamine, epidermal growth factor, cholera toxin, hydrocortisone, insulin and 
5% horse serum. For all experiments, the cell lines were cultured within T-75 flasks and 
maintained at 37°C and 5% CO2 with subsequent change of media every two days. The 
passage number used for various experiments for different cell lines are as listed below 
for consistency for the experiments: MDA-MB-231 (17-22), MCF7 (5-9), MCF10A (10-
13), CAFs (54-62). 
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IC 50 assay 
Alamar blue assay (Thermo Fisher) was utilized to study the metabolic activity of cells 
and IC 50 analysis within 96 well plates after exposure to individual treatments for 48 
hours. To calculate IC 50 on 2D surface, the cells were trypsinized and plated within well 
plates at the cell density of 3 x 104 and 5 x 104 for MDA-MB-231 and CAFs respectively 
and were allowed to adhere to the well plate overnight. For studying IC 50 values of drug 
in 3D hydrogel, the cells at above mentioned cell densities were encapsulated within 
4mg/ml of collagen I and 30 µl of the cell embedded gel was pipetted in 96 well plate.  
Tranilast and doxorubicin at various doses was prepared from stock in cell culture media 
and added to cells for 48 hours. The media was removed, and cells were washed with 1X 
PBS three times. Alamar blue was prepared at the dilution of 1:10 in cell culture media 
and added to cells for 3 hours at 37 °C similar to our previous work. The plates were read 
using a plate reader as per manufacturer’s instruction. 
Development of the 3D tumor model  
The 3D tumor model was fabricated using micromolding techniques (Nelson et al., 
2008). Specifically to develop the model, we primarily fabricated PDMS stamps and 
holders using soft lithography techniques. While the holders were utilized as a substrate 
to immobilize collagen I hydrogel, stamps were engineered to micromold the gel and 
create a high-density array of microwells. Both PDMS platforms were prepared by 
mixing SYLGARD Silicone Elastomer Base and the SYLGARD Silicone Elastomer 
curing agent in the ratio 10:1. The mixture was then vacuumed until no air bubbles 
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remained. The mixture was poured on a silanized silicon wafer and degassed for 30 
minutes after which it was incubated overnight at 80 °C. PDMS holders were first 
threated with air-based plasma for 4 minutes and then immediately immersed in 2% of 2-
(aminopropyl) triethoxysilane (APTES) prepared in 95% ethanol. The holders were 
incubated in APTES for 1 hour at 60 °C. To remove unbound APTES, the holders were 
transferred to 100% ethanol solution, and sonicated using a water-based ultrasonic bath 
for 20 minutes. The holders were washed with 100% ethanol in five 10 minutes intervals 
followed by 1-hour incubation at 80 °C. To allow covalent immobilization of collagen I, 
the PDMS holders were then incubated in 2% glutaraldehyde (GA) at room temperature 
for 1 hour. GA was removed by five consecutive 5-minute washes with DI water and then 
incubated overnight at 80°C. PDMS stamps were made protein-repellant through 
incubation with a 1% Pluronic F-127 solution.  
To fabricate the tumor model, rat tail collagen I was used at the concentration of 4 mg/ml. 
CAFs were mixed with collagen I at the optimized cell density of 2 x 106 cells/ml (Figure 
4-1A). PDMS stamps were removed from pluronic solution and washed three times with 
DI water. The collagen solution was then added to each stamp immediately and further 
inverted on top of the surface treated PDMS holders (Figure 4-1A). The whole assembly 
was then kept for polymerization for 30 minutes at 37 °C (Figure 4-1A). After 
polymerization of the gel, the stamp was lifted off gently and the microwells were seeded 
with cancer cells at a density of 7 x106 cells/ml for 2-3 minutes (Figure 4-1A). The cells 
from unpatterned surface were removed by washing with media. The prepared samples 
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were kept inside the incubator for 15 minutes to allow attachment of cells to collagen 
wells. After 15 minutes, the samples were immersed within 500 µl of media in each well 
of 24 well plate overnight. On day 1, freshly prepared media with drug was added to the 
samples for 48 hours. The experimental groups include control (i.e. MDA+CAF without 
drug), DMSO (0.62%), Tranilast (620 µM), Doxorubicin (280nM) and Tranilast 
+Doxorubicin. 
Cell proliferation assay  
Tumor cell proliferation was quantified by using Click iT-Alexa Fluor -488- Edu Imaging 
Kit (Thermo Fisher) as per manufacturer’s instruction. To quantify cancer cell 
proliferation, the DsRed positive cell (MDA-MB-231) with EdU positive and DAPI 
stained nuclei was counted in Image J using cell counter plugin. To further calculate the 
percentage of proliferative cancer cells, the EdU positive cancer cells was divided by 
total number of DsRed positive tumor cells. Additionally, we also performed the assay on 
non-invasive MCF7 and normal mammary epithelial MCF10A cells for control and 
tranilast+doxorubicin experimental group across two experiments.  
Cancer cell invasion assay 
 To visualize invasion of tumor cells across all groups, prepared samples were imaged 
using fluorescence and phase contrast microscopy (ZEISS) on day 1, before addition of 
drug as well as on day 3 of the culture. Tile images were acquired from 2 random 
locations of the sample. Using ImageJ, we thresholded each image and utilized particle 
analyzer plugin to extract co-ordinates of each cell within an image. Next, we used a 
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custom-written MATLAB code to perform delaunay triangulation modelling similar to 
previous reports (Nawrocki Raby et al., 2001). The area of each triangle within delaunay 
plot was calculated using MATLAB. We calculated average area of all triangles and 
quantified area disorder for each delaunay plot using following equation: 
𝐴𝑟𝑒𝑎 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟 = 1 − [1 + (
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑟𝑒𝑎
)]
−1
 
The invasion index was calculated based on following equation: 
𝐼𝑛𝑣𝑎𝑠𝑖𝑜𝑛 𝐼𝑛𝑑𝑒𝑥 =
(𝐴𝑟𝑒𝑎 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟 𝑜𝑛 𝐷𝑎𝑦 1 − 𝐴𝑟𝑒𝑎 𝐷𝑖𝑠𝑜𝑟𝑑𝑒𝑟 𝑜𝑛 𝐷𝑎𝑦 3)
𝐴𝑟𝑒𝑎 𝑑𝑖𝑠𝑜𝑟𝑑𝑒𝑟 𝑜𝑛 𝐷𝑎𝑦 1
 
Immunostaining  
To visualize the deposition of collagen I and fibronectin within the matrix of the 
micropatterned mode, primary monoclonal mouse antibodies against collagen I and 
fibronectin were used (Santa Cruz Biotechnology) at dilution of 1:200 and 1:100 
respectively. To fluorescently stain the fibers, Alexa Fluor 488 secondary antibodies 
(Life Technologies) were used at the dilution of 1:400 and 1:200 respectively. The 
fluorescently labelled fibers were visualized using confocal reflectance microscopy 
(Leica Microsystems, SP8) available at KECK bioimaging center at ASU. 
Atomic Force Microscope (AFM) based mechanical characterization 
 The measurement for elastic modulus (i.e. stiffness) of the matrix were made on day 1 
before addition of drug followed by day 3 of the culture.  The matrix stiffness was 
measured by indenting MDA-MB-231 free areas within the platform and convoluting 
elastic moduli of ECM and CAFs since fibroblasts have been shown to match the 
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stiffness of the substrate (Solon, Levental, Sengupta, Georges, & Janmey, 2007). Force 
indentation curves were recorded with a commercial atomic force microscope (MFP-3D-
BIO AFM, Asylum Research, Santa Barbara CA, USA) using sphere-conical probes 
(Knominal=0.2 N/m, LRCH, Team Nanotec, Germany) with a half cone angle of 18.8 
degrees and sphere radius of 850 nm. Force-indentation curves were collected in 4×4 
grids as force maps in an area of 90μm×90μm located in the center between four wells at 
37°C and with indentation speed of 2μm∙s-1. The trigger force was selected to 60-80 nN 
resulting in indentation depths of at least 10 μm. The spring constant of each cantilever 
was determined before the experiment by the thermal noise method (Butt & Jaschke, 
1995; Hutter & Bechhoefer, 1993). Three force maps per sample per day were collected.  
The first 10 μm indentation of each force distance curve was fitted to a non-adhesive 
elastic contact model for a conical indenter with a spherical tip (Staunton et al., 2016). 
Data analysis was done using MATLAB. The poison ration of collagen was assumed to 
be νcollagen= 0.5.  
Quantification of expression of proteases within our 3D microengineered platform 
The quantification for expression of various proteases and their inhibitors was done by 
utilizing a commercially available RayBiotech human MMP1 antibody array (QAH-
MMP-1-1) for quantification of the expression of MMP1,2,3, 8,9,10,13 and TIMP-1,2 
and 4. To perform the assay, the samples were prepared and cultured in 10% serum 
containing media for 24 hours and then washed three times with 1X DPBS to remove 
serum. The samples were then incubated in various drug conditions prepared in serum 
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free media. The conditioned media was collected after 48 hours and centrifuged at 14000 
rpm for 10 minutes to remove cell debris. The supernatant was collected and stored at -80 
°c until further use. To perform the antibody array all the samples were run as per 
manufacturer instructions. To get a comprehensive analysis, all conditions were repeated 
in triplicate technical and biological replicate.  
Statistical Analysis 
Unless otherwise stated, all the assays were repeated three times with three technical 
replicates per condition. The IC 50 results were analyzed using sigmoidal curves in 
GraphPad. The elastic modulus data was analyzed using two-way ANOVA with Sidak’s 
multiple comparison test. All other data was analyzed using repeated one-way ANOVA 
with Tukey multiple comparison test. Due to unavailability of samples for some groups in 
few experiments, the statistical analysis was reported for EdU and Tunnel assay using 
ordinary one-way ANOVA. p value less than 0.05 was considered significant for all the 
results. The statistical analyses and data representation was performed using GraphPad 
Prism v 7.0. All the data was presented as mean ± standard deviation. 
4.3 Results 
Microengineering of the 3D breast tumor model  
The 3D breast tumor model was fabricated by utilizing micromolding technique to create 
a high-density array of microwells within collagen I   hydrogel as shown in Figure 4-1A. 
The stromal region was fabricated by encapsulating CAFs within collagen I hydrogel 
while the tumor region was engineered by seeding tumor cells (MDA-MB-231) within 
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the microwells (Figure 4-1A). As shown in Figure 4-1B, the tumor and stromal regions 
were accurately organized to mimic the native spatial organization of TME and thus 
study the invasive behavior of tumor cells as well as change in biophysical properties of 
the ECM. The experimental groups were designed to study the influence of tranilast and 
doxorubicin on alterations of matrix properties and tumor progression either individually 
or in combination. The control condition included the coculture of cMDA-MB-231cells 
and CAFs without the addition of any drug. The time period for the current study was 
kept constant for 3 days since CAFs exerted high traction force on collagen I which 
caused folding of hydrogel and disruption of the model for extended period of culture.  
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Figure 4-1: Proposed Hypothesis of Combinatorial Action of Tranilast With 
Doxorubicin on Tumor Progression. 
(A) Schematic of the main fabrication steps of 3D microengineered high-density tumor 
model. (B) 3D view of the micropatterned breast tumor model. (C) Representative 
illustration of the proposed hypothesis of the study demonstrating the role of desmoplasia 
on tumor survival, growth and cancer cell invasion. Addition of antifibrotic drug tranilast 
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along with doxorubicin downregulate ECM remodeling thereby reducing overall tumor 
progression. 
We hypothesized that within the control condition (i.e. no drug), the presence of 
tumor and stromal cells lead to remodeling of the matrix and elevated stiffness by 
deposition of proteins such as collagen I and fibronectin (Figure 4-1C). The increase in 
the elastic modulus of the matrix eventually lead to enhanced tumor growth, invasive 
activity of MDA-MB-231 cells as well as resistance to cell death (Figure 4-1C). On the 
other hand, addition of tranilast will reduce the fibrosis of the matrix due to its known 
inhibition of collagen synthesis and ECM turnover, leading to impaired desmoplasia 
(Figure 4-1C) (Papageorgis et al., 2017). Reduced fibrosis of the matrix will 
downregulate the biomechanical signaling of the ECM, thereby enhancing the efficacy of 
doxorubicin and condensing tumor growth and invasion (Figure 4-1C).  
Characterization of IC 50 concentrations 
 
Figure 4-2: 2D IC-50 Assay. 
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(A) Metabolic activity of MDA-MB-231 and CAFs in response to different doses of 
Tranilast in a 96 well plate. (B) Doxorubicin induced metabolic activity of MDA-MB-231 
cells and CAFs with different concentrations. 
Prior to proceeding with our tumor model, we characterized the IC 50 values for 
each of the drugs (tranilast, doxorubicin) on both cell lines (MDA-MB-231, CAFs) using 
2D cell culture and alamar blue assay. Based on the metabolic activity of cells across 
various concentration of drugs, relative IC-50 values were calculated using standard 
mathematical models. Our results demonstrated lower IC 50 value of tranilast for CAFs 
(620 µM) as compared to MDA-MB-231 cells (987 µM, Figure 4-2A). Similar results 
have been also observed by previous studies, on pancreatic tumor and stellate cells 
seeded on 2D surfaces in presence of anti-fibrotic drug, pirfenidone, depicting enhanced 
influence of the drug on fibroblasts as compared to the tumor cells (Kozono et al., 2013). 
On the other hand, doxorubicin had lower IC 50 value for MDA-MB-231 cells (280 nM) 
as compared to CAFs (370 nM) as shown in Figure 4-2B.  Previous studies in the 
literature have reported the IC 50 of doxorubicin for MDA-MB-231 cells in the range of 
0.5 nM to 5 µM (Abu, Akhtar, Ho, Yeap, & Alitheen, 2013; Lovitt, Shelper, & Avery, 
2018; Pilco-Ferreto & Calaf, 2016; Rahman et al., 2016; L. Smith et al., 2006; Tassone et 
al., 2003; Wu et al., 2013). Consistently, our IC 50 value is within this previously 
reported range. Such a wide range of IC 50 for MDA-MB-231 cells can be due to 
multiple factors including passage number, culture conditions as well heterogeneity of the 
cell population. We also performed similar IC 50 assay within 3D collagen I hydrogel. As 
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shown in supplementary Figure 1A-B (APPENDIX C), both MDA-MB-231 and CAFs 
demonstrated IC 50 values for tranilast and doxorubicin higher than those observed in 2D 
assay. In order to experimentally achieve 50% inhibition in cell metabolic activity, we 
therefore expanded the range of concentration of doxorubicin to as high as 10 µM. Our 
results demonstrated IC 50 values for MDA-MB-231 and CAFs for Doxorubicin to be 
2073 nM and 2108 nM respectively within 3D collagen I hydrogel (Supplementary 
Figure 1C, APPENDIX C). Higher IC 50 values for the drug within 3D hydrogel assay 
can be possibly attributed to reduced diffusion of the drug, difference in cell phenotype 
and genetic make-up within 3D systems as compared to 2D systems (Netti et al., 2000; N. 
Peela et al., 2017; Nitish Peela et al., 2017). Similar analysis for tranilast could not be 
achieved as the drug remained insoluble at higher concentrations in cell culture media. 
Such insolubility of the tranilast can be explained due to its super hydrophobic nature, as 
also demonstrated by previous studies (Onoue et al., 2012). Since our main goal was to 
study the effect of combination of two drugs on desmoplasia, tumor growth and invasion, 
we proceeded with IC 50 values obtained within our 2D assay. Therefore, based on our 
preliminary studies, we fixed the concentration of tranilast to be 620 µM and doxorubicin 
to be 280 nM for our future experiments. We also added blank DMSO vehicle (0.62%) as 
another control group. 
Characterization of desmoplasia  
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Figure 4-3: Characterization of Stromal Desmoplasia Under Various Drug 
Conditions. 
 (A) Representative immunofluorescent images of collagen I within 3D matrix across all 
the groups. Inset represent a magnified view of fiber density across all the conditions. (B)  
Elastic modulus of matrix across all the groups on day 1 before addition of drug and day 3 
after addition of drugs. (C) Table of average elastic modulus values across various drug 
conditions on day 1 and day 3 of culture. All values are written as mean ± standard 
deviation. * represent the microwells molded in collagen. Scale bar represent 20 µm. (* 
represents p value < 0.05).  
A major advantage of our 3D platform is the ability to measure the changes in 
biomechanical properties of the matrix during active invasion of cancer cells in the 
presence of the drugs as compared to traditional 2D in vitro as well as in vivo models. To 
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visualize the changes in matrix protein deposition, we immunostained the samples for 
collagen I and fibronectin on day 3 of culture. Additionally, we measured the changes in 
stiffness of the matrix using AFM on day 1 before addition of drugs and on day 3 after 48 
hours of drug treatment. As show in Figure 4-3A, the stromal matrix of the control group 
demonstrated a high density of collagen I fibers as compared to the samples exposed to 
combinatorial drugs. Similar observation was made with respect to fibronectin assembly 
within stromal matrix (Supplementary figure 2, Arrows, APPENDIX C). Additionally, 
both collagen and fibronectin fibers were more punctuated in the presence of both drugs 
(Figure 4-3A, Supplementary Figure 2, APPENDIX C). Such differences were also 
reflected in matrix stiffness across all culture groups (Figure 4-3B, C, Supplementary 
Figure 3, APPENDIX C). Specifically, our results showed that, while both control and 
DMSO treated groups depicted significant increase in elastic modulus on day 3 
(𝐸𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝑑𝑎𝑦3 = 4.25 ± 1.26 𝑘𝑃𝑎 and  𝐸𝐷𝑀𝑆𝑂,𝑑𝑎𝑦3 = 3.53 ± 1.07 𝑘𝑃𝑎) as compared to 
day 1 (𝐸𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝑑𝑎𝑦1 = 1.67 ± 0.49 𝑘𝑃𝑎, 𝐸𝐷𝑀𝑆𝑂,𝑑𝑎𝑦1 = 1.76 ± 0.46 𝑘𝑃𝑎), tranilast, 
doxorubicin and tranilast+doxorubicin treated groups did not exhibit any significant 
change in the matrix stiffness (Figure 4-3B, C Supplementary Figure 3, APPENDIX C). 
Additionally, the elastic modulus for the tranilast+doxorubicin group on day 3 of culture 
was significantly lower than the control and DMSO group. (𝐸𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝑑𝑎𝑦3 = 4.25 ±
1.26 𝑘𝑃𝑎, 𝐸𝐷𝑀𝑆𝑂,𝑑𝑎𝑦3 = 3.53 ± 1.07 𝑘𝑃𝑎, 𝐸𝑇𝑟𝑎𝑛𝑖𝑙𝑎𝑠𝑡+𝐷𝑜𝑥𝑜𝑟𝑢𝑏𝑖𝑐𝑖𝑛,𝑑𝑎𝑦3 = 2.16 ±
1.03 𝑘𝑃𝑎, Figure 3C).These findings suggest enhanced anti-fibrotic activity when the two 
drugs were added together to the model.  
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Figure 4-4: Representative Histograms of Elastic Modulus and Stiffness Maps 
Under Various Drug Conditions. 
(A) Representative histograms showing distribution of elastic modulus of the stromal 
matrix across various groups. (B)  Representative color maps curves of stiffness across all 
the experimental conditions.  
Figure 4-4A, B show histograms and 2D color-maps of the indented matrix on 
days 1 and 3. Stiffness histograms on day 1 demonstrated similar unimodal distributions, 
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consistent to the data shown by Plodinec et.  al. for normal tissues (healthy human and 
MMTV-PyMT mice biopsies) (Plodinec et al., 2012). For the untreated control group of 
our 3D tumor model we found multi-peaks in the stiffness histogram on day 3. Bimodal 
stiffness with broad distribution as seen for control group has been associated with cancer 
biopsies indicating a biomechanical heterogeneity in diseased tissue (Plodinec et al., 
2012). Narrower matrix stiffness distributions on day 3 for treated groups within our 
model suggested lower level of interplay among CAFs and tumor cells. Therefore, the 
control group on day 3 demonstrated significant desmoplasia. Notably, the combinatorial 
addition of tranilast and doxorubicin drugs impaired these biophysical alterations. 
Tumor growth  
Since the stiffness of the matrix was significantly modulated by the combinatorial action 
of two drugs, we next hypothesized that the proliferative behavior of tumor cells will also 
be altered upon exposure to varied drug treatments. To assess tumor growth, we utilized 
Alexa Fluor 488 EdU assay to fluorescently label replicating MDA-MB-231, MCF7 and 
MCF10A cells and further visualized them using fluorescent microscopy (co-expressing 
DsRed and GFP). As shown in Figure 4-5A, MDA-MB-231 cells proliferated the most 
within the control group. While monotherapy with tranilast and doxorubicin reduced the 
tumor growth however, the reduction was not statistically significant (Figure 4-5A, B). 
Further, quantification for EdU positive cells demonstrated a significant decrease in 
proliferative behavior of tumor cells (MDA-MB-231) due to the combinatorial action of 
tranilast and doxorubicin (Figure 4-5B).    
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Figure 4-5: Tumor Proliferation Assay Under Various Drug Conditions. 
(A) Representative immunofluorescent images of EdU assay depicting tumor cell 
proliferation across all experimental groups. (B) Quantification of proliferation of MDA-
MB-231 cells within all conditions. Scale bar represents 50 µm. (* represents p value < 
0.05). 
Similar trend was observed when non-invasive MCF7 cells and normal mammary 
epithelial cells (MCF10A) were cultured with CAFs in presence and absence of drugs. 
Specifically, in the control group both MCF7 and MCF10A cells demonstrated high 
replicative ability (~ 90%, Supplementary Figure 4A, B, APPENDIX C). However, when 
tranilast and doxorubicin was added together, the proliferation rate for both cell types 
reduced significantly (MCF7= 35 ± 5.4%, MCF10A = 30 ± 18 %, Supplementary Figure 
4A, B, APPENDIX C).  Thus, overall our results demonstrate reduced proliferative 
ability of invasive and non-invasive (MDA-MB-231, MCF7) tumor cells as well as 
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normal mammary epithelial cells when the two drugs act in synergy in presence of CAFs 
as compared to untreated condition. 
Cancer cell invasion  
  Based on our hypothesis, we further speculated a limited ability of cancer cells to 
invade the surrounding stroma in combinatorial treatment of drugs. To visualize the 
dispersion of tumor cells within the 3D matrix, we utilized phase contrast and fluorescent 
imaging along with delaunay triangulation.  
 
Figure 4-6: Tumor Dispersion Under Various Drug Conditions. 
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(A) Representative phase contrast and fluorescent images of tumor cell dispersion in 
control and tranilast + doxorubicin group on day 1 (before addition of drug) and day 3 
(after addition of drug). (B) Representative triangulation graphs depicting tumor cell 
invasion into the stroma. (C) Quantification of invasion index of MDA-MB-231 cells. 
Scale bar represent 100 µm. (* represents p value < 0.05).  
As shown in Figure 4-6A and Supplementary figure 5A (APPENDIX C), tumor 
cells demonstrated enhanced invasive capacity across all the groups on day 3 as compared 
to day 1 of the culture. Similar analysis was drawn from triangulation graphs (Figure 5-6B 
and Supplementary figure 5B, APPENDIX C), where tumor cells appeared more scattered 
within the stroma on day 3 as compared to day 1 of the culture. Quantification of area 
disorder demonstrated invasion of tumor cells intro matrix for all groups (Supplementary 
Figure 5C, APPENDIX C). However, quantification of invasion index across all the 
conditions, indicated a significant decrease in invasion of tumor cells in combinatorial 
treatment of tranilast and doxorubicin as compared to control. These results are in fact 
similar to previous in vivo studies where metastasis was observed to be minimalistic only 
when tumors were subjected to combinatorial therapy of anti-fibrotic drug and doxorubicin 
(Ken Takai et al., 2016). 
Assessment of proteases and their tissue inhibitors expression  
To complement our matrix remodeling and stiffness results, we performed a 
comprehensive analysis of expression of various matrix remodeling factors including 
matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).  
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Figure 4-7: ELISA Assay for Quantifying MMP's and TIMP's. 
(A) Quantification of various proteases of MMP array for all culture conditions. (B) 
Quantification of concentration of different TIMPs across all culture conditions. (* 
represents p value < 0.05). 
Our results demonstrated that MMP1 a known interstitial collagenase had highest 
concentration within the control group (1197 ± 508.789 pg/ml) which was not 
significantly different from DMSO (668.93 ±282.191 pg/ml) and doxorubicin group 
(673.98 ± 177.03 pg/ml), thereby suggesting enhanced ECM remodeling within these 
groups. However, upon addition of tranilast, concentration of MMP1 significantly 
decreased both in tranilast (291.3 ± 284.142 pg/ml) and tranilast + doxorubicin groups 
(316.926 ± 276.208 pg/ml, Figure 5-7A). Besides, MMP1 we also observed significant 
difference in expression of TIMP2 across different culture conditions. As shown in 
Figure 5-7B, the expression of TIMP2 within the control group (5449.974 ± 504.055 
pg/ml) was significantly higher than tranilast + doxorubicin group (1389.667 ± 455.242 
pg/ml). Furthermore, the doxorubicin group (7625.03 ± 4234.258 pg/ml) had 
significantly higher expression of TIMP2 as compared to DMSO (2222.955 ± 526.215 
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pg/ml), tranilast (2173.451 ± 1127.598 pg/ml) and tranilast + doxorubicin group. Besides 
MMP1 and TIMP2, we did not observe any significant difference for other proteases 
across all culture conditions.               
4.4 Discussion 
In this study we utilized a 3D microengineered breast tumor model to study the influence 
of anti-fibrotic drug tranilast in combination with doxorubicin on desmoplasia, tumor 
growth and cancer cell invasion. Many previous studies have suggested that tumor cells 
activate stromal cells such as fibroblasts surrounding them to alter the microenvironment 
and make it more conducive for tumor progression (Kalluri, 2016; Tripathi et al., 2012). 
Fibroblasts in particular are known to get activated in presence of tumor cells and adopt a 
myofibroblast like phenotype (CAFs) similar to a wound healing process (Kalluri, 2016; 
Tripathi et al., 2012). Such a change in phenotype of fibroblasts leads to remodeling of 
the matrix and hence induction of fibrosis within the surrounding microenvironment 
(Kalluri, 2016; Tripathi et al., 2012). Therefore, to initially construct an in vivo like TME, 
the proposed model was compartmentalized into tumor and stromal regions by seeding 
MDA-MB-231 cells within microwells that were surrounded by collagen-based stroma 
encapsulating CAFs. Such a spatial organization of tumor- stromal region was 
purposefully chosen to mimic the native breast TME.  The choice of collagen I hydrogel, 
to establish the model was motivated by the abundance of this ECM protein within native 
TME (Fang, Yuan, Peng, & Li, 2014). Our proposed platform enabled dissection of the 
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role of CAFs as the most dominant cell within the mammary carcinoma, on desmoplasia 
and tumor progression.  
To disrupt the desmoplastic response of CAFs within breast TME, we studied the 
action of tranilast, a clinically approved drug in Japan and South Korea for treatment of 
fibrotic diseases such as keloids (Darakhshan & Pour, 2015). While in previous 2D in 
vitro studies, this drug has been shown to be paramount in influencing tumor cell 
viability as well as growth (Chuang & Khorram, 2017; Darakhshan & Pour, 2015; Izumi 
et al., 2009; Sato et al., 2010; Subramaniam et al., 2011), not much has been studied 
about its efficacy on the dynamic change in biophysical properties of the ECM (i.e. 
stiffness) during active invasion. Additionally, a quantitative study on the impact of 
tranilast on matrix stiffness and tumor progression has been missing in the sole presence 
of CAFs. Therefore, our study was motivated by these critical knowledge gaps in the 
literature.  
A major finding of our study was the limited increase in elastic modulus of the 
matrix in combination treatment of tranilast and doxorubicin as compared to control after 
48 hours of exposure (Figure 5-3B). Immunostaining of collagen I and fibronectin, 
further confirmed reduced density and assembly of these matrix protein fibers within 
combinatorial drug treatment, which are known to be regulators of ECM stiffness 
(Dumont et al., 2013; Kalluri, 2016; Tripathi et al., 2012). Such an observation can be 
attributed to various factors including reduced proliferation of CAFs due to the action of 
tranilast (Suzawa, Kikuchi, Arai, & Koda, 1992), downregulation of biochemical 
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pathways and limited viability of tumor and stromal cells in the presence of doxorubicin 
(Pilco-Ferreto & Calaf, 2016). While the mode of action of tranilast is still not clear, 
many previous studies have shown that this specific anti-fibrotic drug downregulates the 
proliferation of fibroblasts of various lineage including dermal, corneal and CAFs 
(Ohshio, Hanaoka, Kontani, & Teramoto, 2014) consistent with our alamar blue results 
(Figure 5-2A, B). Additionally, it has been shown by previous in vivo studies that 
tranilast can downregulate the expression of growth factors such as CTGF, TGF β which 
play a crucial role in ECM protein synthesis and deposition, therefore limiting the 
increase in the stiffness of the matrix (Branton & Kopp, 1999; Papageorgis et al., 2017; 
Subramaniam et al., 2011). Furthermore, due to the known cytotoxic effect of 
doxorubicin on cancer cells, the impaired crosstalk between MDA-MB-231 and CAFs 
can influence the autocrine/paracrine signaling and hence lead to reduced fibrosis 
(Kalluri, 2016; Place et al., 2011; Truong et al., 2016; W. Wang et al., 2009).  Such 
specific action of these drugs also explains the insignificant change of stiffness within 
monotherapy groups, while the synergistic influence of these drugs can significantly 
reduce desmoplasia (Figure 5-3B).  
To further develop a comprehensive understanding on remodeling abilities of 
cells under various drug conditions, we also performed an antibody array analysis on 
various MMP and TIMP expression. Our results demonstrated reduced expression of 
proteases such as MMP1 within tranilast and tranilast + doxorubicin group suggesting 
limited remodeling ability of tumor and stromal cells due to the action of this drug. Many 
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previous studies have demonstrated similar reduced expression of various other proteases 
including MMP2 and MMP9 under the influence of tranilast (Darakhshan, 
Bidmeshkipour, Khazaei, Rabzia, & Ghanbari, 2013; Harigai et al., 2018; Subramaniam, 
Chakrabarti, Prud'homme, & Jothy, 2010). For instance, Darakhshan et al. showed that 
when MCF7 and MDA-MB-231 cells were treated with tranilast, MMP9 mRNA 
expression was significantly reduced as compared to untreated cells (Darakhshan et al., 
2013). While most of these studies have been primarily 2D monoculture of tumor cells 
(Darakhshan et al., 2013; Harigai et al., 2018; Subramaniam et al., 2010), similar 
assessment of MMP analysis for 3D coculture of tumor and stromal cells has not been 
attempted in the past. Such discrepancy in cell culture conditions can be a possible 
explanation for differences in our findings from those of previous studies. Our results 
also demonstrated reduced expression of TIMP2 within tranilast + doxorubicin group as 
compared to control and doxorubicin. Since TIMP2 is known to play a significant role in 
inhibiting the action of various proteases (Têtu et al., 2006), crosstalk between tumor 
cells and CAFs in control condition can possibly lower the expression of TIMPs to favor 
ECM remodeling, an observation made in Figure 5-3 and supplementary Figure 2 
(APPENDIX C). However, in doxorubicin condition such a crosstalk between tumor cells 
and CAFs is altered due to limited number of tumor cells (i.e. less proliferative), thereby 
maintaining the expression and activity of TIMP2.  On the other hand, in combinatorial 
group limited viability of tumor and stromal cells can minimize the overall expression of 
different proteins thus minimizing the concentration of TIMP2.   
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  Another finding of our study was reduced tumor growth and invasive behavior of 
MDA-MB-231 cells within the combinatorial treatment group as compared to untreated 
condition. Our results also demonstrated similar trend for non-invasive MCF7 and normal 
mammary MCF10A cells such that combinatorial action of tranilast and doxorubicin 
reduced their replicative ability significantly. We envision that these findings can be 
primarily correlated to our elastic modulus results where the combinatorial action of 
tranilast and doxorubicin treatment significantly reduced the stiffness as compared to 
control. Various studies have established that stiffness of the ECM can provide 
biomechanical cues by controlling the activity of integrins as well as FAKs, which in turn 
can influence proliferation and migratory behavior of the cells (Dumont et al., 2013; 
Hirata et al., 2015; Kalluri, 2016; Stanisavljevic et al., 2015). For instance, schrader et. 
al. utilized polyacrylamide gels (PAA) of variable stiffness and demonstrated tight 
regulation of proliferation of hepatocellular carcinoma cells by substrate stiffness due to 
upregulation of integrin β1 and FAK signaling in stiff matrices (Schrader et al., 2011). 
Moreover, they demonstrated that the inhibition of integrin β1 and FAK signaling, 
significantly reduced the proliferative ability of the cells (Schrader et al., 2011). Besides 
decrease in elastic modulus, presence of doxorubicin in the combinatorial treatment can 
further target proliferating cells, leading to overall reduction of growth of cancer and 
normal mammary cells within our 3D microengineered platform. In another study by 
Rosa et. al., MCF10A cells demonstrated enhanced migratory and wound closure activity 
upon seeding on PAA gels of high stiffness (Ng, Besser, Danuser, & Brugge, 2012). 
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These findings were consistent even when tumor cell proliferation was inhibited with 
mitomycin-C (Ng et al., 2012). Further inhibition of myosin contractility reduced the cell 
speed on stiff matrices, suggesting the role of integrin mediated myosin contractility on 
tumor cell invasion (Ng et al., 2012).  
Several previous in vivo studies have demonstrated a significant decrease in tumor 
growth with monotherapy of doxorubicin as compared to combinatorial action with 
tranilast (Papageorgis et al., 2017; Ken Takai et al., 2016). We did not observe a 
significant reduction in tumor growth and stiffness in sole presence of doxorubicin or 
tranilast. Such differences in results can be attributed to various factors such as interstitial 
stress, leaky vasculature, and the presence of other cell types (i.e. immune cells) within in 
vivo models (Papageorgis et al., 2017; Ken Takai et al., 2016). In this regard, a previous 
study by Stylianopoulos et. al., demonstrated that the administration of antifibrotic drugs 
such as tranilast and pirfenidone significantly reduce the interstitial stress that further 
enable penetration of doxorubicin into tumor parenchyma, thereby influencing the tumor 
growth (Papageorgis et al., 2017). Since our platform lacked tumor vasculature, 
doxorubicin did not encounter any limitation in terms of penetration within the matrix. It 
is also important to note that the aforementioned in vivo studies were performed for 
longer duration (i.e. 20-30 days) with continuous addition of tranilast as compared to our 
platform (Papageorgis et al., 2017). Nevertheless, our platform provides a unique ability 
to dissect the role of a single class of stromal cells on drug resistance. Additionally, we 
were able to visualize matrix remodeling as well as quantitatively assess the 
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biomechanical changes during the course of experiment within our microengineered 
tumor model. In future, we aim to conduct further mechanistic and gene expression 
studies on cancer cells in the presence of different drug combination. 
4.5 Conclusion 
In conclusion, we demonstrated the use of our 3D microengineered tumor stroma 
platform to assess the influence of anti-fibrotic drug (tranilast) on efficacy of 
chemotherapeutics such as doxorubicin in the sole presence of CAFs. We observed that 
while the matrix stiffness was significantly increased within our control group leading to 
a bimodal distribution of stiffness, such alteration in matrix properties were minimized 
due to the combinatorial action of tranilast and doxorubicin. Further, the synergistic 
influence of the two drugs diminished tumor growth and invasion thereby demonstrating 
an improved therapeutic regime than the monotherapy of each drug. We also performed 
molecular studies by assessing the expression of various MMPs and TIMPs and observed 
significantly lower expression of MMP1 and TIMP2 within the combinatorial group.  In 
the future, we aim to conduct more mechanistic studies by assessing the genetic changes 
in tumor cells and CAFs under different drug conditions for genes related to ECM, 
proliferation and invasion. 
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 Chapter 5  
Conclusion and Future Work 
This chapter summarizes the major findings of each specific aim as well as the project 
challenges and future directions. 
5.1 Significance and Contributions: 
Specific Aim 1: 
In specific aim 1, we fabricated a 3D high density tumor stroma model using 
micromolding techniques. The platform was built such that it had a high-density array of 
tumor seeded microwells surrounded by stroma comprised of collagen I and CAFs. To 
perform in situ measurements of matrix biomechanical properties during active tumor 
invasion we integrated our platform with AFM and confocal reflectance microscopy. We 
incorporated breast tumor cells of varied tumorigenicity (MDA-MB-231 Triple negative 
and more invasive, MCF7 Er/PR+ and less invasive) and studied their molecular 
interaction with CAFs that induce desmoplasia. We also utilized the platform to study 
tumor progression in response to CAFs by performing invasion assays including 
delaunay triangulation and real time cell migration as well as study tumor growth. Our 
results demonstrated enhanced ECM remodeling with upregulated matrix stiffness and 
increased deposition of collagen fibers when MDA-MB-231 cells were cocultured with 
CAFs as opposed to monoculture of either cell type. Similar desmoplastic reaction was 
observed due to the coculture of MCF7 cells with CAFs suggesting the crucial role of 
tumor stroma interaction in modulating the biomechanical properties of the matrix. Using 
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phase contrast and fluorescent microscopy, we observed an enhanced dispersion of 
MDA-MB-231 cells in presence of CAFs, while MCF7 cells depicted high clustering 
tendency. We also observed a significant increase in cell speed and persistence in the 
population of MDA-MB-231 cells upon coculture with CAFs while no significant change 
in migration metrics were detected for MCF7 cells. Proliferation assays such as EdU 
demonstrated an enhanced replicative ability of MCF7 cells in the presence of CAFs as 
compared to their monoculture group. Thus, overall both tumor cells upon coculture with 
CAFs induced CAF based desmoplasia with enhanced matrix stiffness and collagen 
deposition. While MDA-MB-231 cells adopted a more invasive phenotype in presence of 
CAFs, MCF7 cells became more proliferative. 
 In this aim, for the first time, we utilized an in vitro 3D microengineered model to 
study the dynamic change in breast cancer matrix properties during active tumor cell 
invasion in the presence of CAFs. As opposed to traditional in vivo and tumor biopsy 
models commonly used to study ECM remodeling, we designed the experiments with 
appropriate controls and minimal confounding variables and demonstrated the crucial 
role of tumor-stroma interaction in ECM remodeling. Although our current study focused 
primarily on breast cancer, various other desmoplastic tumors including prostate cancer 
and non-small lung cancer can be studied on this platform.  
Specific Aim 2: 
While in aim 1 we focused on developing a physiologically relevant 3D in vitro tumor-
stroma platform for breast cancer desmoplastic reaction, in aim 2 we utilized the platform 
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to perform mechanistic studies to better understand the mode of interaction between 
tumor cells and CAFs, which leads to desmoplasia. In particular, we assessed the role of 
soluble factor signaling between tumor cells and CAFs on ECM remodeling. Our results 
demonstrated crucial role of tumor secreted factors on inducing CAF based desmoplastic 
reaction. Additionally, soluble factors obtained from monoculture of tumor cells 
upregulated ECM remodeling while the soluble factors from coculture group of tumor 
cells and CAFs did not induce any significant change in matrix properties. We took two 
different approaches to characterize various pro-fibrotic factors secreted by tumor cells. 
In an unbiased approach we utilized LC-MS to identify the tumor secretome and assess 
their role in breast cancer fibrosis. Although we observed upregulated secretion of tumor 
associated ECM components within our coculture group, the number of proteins 
identified were small in number to perform a conclusive analysis. On the other hand, we 
utilized an informed biased approach where we identified multiple pro-fibrotic factors 
from various other fibrotic diseases and observed a crucial role of PDGF-AA/BB in CAF 
based desmoplasia. We also inhibited the activation of PDGFR using a concentration 
sweep of specific inhibitor (CP 673451) and observed minimal fibrosis in the presence of 
CAFs.  
 In this aim, for the first time, we were able to clearly establish the role of tumor 
secreted factors on induction of CAFs based desmoplasia. Due to a well-designed study 
with appropriate controls we demonstrated that tumor cell secretes profibrotic factors 
which are sensed by CAFs due to the presence of specific receptors that activates fibrosis 
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related pathways. To the best of our knowledge, this is the first in vitro 3D tumor stroma 
model which established the crucial role of PDGF AA/BB in breast cancer fibrosis. Thus, 
overall, we demonstrated the ability of our platform in performing mechanistic study to 
classify the mode of interaction between tumor and stromal cells and identify key 
molecular targets participating in CAF based fibrosis. 
Specific Aim 3: 
In this aim, we utilized our established platform to validate our model and study 
the effect of an approved anti-fibrotic drug, tranilast, on stromal desmoplasia and efficacy 
of anti-cancer drug doxorubicin in the presence of CAFs. We identified the IC-50 value 
of tranilast and doxorubicin on MDA-MB-231 cells and CAFs in 2D and 3D conditions. 
We demonstrated that while tranilast in monotherapy was not able to reduce ECM 
stiffness, the combinatorial action of tranilast and doxorubicin minimized CAF induced 
desmoplasia by disrupting collagen fiber assembly and fibronectin deposition. We also 
demonstrated that secretion of matrix metalloproteinases (MMPs) such as MMP1 and 
TIMP 2 were significantly affected due to the synergistic influence of tranilast and 
doxorubicin. The combinatorial action of the tranilast and doxorubicin also significantly 
reduced tumor invasion and growth.   
Although tranilast has been shown to be effective anti-fibrotic drug in multiple in 
vivo studies, our study was the first 3D in vitro study to analyze the effect of tranilast on 
desmoplasia in the sole presence of CAFs.  Our results related to effectiveness of 
combinatorial therapy in minimizing tumor growth and invasion were corroborated to 
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previous in vivo data. We also took a step forward by provided an insight on the influence 
of tranilast and doxorubicin on expression of MMP’s and TIMP’s in addition to collagen 
and fibronectin expression, an analysis missing from previous in vivo and in vitro studies. 
Thus, overall, we utilized our desmoplasia based model to test an anti-fibrotic based 
therapy to allow better availability of chemotherapeutic drug and minimize 
mechanotransduction based signals for tumor progression.  
Contributions: 
Below is the list of contributions of this work in peer reviewed journal articles and 
conference oral and poster presentations. 
Journal Articles: 
• H. Saini, K. Rahmani, M. Allam, C. Silva, J.Veldhuizen, D. Truong, G. 
Mouneimne, T. Hu, R. Ros, M. Nikkhah*, “The Role of Breast Tumor Stromal 
Interactions in ECM Dysregulation within a 3D Microengineered Model”, 
Manuscript in Preparation, July 2019. 
• A. Buchberger, H. Saini, K. Rahmani, N. Stephanopoulos, R. Ros, M. Nikkhah*, 
“Reverse Tunable Gelatin based DNA Hydrogel to Modulate Matrix Stiffness for 
Cancer studies”, Manuscript in Preparation, July 2019. 
• H. Saini, K. Rahmani, C. Silva, M. Allam, R. Ros, M. Nikkhah*, “The Role of 
Desmoplasia and Stromal Fibroblasts on Anti-Cancer Drug Resistance in a 
Microengineered Tumor Model”, Cellular and Molecular Bioengineering 
(CMBE), 11: 419-433 (2018), [Young Investigator Award Issue]. 
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• N. Peela#, D. Truong#, H. Saini#, H. Chu, S. Mashaghi, S. L. Ham, S. Singth, H. 
Tavana, B. Mossadegh, M. Nikkhah*, “Advanced Biomaterials and 
Microengineering Technologies to Recapitulate the Stepwise Process of Cancer 
Metastasis”, Biomaterials, 133: 176-207 (2017). [Among the Most Downloaded 
Biomaterials Articles, # Equal Contribution]. 
• D. Truong, A. Kratz, J.G. Park, E.S. Barrientos, H. Saini, T. Nguyen, B.A. 
Pockaj, G. Mouneimne, J. LaBaer, M. Nikkhah, (2019). “Human Organotypic 
Microfluidic Model to Investigate the Interplay Between Patient-derived 
Fibroblasts and Breast Cancer Cells”, Cancer Research, 2019 (online version) 
Conference Oral and Poster Presentations: 
• H Saini, K Rahmani, C Silva, M Allam, G Mouneimne, R Ros, M Nikkhah* ‘The 
Role of Desmoplasia and Stromal Fibroblasts on Anti-Cancer Drug Resistance in 
a Microengineered Tumor Model’, Biomedical Engineering Society, Young 
Investigator Award Issue, Oral Presentation, October 2018. 
•  H Saini, K Rahmani, M Rodrigues, T Cai, M Allam, C Silva, D Truong, T Hu, R 
Ros, M Nikkhah*, ‘Identification of Molecular Signaling Cues between Cancer 
Cells and Stromal Fibroblasts Enhancing ECM Deregulation in a 3D 
Microengineered Platform’ Biomedical Engineering Society, Poster Presentation, 
October 2018. 
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• H Saini, K Rahmani, C Silva, R Ros, M Nikkhah*, ‘Elucidation of the Role of 
Stromal Fibroblasts on Anti-Cancer Drug Resistance within a Microengineered 
Tumor Model’, Molecular and Cellular Tissue Engineering, Poster Presentation, 
March 2018. 
•  H Saini, K Rahmani, D Truong, E Assefa, R Ros, M Nikkhah*, ‘A High-Density 
Tumor Model to Assess Breast Cancer Dispersion and ECM Remodeling under 
the Influence of Stromal Cells’, Biomedical Engineering Society, Oral 
Presentation, October 2017. 
• H Saini, K Rahmani, C Silva, M Allam, R Ros, M Nikkhah*, ‘Investigating the 
Role of Stromal Cells on Breast Cancer Invasion using Three Dimensional (3D) 
High density Tumor Microarray Model’, Molecular and Cellular Tissue 
Engineering, Poster Presentation, March 2017. 
• H Saini, K Gomaz, K Rahmani, R Ros, M Nikkhah* ‘Three Dimensional (3D) 
High Density Tumor Microarray to Study the Influence of Stromal Cells on 
Cancer Invasion’, Biomedical Engineering Society, Poster Presentation, October 
2016. 
5.2 Project Challenges: 
 During the course of this dissertation we faced multiple challenges that we 
overcame to successfully complete the project. Amongst our very first challenge was 
fabrication of our microengineered 3D in vitro tumor stroma model. During year 1 and 2 
of the dissertation we worked exclusively on fabricating the model and optimizing 
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various parameters including dimension of the pattern, distance between two adjacent 
microwells and tumor cell density. We learnt from various experiments, that in order to 
form a high-density tumor cell seeded microwells, the diameter and depth of each 
microwell were the most crucial factors. When the platform was fabricated with 
relatively large diameter (~ 300 µm) microwells, the tumor cells could not be retained 
within the pattern upon washing due to their easy dislodging. We identified that it was 
crucial that the cells get physically restrained by dimension of the pattern to avoid 
dislodging of cells with multiple washing. Upon optimization with different diameter of 
the microwells we identified that the best patterning of tumor cells was achieved at the 
diameter size of 75 µm. We also varied the distance between the patterns to create a high-
density tumor microarray and observed that the large distance between two adjacent 
microwells caused difficulties in removing tumor cells from stroma which is turn can 
lead to dislodging of cells from the patterns due to multiple washes. From a series of 
optimization experiments, it became clear that a center to center distance of about 250 
µm between two microwells was ideal to create a pattern of tumor seeded microwells. 
We also ran optimizations on tumor cell density and observed that a high cell density 
ensure complete filling of the microwells enabling fabrication of accurate tumor stroma 
architecture (Nelson et al., 2008). 
 Another critical challenge that we faced during the project was to quantify the 
dispersion of MDA-MB-231 cells into the stroma in the absence and presence of CAFs. 
Unlike most other microengineered platforms such as microfluidic models, the initial 
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tumor boundary could not be easily recognized as the culture period increased due to the 
remodeling of the microwells by CAFs (S. Nagaraju et al., 2018; Truong et al., 2016; D. 
D. Truong et al., 2019). While tumor migration in many in vitro models is measured in 
terms of the distance travelled from initial tumor boundary to final tumor boundary, this 
metric could not be applied to our platform. Hence, we took inspiration from metrics 
which are used to measure tumor cell invasiveness by using mathematical model known 
as Delaunay Triangulation (Nawrocki Raby et al., 2001). In this regard, we utilized 
ImageJ and our custom written MATLAB code using in built function of Delaunay 
triangulation to measure area disorder and migration index on various days of the culture 
as explained in chapter 2 and 4. Since MCF7 cells mostly clustered, such an analysis was 
difficult to perform for these cells and hence we measured tumor clustering tendency 
using ImageJ.   
One of our major challenge was during proteomic studies on our collected CM to 
identify various tumor secreted factors participating in CAF based desmoplasia. For this 
analysis we resorted to serum free media for easy identification of low abundant tumor 
secreted factors in absence of large proteins found within serum. However, even after 
multiple washes of samples with 1X PBS to remove any trace serum, we observed 
significant amount of albumin and other serum related proteins within our CM which 
made it difficult to visualize tumor and CAF based secretomes. As explained in chapter 3, 
we used traditional gel electrophoresis and in gel digestion techniques to remove albumin 
from our media (Shevchenko, Tomas, Havli, Olsen, & Mann, 2006).   However, due to 
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the use of this technique we lost various low abundant proteins either due to complex 
formation with large serum proteins or due to poor yield of various peptides from the gel 
(Millioni et al., 2011; Speicher, Kolbas, Harper, & Speicher, 2000). It is also crucial to 
note here that our samples were microengineered 3D samples which have lower cell 
number as compared to traditional 2D samples. Despite combining conditioned media 
from various replicates (8 per condition) we did not detect a large number of proteins. 
Additionally, since our sample type was cell conditioned media as compared to cellular 
lysate, the amount of proteins was found to be low.   Due to various technical challenges 
that came up regarding use of LC-MS with our platform, it became evident that a series 
of further optimizations will be required to use traditional discovery-based proteomics 
with microengineered platforms. For starting, different serum depletion approaches need 
to be utilized to retain low abundant proteins. For instance, multiple columns including 
MARS column are available which have high specificity and sensitivity to serum related 
proteins and can remove minimize the presence of various contaminants (M. P. W. Smith 
et al., 2011). Additionally, the depletion techniques of high abundant serum proteins can 
be conjugated with enrichment techniques for low abundant proteins to recover a 
significantly large number of proteins (Millioni et al., 2011). Although in this project we 
resorted to use traditional ELISA technique to identify tumor secreted pro-fibrotic 
factors, the integration of LC-MS with our 3D microengineered model will be a subject 
of future research for our group.  
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5.3 Future Directions: 
 
Modeling cancer fibrosis under in vivo like hypoxic microenvironment 
Cancer is a disease in which malignant cells maintain their proliferative 
phenotype and grow in size (D. Hanahan & Weinberg, 2011). When tumors grow beyond 
the size 1-2 mm, the core of the tumor becomes necrotic leading to secretion of various 
pro-angiogenic factors that leads to formation of new blood vessels to regulate the supply 
of nutrients and gas exchange to the cancer cells (Gilkes, Semenza, & Wirtz, 2014). The 
resultant new blood vessels have multiple structural abnormalities that leads to the 
formation of torturous vascular architecture and leaky blood supply.  The tumor 
associated vessels do not provide adequate blood supply to various regions of the tumor 
and hence leads to development of hypoxic areas. Hypoxia although initially restricts 
tumor growth but later on activates multiple cell survival pathways which leads to tumor 
progression (Gilkes et al., 2014).  
While the effect of hypoxia on tumor angiogenesis, cell invasion, EMT are well 
studied, recent reports have argued that hypoxia may also have a significant impact on 
stromal fibrosis. In an interesting study by Gikes et.al. it was demonstrated that under 
hypoxic conditions breast tumor cells including MDA-MB-231, MCF7 and MCF10A 
shows an elevated expression of collagen crosslinking enzymes including prolyl 4-
hydroxylase 1and 2 (P4H1, P4H2) (Gilkes et al., 2013). Since hypoxia inducible factors 
including H1F-1α and HIF-2α  are significantly upregulated under hypoxia conditions, 
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the authors studied the mRNA expression of  P4H1 and P4H2 after silencing H1F-1α and 
H1F-2α (Gilkes et al., 2013). Authors demonstrated that the loss of H1F-1α but H1F-2α 
leads to a significant reduction in P4H1 and P4H2 mRNA expression. Authors further 
confirmed the in vitro results by injecting sh1/2α MDA-MB-231 clones into mouse 
mammary fat pad and observed reduced expression of P4H1 and P4H2 with condensed 
deposition of collagen fibers (Gilkes et al., 2013). Additionally, using MDA-MB-231 
clones with shRNA against P4H1 and P4H2 authors demonstrated that loss of these two 
factors can minimize tumor growth and lung metastatic burden (Gilkes et al., 2013).    
Many other reports have suggested that H1F factors can also regulate expression of other 
ECM related enzymes including LOX and MMP’s by elevating their expression levels by 
transformed tumor and stromal cells (Gilkes et al., 2014; Muñoz-Nájar, Neurath, 
Vumbaca, & Claffey, 2006; Wong et al., 2011).   
Microengineered models such as ours enable accurate characterization of stromal 
fibrosis by studying dynamic changes in ECM architecture and perform mechanistic 
molecular studies on various pro-fibrotic factors as opposed to conventional animal 
models. While the preliminary studies about the role of hypoxia in ECM dysregulation 
has been performed using animal models, there is still a lack of in-depth studies that 
focus on the mechanism of hypoxia on ECM turnover due to tumor stroma interactions.  
Additionally, more focused studies need to be performed to understand the synergistic 
influence of hypoxia and stromal fibrosis on drug resistance since these factors are two 
critical bottlenecks in anti-cancer drug resistance. As opposed to conventional animal 
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models, microengineered 3D platforms, similar to ours, will aid in better assessment of 
the expression of pro-fibrotic factors under various conditions. Additionally, due to 
minimal confounding variables, our 3D model will help in dissecting the individual and 
synergistic role of fibrosis and hypoxia on drug resistance. Therefore, we envision that by 
culturing our platform under hypoxic conditions and by using advanced biotechnology 
techniques such as gene knockdown strategies we can study the crucial role of hypoxia 
on cancer desmoplasia. Additionally, we can also study the synergistic influence of ECM 
fibrosis and hypoxia on the efficacy of chemotherapeutic drugs. Such an understanding 
will therefore help in designing more targeted adjunct therapies that can be given to 
patients along with conventional chemotherapy and radiation therapy to improve their 
effectiveness. 
Role of fibrosis in activation of other stromal cell within the TME 
It has been well studied that various other stromal cells besides CAFs transform 
themselves and participate in tumor progression (Bussard et al., 2016). For instance, 
endothelial cells show an enhanced proliferation and migration towards necrotic cores to 
form new blood vessels and supply nutrients for maintaining tumor metabolism (Dudley, 
2012). Macrophages on the other hand change their phenotype from tumor inhibiting M1 
to tumor promoting M2 state and secrete anti-inflammatory cytokines and matrix 
components to promote tumor invasion (Noy & Pollard, 2014). Regulatory T-cells 
participate in cancer by immunosuppressing the tumor specific immunity thereby tipping 
the tumor cells towards survival and proliferation (Balkwill et al., 2012; Segovia-
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Mendoza & Morales-Montor, 2019). Tumor cells are generally known to secrete elevated 
levels of various growth factors including VEGF, IGF, TGF-β and PDGF that can assist 
in transformation of these stromal cells to an alternate tumor promoting phenotype 
(Balkwill et al., 2012). Besides tumor cells, some reports have suggested that CAFs can 
also transform different cell types to participate in tumor progression (Gascard & Tlsty, 
2016). While multiple studies have elucidated the role of tumor cells in activation of 
stromal cells and in turn their influence on tumor progression, not much is known about 
how biophysical properties of ECM can activate and transform these cell types to create a 
tumor permissive niche.  
Some recent reports have elucidated that biophysical properties of ECM can 
activate and switch the phenotype of stromal cells. For instance, it has been shown by 
various research groups that stiff matrices as compared to soft matrices promote secretion 
of anti-inflammatory cytokines which are usually  associated with tumor inhibiting M1 
phenotype (Hsieh et al., 2019; Okamoto et al., 2018; Previtera & Sengupta, 2016). 
However, from clinical research biopsies we know that advanced stages of tumor are 
corelated with enhanced stiffness as well as tumor promoting M2 phenotype of 
macrophages. Such contradicting results thereby raise the question that whether the 
interaction of tumor cells and ECM stiffness modulate the secretome that can alternate 
the activation of these immune cells.  Such analysis can easily be performed on our 3D 
tumor stroma model by utilizing different tunable biomaterials whose stiffness can be 
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modulated to study the synergistic role of tumor cells and stiffness on phenotype of 
different stromal cells including macrophages, adipocytes and T-cells.   
Characterization of stromal desmoplatia due to interaction of tumor cells and CAFs 
isolated from patients 
Most of the studies in cancer research utilize cancer and stromal cell lines due to their 
easy availability and culture requirements (Hynds, Vladimirou, & Janes, 2018). While 
most of these cell lines have been established from patient derived cells, it has now been 
accepted that these cell lines adapt a different phenotype and genotype with increase in 
passage number as compared to their early cultures (H. Yang, Sun, Liu, & Mao, 2018). 
Furthermore, cell lines provide a simplistic view of the biological question since they 
don’t represent the patient to patient heterogeneity. Some researchers argue that 
widespread use of cancer cell lines to screen drugs can be another crucial factor in 
clinical failure of various drugs (H. Yang et al., 2018). In this regard, cancer research 
community is slowly moving towards use of patient derived cells. Multiple protocols 
have been established using which different cell types including fibroblast cells and 
monocytes can be isolated with high success from patient derived tissues (Menck et al., 
2014; Orimo et al., 2005; D. Truong et al., 2019; D. D. Truong et al., 2019). For instance, 
one of the recent studies in our lab utilized patient derived CAFs to study their role in 
cancer progression including proliferation and invasion within an organotypic 
microfluidic model (D. D. Truong et al., 2019). Tissue biopsies were obtained from three 
different patients with difference in their hormone and Her2 receptor status. Upon 
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characterization of isolated CAFs from different patients we observed morphological 
heterogeneity with difference in α-SMA expression across the population of CAFs (D. D. 
Truong et al., 2019). Additionally, when co-cultured with tumor cells, 2 out of 3 CAF 
populations enhanced the migration of tumor cells as compared to the monoculture 
condition. The study also assessed the transcriptomic signature of SUM-159 cells in the 
presence and absence of CAFs and observed significant role of GPNMB in tumor cell 
invasion (D. D. Truong et al., 2019). Another interesting study by Rudnick et.al. 
demonstrated that fibroblast cells isolated from either reduction mammoplasty tissue or 
breast cancer tissues are heterogenous in their activity in tumor promotion (Rudnick et 
al., 2011). Authors utilized tissues obtained from invasive lobular, ductal carcinoma as 
well as from various reduction mammoplasty disease free tissues. Despite their origin, it 
was observed that fibroblasts cells which were able to secrete high levels of prostaglandin 
(PEG2) act as tumor promoting by expanding the population of cancer stem cells thereby 
supporting MCF7 tumor growth (Rudnick et al., 2011). Such studies thus demonstrate the 
crucial role of patient derived cells in understanding the heterogeneity in biological 
behavior of tumor cells and their subsequent role in tumor expansion. 
 While most of the studies primarily focused on the role of patient derived cells on 
tumor progression, not many studies focus on role of these isolated cells from different 
tumor subtype of cancer on stromal ECM desmoplasia. By isolating patient cells from 
tumor of various hormone receptor subtypes, similar to our previous study (D. D. Truong 
et al., 2019), we can study the difference in ECM biochemical and biophysical properties 
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deposited by the CAFs. By utilizing novel techniques such as second harmonic 
generation and AFM we can further visualize the changes in ECM fiber organization and 
deposition during tumor invasion. Similar to our ELISA assessments in Chapter 2, 
expression of various factors can be studied in presence of different CAF population to 
provide better understanding on expression patterns of tumor secreted growth factors. 
Additionally, we can study the change in transcriptomic profile of CAFs upon coculture 
with tumor cells to visualize the regulation of genes participating in desmoplasia, 
inflammation and immune suppression. Besides enabling cancer biology, these isolated 
cells can further be useful to test clinically approved anti-fibrotic drugs such as tranilast 
used in Chapter 4 to study their influence in disrupting desmoplasia in presence of 
fibroblasts obtained from various patients. 
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APPENDIX A 
SUPPLEMENTARY FIGURES FOR CHAPTER 2 
 
174 
 
 
Supplementary Figure 1: Characterization of breast tumor and stromal cells. (A) 
Representative 2D immunostained images of MDA-MB-231, MCF7 and CAFs for pan 
cytokeratin, vimentin and α-SMA. (B) Representative western blot for α-SMA expression 
across all the cells. All scale bar represents 20 µm. 
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Supplementary Figure 2: Actin images within 3D tumor model. (A) Representative top 
and 3D view of actin images across monoculture and coculture condition of MDA group. 
(B) Actin images of MCF7 cells in monoculture and coculture group. 
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Supplementary Figure 3: Representative fluorescent images showing cancer cell (MDA-
MB-231, MCF7) proliferation across all monoculture and coculture conditions. All scale 
bars represent 20 µm. 
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Supplementary Figure 4: Representative fluorescent images showing CAF proliferation 
across all monoculture and coculture condition with MDA-MB-231 and MCF7 cells. All 
scale bars represent 20 µm. 
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Supplementary Figure 5: (A), (C) Dynamic modulus plots for MDA-MB-231 and MCF7 
cells across monoculture and coculture condition depicting G’ and G’’ across the culture 
period. (B), (D) Loss tangent graphs for MDA-MB-231 and MCF7 group across all 
conditions. (E) Dynamic modulus plots for CAF only depicting G’ and G’’ across the 
culture period. (F) Loss tangent graphs for CAF only group. 
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Supplementary Figure 6: (A) Representative Confocal Reflectance Images showing 
collagen deposition in CAF only groups across the culture period. (B) Dynamic modulus 
plots for CAF only depicting G’ and G’’ across the culture period. (C) Loss tangent graphs 
for CAF only group. 
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APPENDIX B 
SUPPLEMENTARY FIGURES FOR CHAPTER 3 
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Supplementary Figure 1: List of 35 unique proteins detected in coculture group of 
MCF7 cells with CAFs sorted by their protein abundance. 
  
182 
 
 
Supplementary Table 1: List of Biological Process in which identified unique proteins 
in MCF7+CAF group participate along with the p-value and fold enrichment values. 
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Supplementary Table 2: List of Molecular Functions performed by unique proteins 
detected in MCF7+CAF group along with the p-value and fold enrichment values. 
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Supplementary Table 3: Identification of Cellular location of the unique proteins 
detected in MCF7+CAF group along with the p-value and fold enrichment values. 
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Supplementary Table 4: KEGG pathway analysis on unique proteins detected in 
MCF7+CAF group along with their false discovery rate and participating gene list. 
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APPENDIX C 
SUPPLEMENTARY FIGURES FOR CHAPTER 4 
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Supplementary Figure 1: IC 50 values in 3D assay for MDA-MB-231 and CAFs in 
response to different concentrations of (A) Tranilast and (B) Doxorubicin in 3D assay. (C) 
IC 50 values of MDA-MB-231 and CAFs at higher concentration of doxorubicin. 
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Supplementary Figure 2: Representative immunofluorescent images demonstrating 
fibronectin deposition and assembly within 3D matrix across experimental groups. Arrows 
representing the fibronectin fibers. * represent the microwells molded in collagen. Scale 
bar represent 20 µm. 
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Supplementary Figure 3: Scatter dot plot of data replicates for elastic modulus 
measurement showing variation of stiffness across all groups on day 1 and day 3 of the 
culture.   
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Supplementary Figure 4: (A) Representative immunofluorescent images of EdU assay 
depicting proliferation of MCF7 and MCF10A in control and Tranilast+Doxorubcin treated 
group. (B) Quantification of proliferation of MCF7 and MCF10A cells across culture 
conditions. Scale bar represents 50 µm. (* represents p value < 0.05). 
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Supplementary Figure 5: (A) Representative phase contrast and fluorescent images of 
tumor cell dispersion in DMSO, tranilast and doxorubicin conditions on day 1 and day 3. 
(B) Representative triangulation graphs depicting tumor cell invasion into the stroma 
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within DMSO, tranilast and doxorubicin group. (C) Quantification of area disorder of 
MDA-MB-231 cells across all the groups. Scale bar represent 100 µm. (* represents p value 
< 0.05). 
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APPENDIX D 
LIST OF SUPPLEMENTARY VIDEOS 
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Supplementary Movie 1: Representative movie showing real time migration of MDA-MB-
231 cells in monoculture condition for 18 hours with time interval of 45 minutes.  
Supplementary Movie 2: Representative movie showing real time migration of MDA-MB-
231 cells in coculture condition with CAFs for 18 hours with time interval of 45 minutes.  
Supplementary Movie 1: Representative movie showing real time migration of MCF7cells 
in monoculture condition for 18 hours with time interval of 45 minutes.  
Supplementary Movie 1: Representative movie showing real time migration of MCF7 cells 
in coculture condition with CAFs for 18 hours with time interval of 45 minutes.  
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